var title_f10_27_10672="Giant papillary conjunctivitis in contact lens wearer";
var content_f10_27_10672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Giant papillary conjunctivitis on the upper tarsal conjunctiva",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giant papillary conjunctivitis (GPC) formation on the upper tarsal conjunctiva of a patient from contact lens overwear. GPC can also be due to other prostheses or foreign objects, such as sutures, that abrade the surface of the conjunctiva.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10672=[""].join("\n");
var outline_f10_27_10672=null;
var title_f10_27_10673="Neurofibrosarcoma CT";
var content_f10_27_10673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neurofibrosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan shows sharply defined metastases from an axillary neurofibrosarcoma in a patient with scoliosis and a surgical spinal fusion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10673=[""].join("\n");
var outline_f10_27_10673=null;
var title_f10_27_10674="Auto PEEP and hyperinflation";
var content_f10_27_10674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77948&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auto-PEEP and dynamic hyperinflation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 298px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEqAbwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorlb3xLqf9v3+maRoDX/2JYjLKbtIhl13AAEZ6UAdVRXK/234n/wChR/8AKlF/hR/bfif/AKFH/wAqUX+FAHVUVyv9t+J/+hR/8qUX+FH9t+J/+hR/8qUX+FAHVUVyv9t+J/8AoUf/ACpRf4Uf234n/wChR/8AKlF/hQB1VFcr/bfif/oUf/KlF/hR/bfif/oUf/KlF/hQB1VFcr/bfif/AKFH/wAqUX+FH9t+J/8AoUf/ACpRf4UAdVRXK/234n/6FH/ypRf4Uf234n/6FH/ypRf4UAdVRXK/234n/wChR/8AKlF/hR/bfif/AKFH/wAqUX+FAHVUVyv9t+J/+hR/8qUX+FH9t+J/+hR/8qUX+FAHVUVleFtYGv6BZ6mLdrbz1JMTMGKEMVIyODyK1aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuJtLz7B4m8eXiqJGtoLebZnGdsDHHt0ra8WarPp1jDBpqo+rX8n2azRvuhyCS7f7KKGY/wC7jqRXLeDfD0FprXjbSnuLmc3SW4ubmR8yyu8LBnJ6A88DGBwAMCgDnfCvxzsPEeqeDtPsbaCa81iC6lv4IJi8li0URkVQNo3FtpHbpXSP8YPCY0qTUUuLqW0j05NUkeOAt5cTS+UA3o+/I29eCauaT8NNH0yfwZLb3OoM3hSK4ist8iESCZNjebhBkgdNu3n1rhh8Gr2L4f8Aj/SrR9Nh1bxLfNNDiR/IggE2+OMts3cAueFxlvxoA7G5+LHhyzt9Ta9XUbW6sLqG0eyntik8kkylotqk4w6qxBJGApzjFRWfxf8ADN6lgLSPVri5vGnRLW3sXmmR4WVZFZUzgjcDnpjnNVx8LvDOt6fqfn6rqGq3t1fRXMuqNcxvPHPACiKCqhBsDOu0r/Ec5rW0D4c6bo+s6Zqi6hqV1eWCXCRtOYgrCbYG3KkajjYMYx3zmgDNtvilp8NvEL2O6vry61C9srWDTLKSR5Dbn5l25JyB36dTwKwdT+MkuoapoMPg/TzPZX9jPqMtxeW0nypE5RkAUjaQysCxJAOPWuv0n4aaPperaVqFvc6g02nX17qESvIhVpLpSsgbCA7QCduCCO5NV9D+FWh6MtmLW61Jxa2N3p6eZIhzHcymVycIPmDEgHpjqD1oAyx8YdN0rwd4d1nxPaXcJ1Oxiu5JLWLdDEW6gbm3HHXC7iByah1v4vJaT+NraPTprUeHVgZb+4heWCUSBDllUArnd8o3HcPm46VLqvwP8O6jY2lo2o61BHBpaaQxilizLAhyu4tGcNk9V257irWsfDLw7r194otv7Z1JH1a2toNTs7a4iIXy1URSFShZW2x4/ukZ4zyADWvfiRoNn4lbRpftpZLuKwlvFgJtormQApEz9mOR2wMjJFVtE+Kvh/WNdsNLtodURr6ae3t7mazZLeSWLO9A54JG0n0988VLffDPRbzxK+ryXGorHLexalNp6TKLWa5jACSsu3dkYBwGCkgZBpdL+Guj6b/YXkXOoN/Y99c6hb75EO6SffvD4TlRvOMYPTJNAE/iv4i6B4VutQt9ZluIpbK0ivXVYi3mRyS+UpT+8d5wRVC8+JGmyaxZWekzrKraommzO0DusjtCZdsTA/eA28njnFaPiv4faJ4o8S6PreqrO1zpiuixIwEc6tg7ZQQSwVhuGCMHnmszw/8ACbQdC0vQrGzudSdNI1FtUikllRnmmKlP3h2cgKQOAD8o59QDmIfjXNeaXoeoW/h2+hjvNYfTZoWheZ2VRLzDgDc+YxkYwucH1rpk+Lfh6bStPu7W31a4uL17hEsIrQm5Qwf67emcLt4zz3GM1HpHw48P2upQwWms6hM2lap/a8dibiJhaySCQ7SAm4I29j8xycDB4NOk+EuiiOM2mo6xZXkd1d3KXltNGsoFycyx8oVKHjGRkY4OeaALy/E7w1JaXl1DczS29rpSay7pEcG3bOCP9r5T8vUVH4V+IkPiLxxrPh6DSb6KOxht50vWUlJFlQv8wx8nT5eTu56YrM1X4MeHb2GOC1vdZ0u3GljSJIbG5VVngBJG/crZIJJz3zzmui0TwPY6J4nm1vT73UUluLSC0uLcyIYZhChSN2G3duAJ6EDnpQAvwu/5ETTP+2v/AKNeuqrlfhd/yImmf9tf/Rr11VABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFeffG/xJrfhLwZ/bPh+4s45YriKKSO5tzKJBI6oMEOu3Gc989OOtAHoNFeUeJvitP4VuNYtLvQ7nVV8PRWbatqFvJHAgE4++kTMW6g/KCcd27l8/xhtofFusaLJpEkP9mi5LG4uUhmmEMbOWjiYZZG24Ugk4OcAZwAeqUV4tr3xjdfDN/O2mX2kTtokGu2UyPFO0lvJJGhOD8qsC44Ocg54PFdTcfEYprHiezh0O4e18PhvtV9JdwQwhvJ81Fy7AjcSFzjA6k0AegUV4XffHDULjTZzo3h1RqNrqVjaTRzzbo3iuS21kY7Dk7SASMDIPIrqdS+KqafrNzbT6HdfYbC4tLLUbsTp/o09wFKqE6uF3KGYEewNAHpdFeXP8Wtmj6trL+GtQXRNMvGs7i9M8RXKziJmVA2/AzuOQBjPNdf4I8UQ+LtOvNQsrd47GK9mtLeZmBFysbbTKmP4SwYD6UAdFRRRQAU2WRIYnkldUjQFmZjgKB1JPYU6uU8Ut/bmq2vhqH5oDtutTI6Lbg/LEfeRlxj+6r+1AC+Glk13VX8S3KstqYzBpcTrgiEkFpiD0MhC49EVe5NHh3/ke/F3/AG5/+ijXVAAAADAHauF+33Gh+NfEM0ujavd294ts0Utpb+Yp2xkMM5HOaAO6rwXx9qHjZPilGdEt/EcNlBqFkmIopp7W5t22iVvlXy0UZOdxLZ5yB09Q/wCEy/6lzxJ/4A//AGVH/CZf9S54k/8AAH/7KgDy/R7TxpqGt6Lpstz4h0fT7nU9b+2XNrbCMrEGQ25LPGVAPzbWI55wc81V1/Vvido+t62bGz1e/sNCvJp4gsDSf2lBc7BDGmB8/k7nJx0wM9K9a/4TL/qXPEn/AIA//ZUf8Jl/1LniT/wB/wDsqAPGviNJ8QtN0rSLTTW8US6rbaNFM95ZpLOlxd7iZIyka7Qw9ZCQVwAvc9Dp2peLp/jSPC0uoXH9koyeIJZgw3rA0Wz7KeOF87nb1wK9E/4TL/qXPEn/AIA//ZVVh8Q2UGoXF/D4Q1uO+uVVZrhNMUSShfuhmBywHbPSgDmPjJN4nj1qAaWfEC6T/Zdwbc6HEZJDqO5fKE20EiPGeuFznNcDq9t44tvE3iG7trXxDB4qvrbRfs8lhbMbGa5SPE4mk2+X5almGCwHJ64GPb/+Ey/6lzxJ/wCAP/2VH/CZf9S54k/8Af8A7KgDye7j8b6l8Q9f0+Q+I7rSrk30UcirJaQ28flMsS4ZDDKucbWRt5OC2ORTfh3pfid7TwHokV54v0jTksLhdSZ7byjFMgi2RgyREKn3gp6n5sGvWv8AhMv+pc8Sf+AP/wBlR/wmX/UueJP/AAB/+yoA80sNc8c/25p2kzWPiETQ+Jrj7TdSWjfZXsSHMQ8wDBT7vI6Y5PTPLeItN8UeIPhrqlrqi+OrjxSsaT31o9ufsTsl3EcQ4XaxCbmURk5CknkAV7p/wmX/AFLniT/wB/8AsqP+Ey/6lzxJ/wCAP/2VAHmF/J4wRvGUmhR+ITZtHo32e4mtCl5JBhvtJj3IC0wXGRjKk9AcCltB44vbPSrSO58T22lXHiSSGO5kiK3q6d5Jw0xZCUG/IDOA3TpxXp3/AAmX/UueJP8AwB/+yo/4TL/qXPEn/gD/APZUAUfg8dcXwrcW/iSTUJbq11C6t4Zr9Cs0sCyERuSQN2V/i713Fcr/AMJl/wBS54k/8Af/ALKj/hMv+pc8Sf8AgD/9lQAfC7/kRNM/7a/+jXrqq5r4cW1xZ+CtMhvbeW2uArs0UowyZdiAR64IrpaACiiigArgI/D+ma/488THV7drn7OtqsQMzqEBjJOACB1rv65Xw7/yPfi7/tz/APRRoAjbwJ4TVnVrFAyLuYG5k+Uep+bgU9PAHhZ1Vk00MrDIIuJSCP8AvqvJ/iT4a8Vaj47+IlzoZuLWzn8NCE501rgX58t8wRNkYc5xxuPI4qrcXHjLRh8OfDOmXd5Zp4i0SxtHjb5ZtNltxE1w4UjIPlEqQR1HagD2P/hX3hj/AKBn/kxL/wDFUf8ACvvDH/QM/wDJiX/4qvJ9J1vxVqnj66g0u88QXEtl4wltZU8snT4tNVVMiu+3bv5+UEls4wOcnHsrz4oR2+sy3s/iJdZ+w3yy2q2M0kJlAJhaBwvljBAACEls8jPNAHtL+CfB8d3FaSWkK3Uqs8cLXcgdwOpC78kDIz9akm8BeFYYnlm09Y4kUsztcyAKBySTu4FcDqdl4t0290Z7e613UpZNB1G4muJrdWaG6MMflxgpGAp3A7V6k561x/iTR/HN14VvbK5ufFeox6n4OivbiGaEvs1DzYg0ChUG07S4Mf3iASc4zQB7FpnhfwLqu7+y1sr3aoc/Z79pMAkgH5XPGQR+Bq//AMK+8Mf9Az/yYl/+KryWfRdb8K3PjFtD0rXLhf7H0yC3ltlMcrsHfzdjKnzMoYlgg3Y9Cc1hXGn+MNV8N6fLrf8AwllxFpPi2KaOSOzmFyLMw8zIjqZG2scAnJG5s+wB7ha+CfB92Zha2kM5gkMMvl3cjeW4xlWw/DDI4PPNT/8ACvvDH/QM/wDJiX/4qvMJX8XxW2p+ZD4hg0hvFtx9qextWW8ax8hPLaMKu5kMnVlBPB96r2dv8QtXtdHtNVvvEunp/Yt9O8tsgSVpVm/0ZZmCkCUx7cqMMe/OaAPV/wDhX3hj/oGf+TEv/wAVSN4A8LqpZtNAUDJJuJcAf99Vzl9L4uuvgRZ3tsb6PxhDp8F28flFJpZU2tJGyYzuYBl246npXJeHr74j6l4qs7bVINWtdKvDPrrO0JUQRMjrFYsSOGDeWSh55NAHpVr4J8H3dol3a2kM9q671mju5GRh6hg+CKWz8EeEL22jubOziuLeQbkliupHRh6gh8GvH9B0XxB/bXgDVdZtvEccj6DNaXAgtWAjn8wERzKE/dqw65xnA5rW+DGkeKPDt34Gt7iTX/7Mu9HnF/Z3kREFnKjL5agbB5bHJ4PJx3oA7uTw/pmgePPDJ0i3a2+0LdLKBM7BwIwRkEkda7+uV8Rf8j34R/7fP/RQrqqACiiigArA8Y+ENF8ZWEVl4itZbq1jfzFjS6lhBYdCfLZc4xkZzg1v0UAcnc/DzwxdWWrWlzpzzQ6rBb2175l3MzTxwDEQLF92QP4gcnuTVXVvhn4dvpNTuorV49TvIrlUuJZ5ZkgknVleRImfYpO452hc88121FAHnug/CLwtp/hZtHvrM6g1xYwWN7cyzzB7hYgpAXLkxKWXdsQgD8K6ObwfoM8evRzaekkeukHUVd3InIQIOCfl+UD7uOmevNb9FAHERfCvwdHZahajSpWivzA1w0l9cPIxgJMRDtIWUruOCpBq5N8PfC8+s2+qzaWJL6DySHaeUh2iGImkXdtkZR0ZwWHrXV0UAcpqfgmwfwVr3h3RgmnxautwZJHVrgLJPnfJtZuTkkgZABpLOG3+HngvSNPstPvr7T7CNLeVrOIPIiBTumMYO5styQgY/MSAcV1lFAFLR9VsNa0+K+0q7hu7STO2WJtw46j2I6EHkVdrltY8IRy6hJq3h+7fRNbc5kngQNFc+08XAk9M8OOzCoLPxfJp95Fp3jO0TSLuRgkN4r77K6Y8AJKcbGP/ADzfB9C3WgDsK4641FfDnizUrjVLa4j0/UfJEN5GnmRq6IQVfbllPoSMH1zXXeYnmmLevmhd2zPOOmcelPoAw7PxboN5M0MOq2omUA+XK/lsQTjIDYJGeMitysXxgumJ4d1C61qyhvLW2t5JGjkjDbhtOVGe56cUvg6yvNO8Mabaam++7iiCyfvDJt9F3HlsDAyeuKANmiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArlfDv/ACPfi7/tz/8ARRrqq5Xw7/yPfi7/ALc//RRoAPH3jnTfA9rb3Gr299LBKHJkt41ZYwu3O4swGTu4AyTg4HBrmLr4ieGYdaudZvUtp7e0sbKa1uorBnukjvD8oDddrfL8qgH1zW548+HWl+NL+1vL+81G0uLe3mtQ1o8Y3RS43KQ6MB06rg+9ZrfB/QDaG3N5qmw2un2mfNjzssiDEfudTj5vXtigBr/Enwf4dttWuJrK70dkEeoXUUmnNbzTec5j80oQGZspySM4XNaeo/EnRbPT9SvYob68t9Pvzp0728SlRKE3t8zMF2gYBYkDJA6mpPFfw60LxT4n07XNWW4e5s7eW18lXAinjcMMSKQSdu5iuCME96yIfg7oEHhfR9Ft73Vohpd49/DeebG07yvu3M+5CjcNj7uRgc5ySASxfGLwi+lJqJurlLV9OfU0Z4CN8aTeSyj1cScbR6g9K6bxL4qsPDmj2t/qMd1m7mjt7a1iiLTzTSfdjVf73B6kAYPNee6p8GLN18BaZYyCXRvD17PdXEl5Jm4lV5PNEYCoFZTJjOcYCjGTmvQ/GHhiy8Vadb219Lc28lrcx3lrc2rhZbeZM7XUkEZwSMEEEE8UAcRqPxbgGs+GY9I068vbTUTqEV3bpbMbyCa1CZjCZADAsc54wODV7/hcPheabSotP/tDUJtRtUvI47W33MsbMUBYEjJ3Kw2rk8dOlNk+EWkgaZJY6zr1hf2Mt5P9ut54vPnlutvnSSM0bDcdoAKhcfliHVPgp4Y1Gy0qwll1FNL06GOGOzV4yhCtuzvZDIjMT8xRlzQAmnfGHTXj12XVtJ1Swg0zVzpKyLA8wmclQvAUEOS3KDJAwcnNbMvxL0GC01ee6TUbb+yrOK+uop7Ro5EjkJC/I2Dn5TwarXPws0ie71CU6jqyQX2qxazJarLH5S3KMrblyhbDbFBBJ4HGKTxr8KtI8W6pqF9dalrVi2o2i2d5FY3CpHOiklSwZG5Gfp6g80AT3/xK0uG9v7Wx0/WNTewVftMtlZtJFC7JvWNmH8RBHQHGRnFY3hf4rw67B4Vu7i1OkW+rQXk0sV1G7HbBGjlo5OAUAblivOCB0Nb0Xw7sLbXJ9QsNU1myiupI5byyt7hVt7p0UKGcbSwyAA21lDY5zVDRvhNommx6JC99qt9baRHdwW0F3LGyiG5jVHiO1ASoC8c5yxyTxgAW2+LnhqbTr69lXUrWK1sF1RRcWpRri0ZtomiH8S5I64PI4rZ8H+OdM8VahqVhZQaja3lgsbyw31q0DGOQEo6huqnB9D7Vz0fwc0EaVf2E+oazcpc6cukRSzzoz2lorBhFF8gAGQOWDHgc8V1Wk+FLHS/E2oa5by3LXd7awWkiOylAkO7aQAAcncc5J/CgCr4i/wCR78I/9vn/AKKFdVXK+Iv+R78I/wDb5/6KFdVQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVDe2tvfWktrewRXFtMpSSKVQyOp6gg8EVNRQB8qeKfh38UfCfxGbxZ4PjivrG2cpaWcF68nl2m4kQMkpBK8/dUkAn5cYGPXNJ+LltqFvGP+Ef1eG+h+XULSWMRvaPxlfmI39yMdR6HivTZlZ4nWN/LcqQr4ztPrjvXi+paDq3hhZG1KJr60Z2lfUoFLFmZiS0qdVJJJyMr7jpV04xk7SZzYupVp0+alG7Ow1HXNL8U3fh+ysryOW1lvDNcxN8r/ALpC6xuhwQd+xsEchfeuq1/Uf7I0me98rzvK2/Ju25ywHXB9a8O1HSdM1uKOW4hhn4zHMuCcex7j26VJFo9rHZralrqW2XpFLdSOn/fJbH6VssO0/I82WbxdNqzUvvs+53o8fXN2fJsNMjFwThd8+7J9MYGT+NSf8JD4r/6BNv8A9+2/+Lry3WU0jTLXEUNlDch0aNERRIzBgRgDknjtXb/8LMsf7p/78S//ABNFSdOk7OP5sWDwuNx0HONZ6f4Ym2PEPirIzpMGP+ubf/FVk6h4x8Y2s8m7S9MigB+VpkmHHvjIqu/xS0mNlW4u7O2ZjhftTGEMfQb8Z/Ct3TfF9reRh2jR4G6SwSCVT/n8aj21Gelrfh+Z1rLsxw3vKTmvlJf+S6mbYfEjVYf+Qt4eF1EOs2k3Idh9YpdhH4M1bEHxR8LNgXl1eaa3Gft9jPAo/wCBsmw/gxon0XStXjM+nusM3/PSHjB/2l//AFGuavba5064EN9Htz9yVfuP+Pr7VlVpzh70NV+J24HF4fENUsR+7k9E1rFv56p+TfzPTNI1vStaiMmj6nY6hGBnda3CSj81Jqn4U1t9Zt75LqFIL+wvJbO5hVshSpyjDvho2jcezV5Rf+H9Jv5xPdafbNcqcrOqbZVPqHGGH4Gul+FWjf2Z4h1q6XU7+4F5DDvhu5TMSyblDh2JbIUhTknPHPFYQrKbsetistnh4ud7o9OooorY80KKKKACiiigAooooAKKKKACiiigArmtR8IW95q91qUWp6vY3FyqLKLS58tW2DCnGDziulooA5X/AIQ3/qY/En/gd/8AY0f8Ib/1MfiT/wADv/sa6qigDlf+EN/6mPxJ/wCB3/2NH/CG/wDUx+JP/A7/AOxrqqKAOV/4Q3/qY/En/gd/9jR/whv/AFMfiT/wO/8Asa6qigDlf+EN/wCpj8Sf+B3/ANjR/wAIb/1MfiT/AMDv/sa6qigDlf8AhDf+pj8Sf+B3/wBjR/whv/Ux+JP/AAO/+xrqqKAOV/4Q3/qY/En/AIHf/Y0f8Ib/ANTH4k/8Dv8A7GuqooA5X/hDf+pj8Sf+B3/2NH/CG/8AUx+JP/A7/wCxrqqKAOa07whb2er2upS6nq99cWyusQu7nzFXeMMcYHOK6WiigAooooAKKKKACiiigAorzLwP8YNL8U6bcao2m3umaNBbvcve3UkLKFVwhBRHZxzk5KgYUnPSuoufHfhe2SV5tbs1jimit3kDZQSSruRdw4yV5xnpQB0tFchb+PtGv7zRE0m7tbu11KS5iMpmMbxtBGXdfLK5JGOQcEDnmkT4meDpdPe+t9etbm2SRIma2DTEO6syrtQE52ox6cBTmgDsKK4e3+KfhW68S6Rotpfm4l1W2Nza3ES5hYb9gQnOQxbPGP4Tkg1dtPiJ4SvPt5ttds5FsYnuJ2BO0RIcM6nGHUHglcigDq6K5ey+IPhO+V2s9fsJkSKWdnSTK7IgDI2ehCggn610Gn3lvqFjb3tlKJbW4jWaKRejowyCPYgigCdmCqWYgADJJ7VwfjPxnbPpf2Hw9epLqN4TGJIjnyI/4pfwHA9yPQ1d8fa61lDDp1lLH9quTtlHDNHGQedvvjFcJLZQvbRrNy0S4Eo+Vlx3B7VnKqoSVzmxFVwXLHdlLaLG2trSwtzJKxWC1t06u3YfTjJPYAk07xB4YmufhDe6wNQvBrUkG2NVmEcMUhkCZG0Alc5+9niuo+HFnbQzatrN9MbqayUxxSYG2OPbubaB/EeMn0A6ZNdd4ItNvgnR4ryNXeS2SWVGGQHcbyPwJ/Sumdbn+HY5sFgY0o81TWTPEbUWnwv+LLT3mmyz2MWkQxFoVLOrsEDzxhj+83MhDAZfpgHJB+gNG1bT9b0+O+0e9t72zk+7NA4dT7ZHQjuOorzzxt4NPiH4v+G7zU9Ii1Hw/Hpt1BOZkWRElPK5U9DgnDevpVnw18MU8J+Ol1jw3qt9BpFxHIt7pc87ypI+MI6kknI6fNk4Awe1YnqNppW3PRpEWRCkiq6HgqwyDXKan8OfCeoStM2i29pct1uLAtaSk+peIqT+NdbRTEm1qjyDxB4b1zwQP7W0S9u9Y0qE5nt5U33kEfdkYY85R1KMC2OhJ4rpPD2v6f4psFjbyZlmjEiFDujmX+8p/wAkV3deJ+P7S18FePdPv9NhhsrbWl2BII9oF3GSSxUD/loj8n/pnz1zWlF2ko9DizCCnSlVteS1fmuqfd2269NjX1PT3026aBiWj6xue6+/uOn/AOurXhi6+ya7auThZD5LfRun/j22tm+ZNY8OJdxqN+zzR7EfeH8/yrkssOUbaw5VvQ9jXFiIeyq3PpsnxCx+A9m3dpW+XR/12PX6KpaLqUGr6Va39o6vDOgcFenuPwOR+FXa6TxWrBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB49e/GFpLy4SxtrCytoZnh83U5nVnKsVJIC7VHHdj9BUqfEnVnUMk3hllPQi5cg/rUUqqut64FAA/tCU4AxycE/qTVVtMsGYlrG1JPUmJf8K5J1pKTR9Bh8tpTpRm1uvP/ADLdz8T9Sto99xc+F409WuXH9a2PAnxLHiHXotHurOITyxPLFc2js8TBcZDBlUqeeMFgcda56LT7KFw8Npbo46Msagj8cVs+D4jP45tSOFtrOaVvqzIqj8t/5VVOq5SsZ4zL6dKi6i0t6/5nqFFFFdJ4YUUUUAFFFFABRRRQAUUUUAePfD74Qah4J0W+0+w1/R3eezltY7v/AIR9FnVncNukfzSZQBuARuPu9lwc6/8AhLq3h7wxo2ieEb4XlpbeI7HUojcQIHtFT/WyO29fOG4BgoAbHygnjHuVFAHluk/CY2Wq6Xqc+uG4v4L/AFDUrx/sgRbma7g8k7VD/u1UBTj5s46jNPuPhZcHwB4Z8M2viAxDRmBkd7UtDeLhhtkiEgyMtkDcRkcg16fRQB5R4S+Ek3hmTww9pr6yHSbe6s7gPY4W6hnnMxVcSfu2Gdu7LeuBVOL4Jn+yJNNuPEbzW1vpVzpOmf6EFa2jmOWaQh/3rAAD+Ae2ea9jooA8i+Lvw4u/FGkeC9L05JXaxuUtry9jkWLy7Jotk4wTk7gFG0Zr0/Ub2z0TSzPPiK1hCoqoPoAqj8gBV6vLfH+uQahqH2aO5lXTLNWknmTCxiRTnlv9kA+3WplLlVyZyUVdnJeKNXv7icLbyuNb1aQxQl0XFvGvWXbjGEX16sVB61pXszhobaGVDdSMoCuufMBODwB+PFZHhlGu3ufEd+rRvdoBbI4wYLUcqMdmb77d+QD90V6X8PdGSTOt3PmtOS8duGXaFjz94Dqc+p9OK5Yx9pLU4oR9pPU3bLQzZ+EW0eJ4/MNs8XmBdqlmUjOPTJqp4O1qN7a30XUYzYa3aQrHJaSnmQKNvmRHgSIcZyOmcHB4rp6z9Z0bT9athBqlpHcIp3IW4aNv7yMOVPuCDXYd5oUVzS+H9UtFA03xNqAUdI72OO5X/voqrn8XNOWPxdF8rXOhXOP+Wn2eWHP/AAHe/wDOgDo6K5xpPFkI3m20S6A6xJNLExHsxVhn6j8R1qTT/E0EuoR6dqdrc6TqMmfKhu9u2fHXy3UlXPfGd2OSBQBv14xr3neNPj5omnPYX8Ol+GYJrmaWWPYk0z7QuCQQy424xyct2Bz7PRQB518Or4XFtf2ZUr9nndNjHJUhmR1/BkIrKu4vIu54u0cjKPoDx+lM8HTfZvHviBScJPqVzGB2B+Vv1OfxNafim3MGsM+PlnQOPqOD/JfzqsWlUp86/rozHh2bwWMeGls7r/26P4afM2vhD/yTjRf+ub/+jGrsK4j4OThvBKWhOZNPu7m0b6LMxQ/ijIfxrt6hbHTUVpNMKKKKZAUUUUAFFFFABRRRQAV5V8VNcv08d+FPDQ12Xw5o+pR3E1xqEJjSSV4wNsKSSAqh5yeMngfX1WqGs6NpmuWotda02y1G2DBhFdwLMmR32sCM0AeH614r8TaB4rvW8O65a+I7DTfCbalLJfzkRzCO6mDMohG1pdqBM8D5ea1JPjHqD6h51vplimmQTabbzW0szfbJWvERw0QAwQu8cEfNtJyK9WTw3ocaOiaNpqo9qbFlFqgBtySTCeP9Xkk7OnJ4o/4RzQ/t1pe/2Npv2yzjEVtP9lTzIEAwFRsZUDsBQB474F+JWoL401zw7debdFdZ1eUT3RY/uIGG22tx/G4BztzhV556VvfCX4ma1401WEX+kWtvpd5ZtdW08EhJjZXA8ptx+c4OdygYIxivRP8AhHNE81Jf7G03zY7lr1H+yplbhvvSg44c926n1o07w3oemajPqGm6NptpfzgiW5t7VI5ZATk7mABPPrQB5n4g+Kmq6Z4l1a2jsdMfT9N1e00x42mcXVwJ1Q5jXplS2cc5APTrVaL4s6ld6iIpLGyXT76bUrK3ihncXtu9qjtvkHQBth4GCuQcmvQNN8BaBY+KtT8RGzjutWvp1uPPuYo3a3YIExE23cgIUZ5PNayeHtFTUbq/TSNOW/ukMc9yLZBJMp6q7YywPoaAPGo/ih4kg0CyXRdP06c2/hKPxHcS6lcyu5UM4dAQMs2E4JI5PNdD4F8Z+Idf+J99aTy2EehPpVlfQ2jH97H50bN8pCgsc9cnAAGOprstf0nTNK8Paldad4a027mg017VLRYETzrdQT9mztPyHnCY25PTmrWj6f4fv00vXdN07T2f7IgsrtLZBIluy5VUbGVXB+6OOaANyiiigDxawka4+13cn+subueY+2ZGwPwAA/CrdZ+hssmmRSIco7O6n1BYkH8q0K86fxM+0wytSil2X5BWr4A/5HK7/wCvAf8AoysqrnhG4Fr45sgThby1mt/q6lZF/wDHVkq6L99HNmabw0reX5nqVFFFdx8oFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcp4t8Sy6dcLYaYkb3pUPJJIMpCp6cA8sccD8T772t340vSbq9ZDJ5MZYIDjcew/PFeVJ5rvJNcv5lzM5klf1Y+nsOAPYCsqtTkWm5jXq+zWm5f1DxLr5027iSaCV5IyFYZhdD6hhkfp+NebreweJbyLw/b209nHCRcatbzgh1APyxejB25LAkFQf71S/GXVzpHw71Vozie6QWkQHUmTg499u4/hXK/CnwDq0Ggtc6/czWd9IwlszGALi2+UDLP1IKqo8tsrgDIz0w5nKN5M5eZyhzSZ63Dbtqeq22mW8roZG2zCOPcVjIOWz0H1r2K3iWCCOGPOyNQi59AMV558MDHa3lza3rvLqbxgrcMcLLGp5AXopBOSO+fy9GrelFKOh1UIqMNAooorU2CiiigArnvH0Mj+Frqa3ieS4s2jvYgn3t0Tq/y+pwpGO+cd66GigCK0uIby1hubaRZbeZFkjdejKRkEfUGpa4zwRf2tlrms+FIbiOQae/n2qq2dkMnJiPvGzYx2Vo67OgDw5XaHxB4lkTie21mSTB7HajD81YH8a7zxMqXmjW97FyEKuD/stx/UH8K5jx3p50fx+t2o3WXiCLY4/uXUKY/J4h+Hle9dH4VYX/huWylOWj3wH6Hof1/Sro+9GUH/AEmc2Yt0a1HFU+qt/wBvQd196f3IxPhre/2Z421jSZOIdViXUrc9jLGFimX67RCf++vSvVK8M1q5fRptO1xgVfR7tZ5wM8QnMc/1xG7tj1UV7kjK6qyMGVhkEHIIrCk3y2e6PWx8Y+09pD4Zq6+YtFFFaHEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXG/D/8A4lN5rfhZ+F02f7RZj1s5yzxgeyOJYx7RiuyrjPGn/Em8R6B4lQYhSX+y74/9MJ2UIx/3ZhH9A70AdnWJ42vjpvhLV7pDtlS2cRc4zIw2oP8AvogVt1wHxQuTNeaNpIP7tna9mHqI8BAf+BuG/wCAVMnyq5pRpurUUF1OZs4FtbSC3j+5Eixr9AMVPRRXnH2yVtEFVrz7RGYLux2/bbOUXEAY4DMAQVPsyllz2zVmihOzuiakFUi4S2Z6foWq22taTb6hZMTDMucH7yHurDswOQR6ir9eRaLq7eF9Ua7JP9j3LD7ag/5Yt0E4HtwG9ue3PriMrorowZGGQwOQRXoQmpq6Pj8Th5Yeo4SFoooqznCiiigAooooAKKKKACiiigAoorlfEvimXTNSFjYWsVxKiCSVpJCqqDnC8A8nGfYY65pNpK7FKSirs1vFFnLf+Hr+2txmZ4jsHqw5A/EjFeYRyh2dCHSVDh45FKuh9CDyK6i6+ICW+nTPLp08V2B8gz5kRPqWHIA6nIHtXJxKs0pvZJBcXU2We44y+fp24GB2ArnruLSZyYlxkk0QahpVpqNzZTXsQmNnJ50KtyqyYwHx3IBOPTPrV6qtzeLbTxpMjiNwcSAZAPofTgZrDvdMm+2m68M6nLHqNy2fsmftEFw3vGTle2WQr6nNc6i2cyi3ZHeeDY3m8VQmNSywQu0rdl3cKPqefyNelV5t4W1xfCFr9j8a2D6PdTybn1Ld5tjMx4A84D93gcBZAvsT1r0eN0ljWSNldGAZWU5BB6EGu6nHljY9GlDkikOoooqzQKKK5/UvE0Md4+n6Pbvq2qL9+CBgEh95ZD8qfTlj2U0Ab7sqKzOwVVGSScACuPv9duPEcg07whK3kuStzrCpmGBR1ETH5ZJD0GMqvU9MGc6BqWuMh8WXNu9kDu/suzDCFj281zzKB/dwqnuDXUoixoqIoVFGFUDAA9BQBxWt6Lb+HNP0O60WzlI0u7BkMR3SvFL8sxbJy5JKse5Kg9q7aiigDj/AIpaLeat4cin0lBLqWl3C39vD084qrK0YPYsjuoPqRnjNcn4H1qCS+tbm2k3WOpxKyN05IyuR2PbHvXrleIeJ9Jbwv4ums7cgadqPm6lZAcGCUOvnxD2LSLIv+846KKqlpUTfXT+vmYY5OphJQW8feXqt1843X3HUeLtPRbhnZA0FypDqRwTjBH4j+tXvhBfyS+F30m6cvdaJMbAsxJLxABoWOev7tkBPdlapfETC78PwXajjKScejcf+zCuY8HXf9lfEaFGOLfWrU255/5bw7pE/ExtNn/cH4ZTXJV9T0MLUWKy9W3pv8Ht/Xket0UUVZzBRRRQAUUUUAFFFFABRRRQAUUUUAFFFUtU1Sw0m38/U7y3tIicBppAoJ9BnqfYUAXaK5rRPGmk6zqSWVmbpZJUZ4Wmt2jWVVxkqSPQ55xxWF8QtWuZtat9Gsbya2hjh+0XbW8hSRtx2om4cqOHJwQeB26y5JK5rTozqVFTS1Z6FXH/ABeW/f4beII9J0tdUuZLR0+ymQoWUjDFcAksBkgDBJHBzXlWmyM/jC8i03UbyK3t7KCTdb3b8ySPL1OTu4QcHjkGvUvhzrN3eJfaXqUpnurEq6TsfmlhkLbC3HUFWU/QHvUxqqTsb4jA1KEed6rY4f8AZg+IWtePtC1uTxHcRz3VncRohSMIFjZOOg5OVY5JPXtVy/ZrnxRrlzOxeZbk2yE/wRoBtUegyWP1JrpvCXgW08H+NfE+s6W0UGma3HFNNb9BDPGX3MvYKwfOOxB7YxxtjcXHiTxFrd34Y02a6sJbk4m8zbCSo2s+5uMsRnaueME4zSrRco2ReXVIUq3NPaxcqhY6HqltoI8S2glubK8ke4lsh8zpCT8ksfrlcMV7g5HOQZdTsNae5i0abS7m2ur/APdxToyvEqnG994PBVSTgjJxxmvZbaCO2t4oIFCQxIERR0CgYArKlS0fMjtx+YLmg6EttTyC2niuYI5reRZIpBuV1OQRUtdZr3ga2uZZLzQ5Rpt853OoXMEx/wBtOx/2lwfXPSuLuHuNOvVstatjZXb/AOry26KbHeN+jfQ4YdxWc6Ljr0O7C5jTr+69Jf1sTEBlIYAg8EHvXXfCgFfCrIhc2qXc0dvkkgRhsYXP8IIYDtxxXDX900ZS2tQJtRuDstrcH5nY8A+yjqT0ABr1rw7pq6PoOn6crBvssCRFh/EQAC34nJ/GtMPF6s4s5qRfLBbmjRRRXUeEFFFFABRRRQAUUUUAFFFFADJ5Ut4JJpmCRRqXZj0AAyTXkAuJL2ee+mBEt3IZiD1UHhV/BQo/Cu2+It75elRaeh/eXz7Gx2iXl/z4X/gVcXXNiJbROPFT2iFU5LLYxlsiIZc5IH3H/wB4f1HNXKK5U7HIm0anw8Vb7xBLNdKIZ7OL93CzAlmbILr6gAYz/tGvRobS3gctBbxRseCUQKT+VeQTgKFmWVoJYfnSZThoyO4P8/WvVPDt1cXuh2VzepsuJYgzjaV59cHpnriu2jJONkd+HmpRslsX5ESWNo5FV0YFWVhkEHqCKxdB8L6X4furiXRopbOCcfNZxysLZWzkskWdqE99oAPpWvc3MFrEZbqaKGMHG+Rgo/M1zb+Km1J2h8J2R1ZwdpvC3l2cZ/664O/HpGG9yK2Og80+DvxI8X+KtButa1OxN7HHZSzxWlvpclskrpLtxHdO5RzgN8oA54yMGodc+OEusafplz4E069mWTW7OyDTRhFu1k5eLew2xkkhASc8E9Bmuh8NfAzw3plncQ3r300NxGYnsra/uYbVEJyVVfMLEZ67mOfQVuah4T8CeH305bmxisEvNWtZLSGOSVImvo1PklUU7VOEOeAGx82aAPP5/Hd7qujXF54ltZzeQ6tNpD+H7a+FtH5kaBz86bpLjhl4Hy8n5cc1c8LfEy3N/wDadIs7bT/C6+FRrEent5VuFn+1SRNmToM7MZPB64ya9DvPhv4VvHkebTGEr38mpmWO6mjcXEihJGDK4IDKoBUHacdKhg+F3g2CwayTRUNq2n/2WY3nlYfZvNMuzljzvYsG+8D0PAoA4O/+NeoT6NNLo3h0LqVrq1nYXENxLuRo7jlWRjsOWHAJGBkHkVtt8S5dPvtagubK7utQGrWmlWmnlokVZ5oRJs8wfwjDEsc9OK6FPhf4RWw1CzOlyvDqEkM1y0l7cPI7xf6thIXLqy+oIPrVmX4eeF5rW+t5dMLpeyw3EzNcylzLEoWORX3bkYBR8ykH8zQByy/Ft7mTTbHTPDN5ea5d3F/ZvYi6iTyZ7Tb5imRjtIO8EEflXa+AvE1v4x8IaZr9nBJBDfRbxFIQWQglSMjryDzUOmeBvDml3GkT2GmrDNpXnm0cSyEoZ8eazEt87NgZL5NaPh/RtL8LaDbaXpEK2el2akRxtIzBFJLH5mJPUk8mgDUrhvjJpZvPBVzqVupN/oudStyo5OxT5ifR4y649wewrbtfGPh67u4re31a1kklfy4iG+SRv7qv91jweh5xWzdQR3VtLBMoaKVCjqe4IwRQBxHh6RdU8DhY2DkxOikdO5X9MVwuvT/ZYtL1JePsWo2lwTzwnnKsnT/pmz1u/A2WX/hEI7Sdt0tsqRuem5lGwn8SmaxfGdk0/hzXbKHIk+zzxR47MAwX8iBTxu8Zef5mfDLbjVod42/8BbX6nudFU9Fvk1TR7DUIseXd28c649GUMP51alkSGJ5JXVI0BZmY4CgdST2FI0HUVyNnea94mjS606aLRtHcloZmi825uUzw4VgFjVhyMhiRjgVZ/wCEd1KPEsHirVmuh/FOkDxt7GNY1GP93B96AOloqppa36WgXVZLaW6BIL20bRow7HaxYg+2TVugAooooAKKKKACsnxJr1l4esVub9nJdhHFDEu6SZz/AAqO5/QDkkVrV5Z8WtWjsPEWkG5hupIIbaV/9Ht3mKl2UbiqAnACEZx/FUyfKrmtCmqtRQbtc6XR/Hul3cy2+pLLpF2xwiXhUI/+7ICUJ9sg+1cN43v7GbxJreoyv9vtrG1RB5J83Yuws6oBxk8ZxyeK8+8WfFfQNMmjsYdl7NOmQX+WKM7sYkBG5T3xt/Ko9O8XX9vp3721tb61kU/vNO/dPyOqgkqfrketYSlKUbNHvYXLUqrqUHzKO+l7f5/JGd8N/iBo+tw2mkTvLZzaYqLa3skojkdg2xNuOQduM885Irp9W8QvpmrXFnpEcV3cZ829ubmVmYyN0UkclsD8BtFeTeFPDD6Prd+lwgktLu2DAN8wB3fMhPfH0712lvBFbx+XAgRck4HqeppSir6bHvZXk9Soo1MTo1dPSz02V+3W/wDw5578OozpPxG1TWru232lhcSpIIyfk3lhuA/iCjnHXBz1r65+Gkay6nrerFl+zxpFaI+flO0GRzn0+dBn2NeBRWMEKXSxrj7S7SSHuSQAT+QFaGi6l4guLOPwpLfRPp8ySzNDEPLecrtwJHHIU9DjHOOtWmubmZ5+a5LVwuHUaKum7vy10/RfI9oa9ufiNq32XTiYvBtpLi6uSMHUnU8xJ/0yz949+lei21vDa28cFrFHDBGNqRxqFVR6ADgVznhTxHoNxolutlJb6ckA8lrKVlja3YfwFc/qOCOa1dI17SdYeZNK1G0vHhOJBDKGK+/Hb36VufHtNaM0qKKKBBVe/srXULZ7a/tobm3b70UyB1P1B4qxRQBmaNoGlaKZDpen29q0n33jT5m9AT1x7dK06KKACiiigAooooAKKKKACiiigAooooA4v4hS6LHJajUp7m3vijeRLBGXIGRkFehGccdfp1rj7VpHt0aZdshHIxjH869a1GwtdStWt76BJ4W52sOh9QeoPuK4DXfDN5pBMtl519YclhjdND/8WPoM/WsK1NyV0c2IpuavFHI+I9Jl1OCGSyu3s9RtW8y2mXJUNjBV16MhHBH5YODTPDmuf2n51pew/Y9XtcC5tSc4z0dD/Ejdm/A4IIrVtWlv72C107yXklVnVpZNitj+EHB+Y56VWv8AwTf+KL5BbpLpGp2CsReyxn5cj/VHBG9GPXBxgZBzisI05S0sc0KUpJKx03hLRP7ZulvLpc6ZA3yKelxID+qKfzPsOfSK5bwN4hi1KCXSruzXS9b01VjutOzkIOiyRn+OJsfKw+hwQRXU12RioqyO+EFBWRFdW0F3CYrqCKeInJSRAw/I0S28Ulo9syAQMhjKr8uFIxgY6cVLRVFnz7pXgbx9beHPFCX8Kahf2liuj6NDcXnyXluLhpGmfa4w5Qqo3FT8mG4Jqv4a+H3i62GnQ3GmXUdhbeLLPVI4bi6gJhtlgdZW2o5UfOw+Vcn0z1r6KooA8E0v4feOkbxPZ/b5bW3sLG6svDlw13uMvnytJ5jkEsrKu2MFhkZyOldH8DfC+teHJtWOrWWoWENxHBiC4uYZYvNUMGaMRu5GQRljtLcZHFesUUAFFFcnrmrXmralLoHhqXy548C/1EDctkp/hXs0xHQdFHJ7AgFrVPELm9fS/D8C6jqq8S/NiC195nHQ/wCwMsfQDmooPCFtdSLceJp31y7HIW5UC3jP/TOD7o+p3N/tVsaHpNnommxWOnReXBHk8nczseSzMeWYnkk8k1foAqX2nWd/p0lhe2sM1lImxoXQFCvpj27elZHgSaX+xX0+6kaW50ueSwd2OWZUOY2PuY2jJ9ya6Kub00C08ea1AOFvbW3vB7uu+J//AB1Yv8igDh/hNHJZXWrWEww8NxcRf7wjuJEDfiOfxq1rUflardL6yFvz5/rSeGZGT4g61CylWW5nVgfRmEgP5Mpq14oAGryEdSqk/lTxy/dx+X5GXC0v9tq37zX/AJMmbPwgfd8NNAXduWK38hPZUYoo/AKB+FWPGqnUZdJ0EDMWo3G+69DbxYd1Psx2IfZzWZ8GnZfCl3anJW11O8jQk5+VpmkA/DzMfhWpbt/aHxCuJUGYtJsfspf/AKazskjKPcJHEf8AgYqU7q50VI8s3HszpwAAABgDtRRRTICiiigAooooAKKKKACuA+IWmai2t2OpWVlLe2/kNbSrBgyRnduDbT1HUcdOK7+vGr/VtR8QLJcapfvDYK77bS2YwxhVYjLsDuc8Z5IX2rOq4qPvHZgadWdVOluu55Z8UPB+la1MPEFzBeGaCX7NeQyblMSLlfujkbWwT2wSax9A0LTtKTfpTSiGQZ2idnRvfBOPxrpde8SfZdRn03R9SsrKxjVWMkRVpHZ+WO5iR+hPPWsfToLePzpbaXzfObc7hgQW/DjNYq9rH3mS4a0vayhF366Xvs7bu3rbuXaKKKD6gKj0173S7u6n066WN7kguZIVdgAOFBP8PfHuarW2p2N1K0UF3C8qnDRhxuB9x1qTUJ0t7KaWQMUVSSFOD+fb60eRyYiFDEU+aprGOu/+Re/4T/TdJuXi8Ymzcsm6K4ihy7Y/hZBk/Rhx9K2LLxt4d1jSrPVNM1CC01NMvaIxX7REysQAUBJCnHI6FTXD23wwtdV1eBLrQ5bWIt5lxc/aSVZMcbCGO4kkduMc16JoOmaboXhyXRPDa3V4GaSOGMAyEyMSNu4DGAepPTnNS1G65dz4bE6Tmm4qm9t38tUmz6E0y4a7061uXUK00SSEDoCQD/WrNVtMt2tNNtLZyGaGJIyR0JAA/pVmuw+TCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAyZPD2mPrMWqfZVW9jJbevAYkEZYdCeTz1rWoooApT6VYz6ra6nLaxNqFsjxw3GPnRGxuXPocDj2rw7RPix4lm+JL6bfrZJoR8S3WgiRrGREXZnygLgOVMrdNhXtnPPHv1eU2Gk/DCPxtcTWcRn1yPV2llUSXU8MeoOSS20kxLJkHnA24A44oAgsvjdpx1W/ttQ0ySG0t7O5vY7u2uFuEmWD76ggBd2P7rMM8EijxH8S/FNhpOg30Hg9YF1TUrK2iE95HJ5sU+75RtK7JOAOcqNw684v8AhXwt8MmubafQ4rRpLpbyztreW7lKyJnFzHHBI+NgPUKuBntmthfhb4QXTZrAaZMbaSSGTDX1wWjaEsYvLYybowu5sBCAMmgDDj+L9vJ40XQo9DvXjXUE0ue5RwxhuCBn5AOY1LBS+R64xzVW3+KVzrNj4Y1C20nUdL07U9bi06O4Z4JFufmnV1xksqgxcthT6ZHNdl/wr/w0NbXV47CWO+EkcrNFdzIkjx42NIgcLIwwOWBPFS23gbw7baTpGmQ6dtsdJvf7Qso/PkPlT7nbfktluZHOGJHPTgUAcz4c+K1vrHjyLw22mGNblrlba9huVnjkMH3gSAADjnhmxkA4r0uuQ0b4ceFdF1u31bTNMaC9tmmeAi6mZIjL/rNkZcooOegAHpitvxFrCaNp/neU9xcyuIba2T708p+6g9OhJPYAk9KAM3xNfX93qMWgaFMsF3LF511eYybOAnAKjoZGIYLnj5WPOMHX0PSbPRNNisdOi8uCPJ5O5nY8lmY8sxPJJ5Jqr4Y0iXTLaaa/lW41W9k8+8mUYUvgAKvoigBR7DJ5JrZoAKKKKACub1L9z4+0OUfdnsru3b67oXX9Ff8AOukrnPFX7rWPC1z2TUjGx/2Xt5lH/jxSgDmYUjh+KuqkDDTMpPufs8Y/ktL4pQrqzE9GRSP5f0qldXJHxevYVHKNC2f96ED/ANlrV8YAfbID3MeP1q8X/BT/AK3Ofh52zOpF93+SZJ8Hf+QHq/8A2Frj+a1s+DAA2vEAZbVZyT68KP5AD8KxPg64/snXYv8AlpDq8wcem5I3H/jrqfxrc8G/8xz/ALCk/wD7LWUPhR3Yj+LL1f5nRUUUVRiFFFFABRRRQAUUUUAFfPt5peqXQvdNiv7a0so5ri2m/wBG8yVsSuDgltoBXB5U9a+gq4/W/BEV9qtxf2Ooz2MtyQ08axq8bsABuAIyDgAHBwfTPNZ1YOS0OzBYiNCbc9muh8i2vwZvdHuEudSg/tWAsQsNo/K8nBcHGQRjoeD1yOa7GexvdHjtY73TfsdtJ+7jMbKyo2MhTt6d/bivc9Z8Ef2foN9fR63em/t4nnEkpQQnapO1kC8Lgdc575r5u+NXj0y3VhomiJP/AGijLJLlSFV2X5FUfxMN3XGOR1PTNqd0me9l2a0sHFujok1fRXfz3/E6AHNLWTb6PqPh+PTdPvbmNbghpJoVHmHYAMyM/qzlvwH1q14dn/4SWaxTT5xBDctL++ZN52xkjIGR1x37HpU+Z9nSzSlOk6jTVun3Xt82lrYfeWNrertvLaGdewkQNj865vWYk06CWTShqW2JhHKIJd0SMRwpEgZAT6cdvUVueJ4LvTrPXLKSYNc2sLNFOg27gU3I2OxB4P096t/A/WF8RLqbNGnlmKM3cLKNvnZIDAehVf0FO9lzHnZjjqcowVKylLW9tbK6dvNP8LnAeE/itfaG02mx2YuILhwkayyGAwMRt4OSAO/QDjtX014X+KNpouladY634c1HS9Pgt0j+3W+27thgAbiYiWCn1I+vrXOS+D7PWZbfXYPCn2qGwnYRXVuEDuVyCRGCDIobI7nIyBWfqGleG2tZ5tMVba8fMYgspWt2mkPHlvECAxJ4IZafO4u6W58bOgq6kp1E+W9ulu/Q980TxRoWuuyaRq9jeTL96KKZTInsyZ3KfYgVsVgXXhTR9V0uzttf0uw1F7eJEDzwK5UgAZViMjkdRVEeClsx/wASDXtc0rHSNbr7VEPbZOHAHsu38K6DxTraK5D/AIrjTm5/sLXYB/10sJsf+RUY/wDfA+lOPjZbIf8AFQaFrmkgdZWtftUX13wFwB7tt/CgDraKytC8R6Lr6M+iarY34X7wt51cofRgDkH2NatABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV4Povw613R5EfT7Ca3Z/HR1Gbbeg7tNXzdjEF+R84yv3zkZBxx7xRQB89aL8NdcstW8D6jfaDLc/2dqGpm8iivkRo45pt8Ev8ArACoyWIBLYOCD0qjovw88d2S64buPUpdYn03UbZ76K+hEN/JJG/kscyeZu3bNuVUL64FfSdFAHNfDrw+PDnhOxtZFuVvpIo5b37RdPcMbjy0V/mZmwMrjCnaMcCuloooAR2VFZnYKqjJJOABXK+H93iLWP8AhIpVI0+FGh0pW/jU/fuMdt+AF/2Bn+MipPHcjXdna6BbswuNYk+ztt6pbjmd/b5MqD/eda6WNFjjVI1CooCqo4AA7UAOooooAKKKKACuc8d/u9N0+46eTqlic5xgNcIh/Rz+FdHXO/EIN/whupzICTaot3gdf3TCT/2SgDhbtWHxm1BiPlJtgD7iM5/mK3fGI/0uA/7H9aiRINU+IVxc2uGhhAZnXo7BQvX/AD0o8WTCTUVjX/lmmD9Tz/hV4v3aKj/Xc5eHb18ynVWyb/BcpH8J+Nd8WqOFM1s5HuYsZ/JR+VdL4IPmWmq3C/6ufVLoofULIY8/mh/CuO+GuoQ2XjrX9OuZY45L21t7233HBcJvSQD124jJ/wB+ux+HZ3eCtKlAIWaMzrkYJV2LqfxDA1jT+BHqY1WxE/U6OiiirOUKKKKACiiigAooooAKKKKAOH+LK3smiWyQW1zcad526+S2Uu7RhSQCo5KlsZxngc8Zrxzw54S/4TzXrfUZBavqsTC989x5sdiqf6q3+Vhlstubrzk9lr6brlviJeNpPgzVJbSMo8w8ppY14i8whWlbH90Etn2qJQTd2dFLEShB04rc+a/i1b3beFJ9f0tLpry5iENyluBLEkaht0m7GQoG7n3BqT4H6ObPwpYXL2F0+ttcvZxQzuYwhZ/Q8KMck4J4OPSuv8X3FkfDaafbTweVPLb2pCuCEiMihyfQBN1dFpkJ8S6pp9tpfmSQJcx3E15Ep8uFY23/ACv03EqFGCepPQVzRbklGx71eXsr1HPVR0XS710XrqUPFPgsQ6hB/wAJDYaXcy38TxrNEXYoyr0KsADweG4PHQV5/wCBPBcHgHxDfx2xutSv5LFZrfEgiEwDYlXaTtyDsIyf4xz3r6V8aeH5NetLU2c6W99aS+bE8gLIQQVZWA7EH8CAa5y0+HJvL2K58R3qSiEFY4LJTFw2N26Qnfg4HC7enOa1lTd7R2PPpY2nyKdXWaemhlfBfxFHqOq6npVjc3JtLSISPZXSbZLSVnOV5GcdTjJHocGvU/slt9q+0/Z4ftOMebsG/pjr1rC1HwVoN5ZW1ulilk9pk2txZHyJrcnqUdcEZ7g5Ddwazv7U8QeFjt8Qwvrejr01Syh/0iFfWeBfvD/biH/AB1rZKyseZUnzycrWudrRVTSdSstX0+G+0u7gvLOYZjmgcOrD2Iq3TICiiigDH1vwvoWuur6vpFjeTL92WWFTInur43KfcEVkHwZNZnd4f8S65poHSGScXsP02zh2A9lZa6+igDkjL4204fvLfQ9ciHeF5LCXHsjeYrH/AIGo+nSkXxzb2vGv6PreikdXuLQzRD/trAZEA92IrrqKAM7Rtd0nXITLo2p2V/GOrW06yY+u0nFQeLvEem+EvD13reuTNBp1rs82RULkbnVBwOT8zCk1TwtoOq3kV5qGkWM95EweO5aFfNQj0cfMPzrJ+LPhm88YeAtQ0PTZLeO6uJLdla4YhAI545GyQCeiEDjrigC9pHjPQtXvja2F8sriwj1PftIT7PJna+48djx1HetK31nTLm0iurfUrKW2lfy0mjnVkdv7oYHBPB4rxWf4G30d143ttM1O1t9G1i1ji06Fi5Nrtn89omXGPKLbhwSdrHircvwj1PUp1udTj0GOK48RWmq3WlQb2tEt4bdomVAyDe77gSCqg+tAHrza3pSSwxNqdiskxURobhAXLDKhRnnI5GOtMk8QaNHpy6hJq+npYM/lrctcoIi3Pyhs4zweM9q8m8X/AAbk1nV/Elza22hJBePpS6ckkZBtobbiaMAIQgZQAAvBAwcUXnwq16HStRsdJk0WOzuPEs+rLZ5aJPszwqioHEZMTghs7ByDjcMmgD06DxVplx4rh0C3kaa7m046nHLHhoWhEgj4YHk5Yfh3rM1z4jaBo3iSTQbn+0ZtTjjSV4rSwmn2K/3SSikAVyHwj+GWs+DtY0W61O50+WKy0W501xbyOxMkl8bhSu5R8oQgHPOexHNad58MYtW+LOo+KNa2y2ElpbxWscF5PDKksZyS4QqCvTgk/SgDWs/ij4WuvETaKl1dJdi/k0sSSWcqwtdJ96ES7dm72z3HqKksfiRoF/4hbSbD+0LkrcGze9hsZXtFnHWMzBdu78ce9eeaZ8IPEGmeOG8Sw3+n3J/4Sa81T+z7ieU2/wBmmACuF2YW5X5uQCPu/NxWp4c+H/jbw80eiaTr1jaeG4dQmu47uEn7b5chLGJo3jaJ8E/eJ/AcYAPYqK5EJ420w/LLouvQDtIr2E+P94eYjH/gKD6Uf8JutkP+Ki0LWtIx1la2+1Qj38yAuFHu+2gDrqKzdF17SNdhMui6nZX8a/eNtOsm0+hweD7GtKgAooooAKKKKAK5s7c6gt8YVN2sRhEvcISCV+hIB/AVYorm/FHjTRPDXmLqNyxuEj8wwQoXcL2J7KDjgsQKBpNuyOkormfDHi+21y8eye0ubG/RPM8mcqdy5xlWUkH+lcL421mLV9avpTcPLo+kxsii3LASS4zIcgjcV2hRjgHd36RKaS5jalhp1Knstn59D11Jo3keNJEaRMblDAlc9MjtT6+VPh7rnhjxJrutLpjAy+YskEYieNlhEcYZt2BjMhbPOTwT2r1zwrrOpaW8+mxu19Ey+ZAbufH2ZQDuy5yWQYB5ORzyeMFOXPLlS1DGUVhaPt5SvG9tLvX5Hpc00cETSTOsca8lmOAK8++KPjOPRdL8l1MMd0m3LrmSUHICJH1JboB19u9Zz+MJdRntpfDhg1dxmSTU7yOSKwgGOEhAGZXJI5XOBklhwDa0jSLbTruPxF4mvG1XxLLAqiaSNVEC85SCMD92vJySSx7sa3hKEJa62PNr0MTiKVoJx5nbTfz9Plt3J/h9a3ml+GnvtdtUsrucmQwB9zRx/wACsem/nkDjJxzXL6/4l0uxvC+q6jaWsk0mAssoByeR9Bjv0qfWPGkd1oi6nfA21oCQkCEuzvuKqoAGWcngADqa634a+E49O0Bb3W7GBtd1ItdXjSRhmj8wACDJGdqIFTHQ4J71z1ZvES8kevl+Hjk1FNJc8unZHmXjm2jv9HtltmA1CSdBYTo2DHIerBh/Ds3Z9VyO9eg+FfiDZwfY9I8SWI0K5CrBbyeZvs5iBgKkvG0nHCuFPYbq4Xxv4fi+H3iHTLqCV28Ku8rJb7C505iuGIPaDn/gGT/D02pore9tWjmjiuLaVcFXUOjqfUdCKw5pUdOh6vsqWZRdRO0l/Wp7LRWP4Ptrez8M6dbWcYit4ogiIvRQOwrYrqTurngTi4ScX0CiiimSFFFFABRRRQAUUUUAFIyh1KuAykYIIyCKWigCiuj6YjBk06zVhyCIFBH6VeoooAKKKKACiiigDldV8Hx/b5dV8NXbaJrEh3yyQoGguj/03hyFc/7Q2v6NUNp4wk066Sw8aWa6PdOwSK9V99jck9AspA2Mf7kgU+m7rXYVDd20F7bS215BFcW8qlZIpUDo4PUEHgigCaiuK/4R3VvDGH8GXCz6cvXRb+VjGB6QSnLReyncnYBetavh3xXYa1cy2RWew1eEbptNvVEc6D+8Bkh1/wBtCy+9AHQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGHrXhLQNamE+p6RZz3K8rceWFmX/dkGGH4Gs3/hEtRsOfD3inVbVB0t78i/h/EyfvfykFddRQByJ1Hxlpv/AB/aJp+sxDrJpdz5Ep/7YzfKP+/ppU+IGiQsE1prvQpScY1a2a3TPoJT+6P4Oa62kZQylWAKkYIPQigCO1uYLuBJ7SaKeBxlZInDKw9iODWH4r8Tw6A1rCtu93e3JYpBGwUhFHzOSeABkD3JFV7rwD4ckuHubTT/AOy7xzlrjS5Xs5GPqxiK7v8AgWRXkPjyDxVpHjO5GjXVxrqQW8cW2/WEuqHLhQ4aLux5O48DOamcuVXN8NSVWoovbyPU7H4g2BlMesWlzpjfwSOvmxN7b0zg+zAe2a8n+IN6z+GvGGp6ZaRXi3UsxCzhkE0RAQnpk8Zx64ryPxd8V9Xj1yXStb0kWUNvIpkhhnzIG2d2HDDnOB+ZxW1pPi231Kxeyt9TkiiuAM2t2MOOf4d39CRWMuaSVz3MDgqU5y9hPXVWej9dbL9fIk+FXjk+IrSceLgsjW8gWC5WPHl/JjBK/Nk8898kVsyaleXURWKeSzsipSK2hAQJHzgH1OMZrn9E0RNI1XVJrYKtteFJAg/hf5tw+nIP4n0rYkkSKNpJXVEUZZmOAB6k1LSvofV5dkypR58T7z1X47366bX2uct8FYpvC0EupToWS7kMcyBAWESkgMO/3snHcY9q9PbU9P17W0s57P7VpsriMtOxCvng4T+7z3PPPGK8K1DWfEmqa8NJ0d0t7V8tFLBEUBhzjfuPOPcYz2zxXpfg/wAOWRsbq3uNV2XMfTzpCHmfGfMc5BK54AB49a0u4PnW58/WwmCq0vZuEpQg+9k5rVNO+3Xt69fVtX1D+z9Nur6dHmS1hL+WCBkKOFGeAO3oK4DSdd8S+I/FelNcrPY6ZKsl2BHHhJ4kynLuA7/O0fIVVIBxu6j0vSr3wffWK3PiO5tWk80SnTJFMhgePBwVG4yDdhlJGD8pAqpe3drrHiy91KwkkldrSG3isjC0c0KRlyQIyAcMz9Rx0GeKy9nyxberOD657avGMfdgt+nyM74Z2Y1TxvbWbqGt9Clur6QHtJJI6QA/8BaY/VAfp7vXm/wS08Q6fr+ozWk9re32pyebFOMOioAqKR+bf8CNekV0Qjyo8fE1PaVG+my9Ec34hRG8U+GlmVWika5hIYZDEwk7fxCt+RrkdW+HN7oxebwPcQi0HP8AY16zeUvtDLyYv90hl9NorsvHEEzaIt5aRPLdadPHfRon3mCN86j1JjMige9bNjdwX9lBd2kiy208ayxuvRlIyD+VVKKkrMilVnSlzQdmYngC5urnwxatf6ddadcKWVre5ADqc57EgjnAI64roqKKErKxM5ucnJ7sKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWT4i8PaZ4hto4tUthI0Lb4JkYxzQP8A3o5FIZG9wRWtRQBxQuPEnhTAvln8S6Iv/LzDGPt8C/7ca4E4H95AG/2WPNdLoes6dr2npe6PeQ3dqxK742+6w6qw6qw6FTgjuK0Ko2+kafb6rcanb2cEV/coEmnRArSgdNxHXHqeaAGz63pkGqSadNf20d/Ham9e3ZwHWANtMhH93PGam0vULTVdPgvtNuYrqznXfFNEwZHHqCOteTfEHwBrniP4rXWrWVxqOn6b/wAIs9it1Y3EKNNceezCBg4J2FWBJwBwPmHSuCu/CviPSY/hx4XjuZbC91zTzpeq2qT5aCKCZZnmQoSobYXTIPIYD6AH1BRXzldaLrWv/EzxPbaHaXZnsNdsZItTN9si0+FYo2kURlssXXIwFIOeSMU6P4f+N4vEusXc8epT3sp1Dy7+C9hWG5jlicRI4aTeMEoAu3CkAhhQB9AXWpWtrf2VlPIy3N4XECiNiGKLubJAwvHqRntUt5cwWVpPdXcqQ20CNLLK5wqIoyWJ7AAZrx7SPAuu6X/wrl7WG+822tLh9dMuomXFw9iI1HzyHI8wYATKjrwOa5SP4VeJY/DdlELC8a/u/DN9aaqsmp7/ADLsqDbKcyEH5h1HyjoeKAPb/Dnjbw94jvFtNG1EXNw1t9sVPKkQmHeUDjco43Aitq+v7PTxAb+7t7YTzLbwmaQJ5krHCouTyx7AcmvDj4A8S6Wkp0TR4ZCPBMWlpHcXfyteee0ksZIfd0ZiDkLnAyBXNR/C7xVJpl0lzod7NaW+uafqNtp8l/BG7wqhFyqbJNiMTjGWHTgk8kA+lLPUbW8u7y2t5GaazcRzAxsoViMjBIweD2zVuvC9a8G+LLm71iQafcz6PJrVndnSv7QRWu7NLYI8QbfgYkwSrFQ23OemU0z4deIL5vBVj4lhupNEt21U31suot/o0Uuw20LurhpNuCOMgYx0xQB7rRXmHw20/wAf6J4B0KwvYdKa8trfy5o7+5cyghmwDIm9SAu3GM8cV0n2rxwh/wCQN4bmB/6i88WP/JZs/pQB1dFcp/anjFRiTwxpLMOvla0zA/QtbqfzApf7d8Spy/g+Vl7iLUYC35MVH60AdVRXKf8ACS62hxJ4H1xvQw3Viw/HdcL/AFo/4S29UfvfB3iVCPvDZbPj/vmY5/DNAHV0Vyn/AAmka8y+H/Esa/3v7Nd/0XJ/Sj/hOtMU4m0/xLG3UD+wL18/ikRFAHV1574w8Pat/wAJBcappsdvc2txColR5RE0TIMZyeCpB9sY9+LOufEvRNO0W9vI01N5oImdYpdLuovmA4DFoxtGepPTmvOJ9RsL/SZ9b8Q6kb6EHdPNMXEKYP3VjPAUEjt7nJrKrKKVpHdgKVWdTmptK3VmJ4g0yPUPsmsWENnDLKrCWOUpGzHPXd0JB4/rXNmOC/tV8+FJYnGSkihh+INZE3izQLq7mnn1G1aR3YKMcIuTtVRjgYxW3CySQq0WRGwyOCvH0rK1j9FyaLdOznGSavZWdm/61RmyXNnpAWxsLcyXDfMlpAORnueyr7nA9PSoLi1HkPf+JJ4zFCPMFupPkRY7nu7e579AK09PsLewiKW0e3cdzuSWdz6sx5J9zXC/FOHWL2S1srGMy2jI0pihy0jlSMkj0GRjHc/SqWrNsdOWGw7qyjzW2itvK/f8uyudxpF2uoafb3yxeWJ03KD12npn8MGrMoj2Fpgm1eSWxgVDptv9k061thx5MSR/kAP6VJOkUvlx3LBLd5FWVim8KueuPyqep2ym6WH56iu0rsyLT4oaL4Se9ig3ah5ihkhtyNquM5+foARjpn6V6X4Y8Z22o3fhfVba01CNmngeSQ2kqxRrKNkgMjKFYAOeRkEgViaR8P8Awz9mub7UbfTL+3ZcpIkCoqxjnJI7+vtXZaZolzJpWn6bo2h39vZM0QiaWMpHHHvB3Esc4Aycde1LRyTij4DF1G1N1JRUZJ2X9M9O8BfPoUtx/wA/N/eTj3VrmTb/AOO7a6OmxokaBI0VFHRVGAKdXWfMBWP4c0iTRvt1tHKrae85mtYsHMAblk/3d24j0Bx2FbFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAFbU7OPUNOu7KcZiuYnhf/dYEH+dfO9z4dl8S6C8Oo6tfCKa38lrWMqkaSBdrbiF3NhwTgtj2r6RrldQ8C6Rd3092jXlrJOxklW3uGRHc9W28gE98YzWdSDlsdmDxMaDfOrpnzj4c+DVlos8covhPMEG6aSAFg/+wM4UfmferHiC1i0O9MU18skSwebIzgL5fOOa9g8beF7Lw3pttqmjsYpIZFhmimleRrsSMo6kk7weR7ZHA6fMHi+LWvGvxZTQryE2di1wInWF96skY3MxboW2np2JAIz1y5Zc3vM93A5rHDwjKhF725buzvtfodpbzJcW8U8RJjkUOpIIyCMjg1UtLSRdTvLy4KlnCxQgHO2MDP5liSfoPSp9Un07T3vbm3jFvp1mhiHJJbYSCxz3J4A9h61r/De3sfEmmSaheWyy70iKgscISuSo/E0m7K59ZPM4+yp1Jx956pX9VfbbsUM9Peq2o2/iKLTbe/0rRU1SCYE7YrjY6ckcqV56dqxfHC3ln4cu5LSO6S6sJBKreWx2BXxlj6bSevXNd78Htfs9Y8GG5jlRZopHa5hH/LEkk9PQjkH6+lEvdVzixubuc406E+V2vpZ79NU9V1XmeceGviLqL3aeGLnRPsbSyu1w0kUsrx/xHMSrnAAwR6ZJxX0f4a+MGn32pW9hqLWKyzzLCslvcjKluF3xPh1G7jOCP1xlQeHtYu4rTXX8O2txIYvNt3ilX7THE4+6QwHzbTkgNjnHWm29o/iLU7PT7aznWUSiSaS4tnT7KikFidwGGONoHcnPQGqTkntufIVY0q0JTnVu1t0f9XPbKKKK6DxgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPOPi1pGtXz2l3pULXEVtDKFEaCR4JmwBMI8jzMDIwDkZOAcmuQ0HQJ4PDV9d2ssml6Tptu8sU15bkyXUvzF3YMAeT1PUljXu1cP8Wrp4NEsonwmnzXkYu5yeI1XLqD6BnVQSeOx61nKCfvM66GIqRSpQdrvc+dfjnompajoVi2kaVGZbqaP7XIrhXZ2IVECk85Y8nttHbNd58NtO1RvDXhjQljjsL97cpK06FvJCLydoI3MeO4HNS6xJFqGqaPHbTLcJa3JuZobZWmkbEbqgCoCfvMD/wGu48FaVqNx4kg1K4sZ7KytYpFU3K7Hld8DATOQAM8kDnGO9YQTlZNaHr4qcKPPUhP3mklsc34t8OP5mo+G9YuTdWd7ab47iNBG4VsqwI5G4EAg4xyPSuT8EeG9M8G32tWMNokNqVjnjvZR9+JhgxtIeMqyscccOOK938V+F4teltLhLqSzvLbcqzRqG3I2MowPUZAPsR9aq6R4E0mymS4vvN1S8Q7llvCGVD6rGAEX64z71bottpbHJTzGMYRlNXmupT+Ekl0fD88TI40qOYjTnddpaI8kDPJQMSFPHGO2DXcUUVulZWPKlLmk5WtcKKKKZIUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSOqujI6hkYYKkZBFLRQBFbW0FrGY7WCKFM52xoFGfoKloooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This diagram shows the presence of auto-PEEP and dynamic hyperinflation with and without expiratory flow limitation. The diagram on the left displays the circumstance of expiratory flow limitation as reflected in proximal airway collapse (\"choke point\"). In the diagram on the right, expiratory flow limitation has not taken place although the patient manifests auto-PEEP and dynamic pulmonary hyperinflation as a function of increased expiratory resistance from the endotracheal tube, exhalation valve, and bacteria filter. The application of PEEP in the patient with expiratory flow limitation would be expected to improve expiratory airflow. However, in conditions without the presence of expiratory limitation, the application of PEEP would potentially worsen dynamic hyperinflation and increase the risk of barotrauma.",
"    <div class=\"footnotes\">",
"     PEEP: positive end-expiratory pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Puritan-Bennett 1994, Form AA-1888.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10674=[""].join("\n");
var outline_f10_27_10674=null;
var title_f10_27_10675="Extracranial vertebral arteries";
var content_f10_27_10675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F59642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F59642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Anatomy of extracranial vertebral arteries",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 510px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10675=[""].join("\n");
var outline_f10_27_10675=null;
var title_f10_27_10676="Carbidopa: Patient drug information";
var content_f10_27_10676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carbidopa: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3221?source=see_link\">",
"     see \"Carbidopa: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F146016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lodosyn&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Parkinson's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701715",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carbidopa or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Glaucoma, melanoma, or skin spots.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with a drug called levodopa.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11487 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4D6C774D8A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10676=[""].join("\n");
var outline_f10_27_10676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F146016\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014600\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014599\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014604\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014605\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014607\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014602\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014603\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014608\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014609\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/9/3221?source=related_link\">",
"      Carbidopa: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10677="Olmesartan: Patient drug information";
var content_f10_27_10677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Olmesartan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8583?source=see_link\">",
"     see \"Olmesartan: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/17/2326?source=see_link\">",
"     see \"Olmesartan: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Benicar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F6860832\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Olmetec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019259\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olmesartan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019263\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10922 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10677=[""].join("\n");
var outline_f10_27_10677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203488\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6860832\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019259\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019261\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019260\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019265\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019266\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019268\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019263\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019264\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019269\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019270\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/24/8583?source=related_link\">",
"      Olmesartan: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?2/17/2326?source=related_link\">",
"      Olmesartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10678="Raltegravir: Drug information";
var content_f10_27_10678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Raltegravir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/59/30644?source=see_link\">",
"    see \"Raltegravir: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F5374882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Isentress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5937103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Isentress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F5374886\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Integrase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F5374921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Oral: Film-coated tablet: 400 mg twice daily. Recommended as a first-line therapy with tenofovir/emtricitabine in antiretroviral na&iuml;ve patients (Lennox, 2009; DHHS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for rifampin coadministration:",
"     </i>",
"     800 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5374920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV treatment:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 2 to &lt;12 years: Chewable tablet: Weight-based dosing based on ~6 mg/kg/dose twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     7 to &lt;10 kg: Canadian labeling (dosing for &lt;10 kg is not found in U.S. labeling): 50 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     10 to &lt;14 kg: 75 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     14 to &lt;20 kg: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     20 to &lt;28 kg: 150 mg twice daily (see \"Note\")",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     28 to &lt;40 kg: 200 mg twice daily (see \"Note\")",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &ge;40 kg: 300 mg twice daily (see \"Note\")",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Children 6 to &lt;12 years who are &ge;25 kg may use either weight-based dosing (chewable tablet)",
"     <b>",
"      or",
"     </b>",
"     adult dosing (film-coated tablet).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adolescents &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment for rifampin coadministration:",
"     </i>",
"     There are no data to guide dose adjustment in patients &lt;18 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F5374922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F5374923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F5374924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mild-to-moderate hepatic impairment: No dosage adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe impairment: No data available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F5374928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isentress&reg;: 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isentress&reg;: 25 mg [contains phenylalanine 0.05 mg/tablet; orange-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isentress&reg;: 100 mg [scored; contains phenylalanine 0.1 mg/tablet; orange-banana flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F5374884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9613920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F5374887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of HIV-1 infection in combination with other antiretroviral agents",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F5374898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (4%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Glucose increased (126-250 mg/dL: 3% to 10%; 251-500 mg/dL: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Lipase increased (1.6-3 x ULN: 5%; 3.1-5 x ULN: 2%), nausea (3%), amylase increased (1.6-2 x ULN: 2%; 2.1-5 x ULN: 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic:  Absolute neutrophil count decreased (grade 2: 3% to 4%; grade 3: 2% to 3%), platelets decreased (grade 2: 2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: AST increased (2.6-5 x ULN: 4% to 9%, 5.1-10 x ULN: 2% to 4%), hyperbilirubinemia (1.6-2.5 x ULN: 4% to 6%; 2.6-5 x ULN: 1% to 3%), ALT increased (2.6-5 x ULN: 6% to 9%; 5.1-10 x ULN: 4% to 6%), alkaline phosphatase increased (2.6-5 x ULN: 1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Incidence of liver function abnormalities higher with hepatitis B and/or C coinfection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Creatine kinase increased (6.0-9.9 x ULN: 2%; 10-19.9 x ULN: 4%; &ge;20 x ULN: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2% (Limited to important or life-threatening): Anemia, cerebellar ataxia, depression, drug rash with eosinophilia and systemic symptoms (DRESS), gastritis, hepatic failure, hepatitis, hypersensitivity, myopathy, nephrolithiasis, psychomotor hyperactivity (children), renal failure, rhabdomyolysis, Stevens-Johnson syndrome, suicidal ideation/behavior, thrombocytopenia, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F5374893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to raltegravir or any other component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5374894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Myopathy: Grade 2-4 creatine kinase (CK) increases have been observed and myopathy and rhabdomyolysis have been reported; use caution in patients with risk factors for CK elevations and/or skeletal muscle abnormalities, including taking other drugs known to cause myopathy or rhabdomyolysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin and hypersensitivity reactions: Severe, life-threatening or fatal cases of Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported. Hypersensitivity reactions (rash [may occur with fever, fatigue, malaise, conjunctivitis, or other constitutional symptoms], organ dysfunction and/or hepatic failure) have also been reported. Discontinue immediately if a severe skin reaction or hypersensitivity symptoms develop. Monitor liver transaminases and start supportive therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Potential for interactions: Use caution with medications known to induce (eg, rifampin) or inhibit (eg, atazanavir) UGT1A1 glucuronidation, as serum levels/therapeutic effects may be reduced or increased, respectively.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Boosted PI replacement: Avoid use as a replacement for boosted PI therapy in antiretroviral-experienced patients with documented resistance to nucleoside reverse transcriptase inhibitors unless the patient is taking other fully active drugs (DHHS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Chewable tablet: Contains phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F5374903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: May decrease the serum concentration of Raltegravir. Raltegravir may decrease the serum concentration of Fosamprenavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: May decrease the serum concentration of Raltegravir. Specifically, minimum serum concentrations (Cmin) may be reduced.  Total raltegravir exposure (i.e., AUC) may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Raltegravir. Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5374906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Variable absorption depending upon meal type (low- vs high-fat meal) and dosage form; raltegravir was administered without regard to meals in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease the levels/effects of raltegravir).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F5374888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5374889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Raltegravir crosses the placenta and can be detected in neonatal serum after delivery. Standard doses appear to be appropriate in pregnant women. The DHHS Perinatal HIV Guidelines note that raltegravir may be used under special circumstances in pregnant women (eg, when preferred or alternative agents cannot be used).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum antiretroviral (ARV) drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5374891\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5374892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F5374925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F5552127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Isentress Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (60): $80.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (60): $322.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Isentress Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (60): $1288.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F5374926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Viral load, CD4 count, lipid profile",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Isentress (AR, AU, BE, BR, CH, CL, CN, CZ, DE, DK, EC, EE, FR, GB, GR, HK, HN, IE, IL, IT, KP, MY, NL, NO, NZ, PE, PL, PT, SE, SG, TH, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F5374909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Incorporation of viral DNA into the host cell&rsquo;s genome is required to produce a self-replicating provirus and propagation of infectious virion particles. The viral cDNA strand produced by reverse transcriptase is subsequently processed and inserted into the human genome by the enzyme HIV-1 integrase (encoded by the pol gene of HIV). Raltegravir inhibits the catalytic activity of integrase, thus preventing integration of the proviral gene into human DNA.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F5374911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Film-coated tablet: AUC increased twofold with high-fat meal; Chewable tablet:  AUC decreased by ~6% with high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~83%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Primarily hepatic glucuronidation mediated by UGT1A1",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Film-coated tablet: Not established; however, chewable tablet has higher oral bioavailability compared to film-coated tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~9 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: Film-coated tablet: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Feces (~51%, as unchanged drug); urine (~32%; 9% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grinsztejn B, Nguyen BY, Katlama C, et al, &ldquo;Safety and Efficacy of the HIV-1 Integrase inhibitor Raltegravir (MK-0518) in Treatment-Experienced Patients with Multidrug-Resistant Virus: A Phase II Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 369(9569):1261-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10678/abstract-text/17434401/pubmed\" id=\"17434401\" target=\"_blank\">",
"        17434401",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kassahun K, McIntosh I, Cui D, et al, &ldquo;Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme,&rdquo;",
"      <i>",
"       Drug Metab Dispos",
"      </i>",
"      , 2007, 35(9):1657-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10678/abstract-text/17591678/pubmed\" id=\"17591678\" target=\"_blank\">",
"        17591678",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lennox JL, DeJesus E, Lazzarin A, et al, &ldquo;Safety and Efficacy of Raltegravir-Based versus Efavirenz-Based Combination Therapy in Treatment-Naive Patients with HIV-1 Infection:  A Multicentre, Double-Blind Randomised Controlled Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9692):796-806.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10678/abstract-text/19647866/pubmed\" id=\"19647866\" target=\"_blank\">",
"        19647866",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nachman S, Acosta E, Zheng N, et al, &ldquo;Interim Results from IMPAACT P1066: Raltegravir (RAL) Oral Chewable Tablet (CT) Formulation in Children 2-5 Years,&rdquo; 18th Conference on Retroviruses and Opportunistic Infections (CROI), 2011 [Poster abstract 715 from 2011 CROI Conference]",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nair V and Chi G, &ldquo;HIV Integrase Inhibitors as Therapeutic Agents in AIDS,&rdquo;",
"      <i>",
"       Rev Med Virol",
"      </i>",
"      , 2007, 17(4):277-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10678/abstract-text/17503547/pubmed\" id=\"17503547\" target=\"_blank\">",
"        17503547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9451 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10678=[""].join("\n");
var outline_f10_27_10678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374882\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5937103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374886\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374921\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374920\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374922\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374923\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374924\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374928\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374884\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613920\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374887\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374898\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374893\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374894\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299978\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374903\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374906\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374888\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374889\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374891\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374892\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374925\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5552127\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374926\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875348\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374909\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5374911\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/59/30644?source=related_link\">",
"      Raltegravir: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10679="Approach to the patient with elevated serum amylase or lipase";
var content_f10_27_10679=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with elevated serum amylase or lipase",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10679/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10679/contributors\">",
"     Daniel Gelrud, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10679/contributors\">",
"     Frank G Gress, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10679/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10679/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10679/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10679/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/27/10679/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 29, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum amylase and lipase are common tests obtained as biochemical markers for acute pancreatitis. However, the interpretation of these tests can be difficult since several non-pancreatic conditions can present with abnormal serum amylase and lipase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In addition, some patients with pancreatitis have normal serum amylase and lipase levels when a blood sample is examined [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several factors can influence serum amylase and lipase levels.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The levels depend upon the rate of production from different tissues and the rate of clearance. As an example, serum amylase and lipase levels may be elevated in patients with renal failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=see_link\">",
"       \"Serum enzymes in patients with renal failure\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Organs other than the pancreas can produce these enzymes. Alcoholics, for example, may have an elevated serum amylase of salivary origin. The most commonly used amylase assays cannot differentiate between salivary and pancreatic amylase.",
"     </li>",
"     <li>",
"      Certain serum factors influence amylase and lipase enzyme activity. As an example, patients with pancreatitis due to hypertriglyceridemia may appear to have normal amylase levels, most likely due to a circulating factor that inhibits the enzyme's activity [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic review will present an approach the patient with an elevated serum amylase or lipase. Elevation of these measures in the context of individual disorders (such as pancreatitis) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AMYLASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amylase is derived from the Greek word \"amylone,\" which means starch. The main sources of amylase in humans are the pancreas and salivary glands, but it can be found in other tissues in small quantities [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/6\">",
"     6",
"    </a>",
"    ]. The main function of amylase is to cleave starch into smaller polysaccharides at the internal 1 to 4 alpha linkage in the process of digestion.",
"   </p>",
"   <p>",
"    Several isoforms of amylase can be identified by electrophoresis; the most abundant are the P form derived from the pancreas and the S form of salivary origin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/6\">",
"     6",
"    </a>",
"    ]. The molecular weight of the isoforms is relatively small (about 50,000 Daltons) so they can be filtered by the kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/6\">",
"     6",
"    </a>",
"    ]. Amylase is excreted by the reticuloendothelial system (75 percent) and the kidneys (25 percent). There are multiple methods for measuring serum amylase activity. The results are usually reported in Somogyi units (SU) or international units (IU). The normal values depend upon the assay used since the tests used vary by hospital.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Macroamylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum amylase levels may be elevated in settings in which amylase is bound to other macromolecules like immunoglobulins and polysaccharides, forming complexes known as macroamylase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/7\">",
"     7",
"    </a>",
"    ]. Because of the size of these complexes, renal excretion is reduced and the amylase level as measured by serologic tests is increased. Such patients typically have chronically elevated serum amylase levels, although the degree of elevation can fluctuate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several diseases have been described in association with macroamylasemia, including celiac disease, HIV infection, lymphoma, ulcerative colitis, rheumatoid arthritis, and monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/8-17\">",
"     8-17",
"    </a>",
"    ]. Macroamylasemia may resolve in patients with celiac disease following a gluten-free diet [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Celiac disease has also been associated with elevation in serum amylase (as well as other pancreatic enzymes) without macroamylasemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/18\">",
"     18",
"    </a>",
"    ]. Elevated levels are generally less than two-fold the upper limit of normal.",
"   </p>",
"   <p>",
"    The diagnosis of macroamylasemia can be established by determining the molecular weight of the serum amylase or by immunologic assays. The amylase-to-creatinine clearance ratio can also be suggestive (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Amylase-to-creatinine clearance ratio (ACCR)'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Causes of elevated serum amylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many conditions and drugs associated with an elevated amylase (",
"    <a class=\"graphic graphic_table graphicRef63497 \" href=\"UTD.htm?39/15/40188\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef64829 \" href=\"UTD.htm?8/6/8301\">",
"     table 2",
"    </a>",
"    ). The cause of the elevated amylase in some of these conditions is incompletely understood. Some of these conditions have similar clinical features further complicating interpretation of serum amylase levels.",
"   </p>",
"   <p>",
"    As an example, patients with severe gastroenteritis may have serum amylase levels up to 2.2 times the upper limit of normal, a situation that may cause confusion in those presenting with abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/19\">",
"     19",
"    </a>",
"    ]. Hyperamylasemia may also present in patients with acute liver failure due mainly to coexisting renal dysfunction but cause confusion as to the presence of coexisting pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/20\">",
"     20",
"    </a>",
"    ]. To further complicate matters, there are no good gold standards for several of these conditions. One example is pancreatitis. It is well recognized that patients with severe pancreatitis commonly have normal serum amylase levels [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/2,21,22\">",
"     2,21,22",
"    </a>",
"    ], particularly in patients with pancreatitis related to hypertriglyceridemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/23\">",
"     23",
"    </a>",
"    ] and ethanol [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/3,22,24\">",
"     3,22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite the lack of specificity, the predictive values of serum amylase determinations are influenced by the clinical context in which they are measured. An elevated amylase level, for example, most likely indicates the presence of pancreatitis in patients who present with the classic symptoms and typical radiologic findings of pancreatitis. The pattern of amylase elevation can be helpful in determining the etiology of the pancreatitis. Patients with gallstone pancreatitis tend to have higher amylase and lipase levels than patients with pancreatitis of other etiology. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute pancreatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LIPASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several lipases in the human body, including lingual, pancreatic, lipoprotein, intestinal, and hepatic lipase. Activity of all the lipases is inhibited by bile acids. The activity of pancreatic lipase depends upon the presence of another enzyme, colipase, which facilitates attachment to triglyceride droplets and prevents bile salts from deactivating pancreatic lipase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41765?source=see_link\">",
"     \"Mechanisms of nutrient absorption and malabsorption\"",
"    </a>",
"    .) One of the commonly used assays for pancreatic lipase takes advantage of this property; bile acids and colipase are added to the assay to inhibit all lipases other than pancreatic lipase, thus providing a specific assay for pancreatic lipase.",
"   </p>",
"   <p>",
"    The main function of the pancreatic lipase is to hydrolyze triglycerides into glycerol and free fatty acids. Like amylase, lipase is a relatively small molecule that can be filtrated by the kidney. Unlike amylase, lipase can be reabsorbed in the renal tubules, which increases its half-life (6.9 to 13.7 hours).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1151735618\">",
"    <span class=\"h2\">",
"     Causes of elevated serum lipase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipase is elevated in patients with renal failure and can also be elevated in several other conditions other than pancreatitis (",
"    <a class=\"graphic graphic_table graphicRef77323 \" href=\"UTD.htm?13/19/13627\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77633 \" href=\"UTD.htm?0/6/103\">",
"     table 4",
"    </a>",
"    ). Between 11 and 12.5 percent of patients admitted to the hospital with non-pancreatic abdominal pain have an elevated serum lipase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Up to 24 percent of patients with diabetic ketoacidosis have non-specific elevations of lipase [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/25\">",
"     25",
"    </a>",
"    ]. In a group of asymptomatic HIV positive patients, 60 percent had an abnormal amylase or lipase measurement on at least one occasion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     APPROACH TO THE PATIENT WITH AN ELEVATED AMYLASE OR LIPASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important step in the evaluation of patients with elevation in the serum amylase or lipase level is to obtain a detailed history and physical examination. Asymptomatic patients should be thoroughly screened for conditions like macroamylasemia, chronic alcohol abuse, renal failure, pancreatic cancer, and other non-pancreatic conditions (",
"    <a class=\"graphic graphic_table graphicRef63497 \" href=\"UTD.htm?39/15/40188\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77323 \" href=\"UTD.htm?13/19/13627\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several additional diagnoses should be considered in patients who have these enzyme elevations in the setting of abdominal pain. The enzymes can be interpreted in many ways depending upon the clinical settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Repeating the test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent elevation in pancreatic enzyme levels should be confirmed by repeated testing. However, for reasons that are unclear, pancreatic enzymes levels (including amylase, isoamylase, lipase and trypsin) fluctuate daily (and may return to the normal range) in patients who have benign causes of pancreatic hyperenzymemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/27\">",
"     27",
"    </a>",
"    ]. Thus, several observations may be required to document the persistent elevation. One study suggested that documentation of such fluctuations may support the diagnosis of benign causes of hyperenzymemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/27\">",
"     27",
"    </a>",
"    ]. However, there are no direct studies that have demonstrated whether such fluctuations correlate with benign causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Amylase or lipase alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, elevation in the serum amylase or lipase can be caused by non-pancreatic disease. In patients with pancreatitis, both amylase and lipase rise early on presentation, but amylase may return to normal before serum lipase because of its shorter half-life and increased renal clearance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/5\">",
"     5",
"    </a>",
"    ]. Amylase and lipase levels do not correlate with the severity of pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/4\">",
"     4",
"    </a>",
"    ] and therefore are not included in any of the several prognostic scores [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. It is important to also note that both amylase and lipase can be normal in the setting of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The sensitivity and specificity of amylase and lipase for pancreatitis depend upon the threshold for an abnormal result. Higher thresholds are associated with better specificity but lower sensitivity. Several studies suggest that lipase may be more specific than amylase in the diagnosis of acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. A lipase level of three times the upper limit of normal is approximately 98 percent specific for acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/31-33\">",
"     31-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While a general approach to patients with an elevated amylase level has been outlined (",
"    <a class=\"graphic graphic_algorithm graphicRef57456 \" href=\"UTD.htm?20/48/21250\">",
"     algorithm 1",
"    </a>",
"    ), the specific order and nature of testing may vary depending upon the clinical setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Amylase-to-creatinine clearance ratio (ACCR)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calculation of the ratio of the clearance of amylase to the clearance of creatinine is primarily of value in patients with macroamylasemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/34\">",
"     34",
"    </a>",
"    ]. In this setting, the ratio is reduced because of poor filtration of the large macroamylase complexes. A ratio less than 1 percent on a 24 hour collection strongly supports the diagnosis.",
"   </p>",
"   <p>",
"    An increase in the amylase to creatinine clearance ratio (ACCR) has been used to diagnose acute pancreatitis. The ratio is increased in the setting of acute pancreatitis but is not more helpful than serum amylase determinations alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/35\">",
"     35",
"    </a>",
"    ]. Hyperamylasuria occurs in acute pancreatitis because the ACCR increases from 3 to approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/35\">",
"     35",
"    </a>",
"    ]. However, even moderate renal insufficiency interferes with accuracy of the ACCR. Furthermore, an increase in the ACCR is not specific to acute pancreatitis since it also occurs in patients with severe burns or diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=see_link\">",
"     \"Serum enzymes in patients with renal failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ratio is measured by the following formula:",
"   </p>",
"   <p>",
"    ACCR = Amylase(urine) x Creatinine(serum) x 100",
"   </p>",
"   <p>",
"    ------------------------------------------------",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Amylase(serum) x Creatinine(urine)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Lipase-to-amylase ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some reports have suggested that a serum lipase-to-amylase ratio of greater than two can be used to differentiate between alcoholic and nonalcoholic acute pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. However, these observations were not confirmed in later studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are important for evaluating patients with an elevated amylase or lipase who have abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/5\">",
"     5",
"    </a>",
"    ]. Their role in asymptomatic patients is less clear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Computed tomography (CT) scan with thin cuts through the pancreas is of greatest value because it can detect a variety of pathologic conditions that can cause an elevated serum amylase and lipase. However, a CT scan was found to be negative in up to 30 percent of patients with acute pancreatitis in older studies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. Some animal and human studies have suggested that the outcomes of patients with severe pancreatitis may be worse when receiving intravenous contrast in the first 24 hours after the onset of acute pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/43\">",
"       43",
"      </a>",
"      ]. Thus, the timing of CT should be considered in the clinical setting.",
"     </li>",
"     <li>",
"      Magnetic resonance imaging (MRI) and magnetic resonance cholangiopancreatogram (MRCP) are increasingly being used in the diagnosis and management of acute pancreatitis. MRCP, both enhanced and non-enhanced, has a strong correlation with contrast-enhanced CT in acute pancreatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/44\">",
"       44",
"      </a>",
"      ]. The advantages of MRI over CT include: lower risk of nephrotoxicity from gadolinium in patients without underlying renal disease, ability of MRI to better categorize fluid collections as acute fluid collections, necrosis, abscess, hemorrhage, and pseudocyst [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/45\">",
"       45",
"      </a>",
"      ], and the greater sensitivity of MRI to detect mild acute pancreatitis compared with CT.&nbsp;In addition, unlike CT, MRCP delineates the pancreatic and bile ducts better, and MRCP is comparable to ERCP for the detection of choledocholithiasis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/46\">",
"       46",
"      </a>",
"      ]. In one report, MRI was reliable for staging the severity of AP, had prognostic value, was associated with fewer contraindications compared with CT, and was able to detect pancreatic duct disruptions [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/47\">",
"       47",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Abdominal imaging using MRI is rapidly evolving both in terms of technology (hardware and software) as well as the protocols used for imaging (pulse sequences, contrast agents, use of breath-holding, etc). This has made abdominal MRI operator-dependent with consequent variability in quality and technique. Its use in acute pancreatitis should currently be dictated by local expertise and availability.",
"     </li>",
"     <li>",
"      Plain abdominal films are useful to diagnose a perforated viscus. The findings in acute pancreatitis are non-specific.",
"     </li>",
"     <li>",
"      Abdominal ultrasonography is of limited value because the pancreas cannot be properly studied in up to 40 percent of patients due to intervening layers of muscle and fat or bowel gas [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10679/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS) are of limited value in the diagnosis of acute pancreatitis. On the other hand, they can be helpful in the diagnosis of suspected gallstone pancreatitis, chronic pancreatitis, and in patients suspected of having an occult pancreatic malignancy. (See appropriate topic reviews.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The interpretation of a high amylase or lipase can be complex.",
"     </li>",
"     <li>",
"      The clinical history is critical. Asymptomatic patients should be thoroughly screened for conditions like macroamylasemia, chronic alcohol abuse, renal failure, pancreatic cancer, and other non-pancreatic conditions (",
"      <a class=\"graphic graphic_table graphicRef63497 \" href=\"UTD.htm?39/15/40188\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef64829 \" href=\"UTD.htm?8/6/8301\">",
"       table 2",
"      </a>",
"      ). Several additional diagnoses should be considered in patients who have these enzyme elevations in the setting of abdominal pain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Causes of elevated serum amylase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serum lipase values are more specific than serum amylase levels in patients suspected of having acute pancreatitis. Pancreatitis is almost always present when enzyme levels measure three times the upper limit of normal. (See",
"      <a class=\"local\" href=\"#H1151735618\">",
"       'Causes of elevated serum lipase'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While a general approach to patients with an elevated amylase level has been outlined (",
"      <a class=\"graphic graphic_algorithm graphicRef57456 \" href=\"UTD.htm?20/48/21250\">",
"       algorithm 1",
"      </a>",
"      ), the specific order and nature of testing may vary depending upon the clinical setting.",
"     </li>",
"     <li>",
"      A CT scan with thin cuts through the pancreas or",
"      <span class=\"nowrap\">",
"       MRI/MRCP",
"      </span>",
"      is helpful in the setting of a high amylase or lipase level when the diagnosis is uncertain. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/1\">",
"      Chase CW, Barker DE, Russell WL, Burns RP. Serum amylase and lipase in the evaluation of acute abdominal pain. Am Surg 1996; 62:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/2\">",
"      Gumaste VV, Roditis N, Mehta D, Dave PB. Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis. Am J Gastroenterol 1993; 88:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/3\">",
"      Clavien PA, Robert J, Meyer P, et al. Acute pancreatitis and normoamylasemia. Not an uncommon combination. Ann Surg 1989; 210:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/4\">",
"      Lankisch PG, Burchard-Reckert S, Lehnick D. Underestimation of acute pancreatitis: patients with only a small increase in amylase/lipase levels can also have or develop severe acute pancreatitis. Gut 1999; 44:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/5\">",
"      Fallat RW, Vester JW, Glueck CJ. Suppression of amylase activity by hypertriglyceridemia. JAMA 1973; 225:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/6\">",
"      Pieper-Bigelow C, Strocchi A, Levitt MD. Where does serum amylase come from and where does it go? Gastroenterol Clin North Am 1990; 19:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/7\">",
"      Berk JE, Kizu H, Wilding P, Searcy RL. Macroamylasemia: a newly recognized cause for elevated serum amylase activity. N Engl J Med 1967; 277:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/8\">",
"      Sachdeva CK, Bank S, Greenberg R, et al. Fluctuations in serum amylase in patients with macroamylasemia. Am J Gastroenterol 1995; 90:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/9\">",
"      Deprettere AJ, Eykens A, Van Hoof V. Disappearance of macroamylasemia in a celiac patient after treatment with a gluten-free diet. J Pediatr Gastroenterol Nutr 2001; 33:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/10\">",
"      Barera G, Bazzigaluppi E, Viscardi M, et al. Macroamylasemia attributable to gluten-related amylase autoantibodies: a case report. Pediatrics 2001; 107:E93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/11\">",
"      Rabsztyn A, Green PH, Berti I, et al. Macroamylasemia in patients with celiac disease. Am J Gastroenterol 2001; 96:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/12\">",
"      Eleccion CB, Hathaway AA. Macroamylasemia in HIV infection. Tex Med 1998; 94:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/13\">",
"      Bonetti G, Serricchio G, Giudici A, et al. Hyperamylasemia due to macroamylasemia in adult gluten enteropathy. Scand J Clin Lab Invest 1997; 57:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/14\">",
"      Yoshida K, Minegishi Y, Okawa H, et al. Epstein-Barr virus-associated malignant lymphoma with macroamylasemia and monoclonal gammopathy in a patient with Wiskott-Aldrich syndrome. Pediatr Hematol Oncol 1997; 14:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/15\">",
"      Cutolo M, Sulli A, Barone A, et al. Macroamylasemia: a possible cause of unexplained hyperamylasemia in rheumatoid arthritis. Br J Rheumatol 1995; 34:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/16\">",
"      Fujimura Y, Nishishita C, Uchida J, Iida M. Macroamylasemia associated with ulcerative colitis. J Mol Med (Berl) 1995; 73:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/17\">",
"      Van Gossum A, Cremer M. Macroamylasemia disappearance after gluten withdrawal. Dig Dis Sci 1989; 34:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/18\">",
"      Carroccio A, Di Prima L, Scalici C, et al. Unexplained elevated serum pancreatic enzymes: a reason to suspect celiac disease. Clin Gastroenterol Hepatol 2006; 4:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/19\">",
"      Ben-Horin S, Farfel Z, Mouallem M. Gastroenteritis-associated hyperamylasemia: prevalence and clinical significance. Arch Intern Med 2002; 162:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/20\">",
"      Cot&eacute; GA, Gottstein JH, Daud A, et al. The role of etiology in the hyperamylasemia of acute liver failure. Am J Gastroenterol 2009; 104:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/21\">",
"      Clavien PA, Burgan S, Moossa AR. Serum enzymes and other laboratory tests in acute pancreatitis. Br J Surg 1989; 76:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/22\">",
"      Spechler SJ, Dalton JW, Robbins AH, et al. Prevalence of normal serum amylase levels in patients with acute alcoholic pancreatitis. Dig Dis Sci 1983; 28:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/23\">",
"      Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am 1990; 19:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/24\">",
"      Orebaugh SL. Normal amylase levels in the presentation of acute pancreatitis. Am J Emerg Med 1994; 12:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/25\">",
"      Yadav D, Nair S, Norkus EP, Pitchumoni CS. Nonspecific hyperamylasemia and hyperlipasemia in diabetic ketoacidosis: incidence and correlation with biochemical abnormalities. Am J Gastroenterol 2000; 95:3123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/26\">",
"      Argiris A, Mathur-Wagh U, Wilets I, Mildvan D. Abnormalities of serum amylase and lipase in HIV-positive patients. Am J Gastroenterol 1999; 94:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/27\">",
"      Gullo L. Day-to-day variations of serum pancreatic enzymes in benign pancreatic hyperenzymemia. Clin Gastroenterol Hepatol 2007; 5:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/28\">",
"      Ranson JH, Pasternack BS. Statistical methods for quantifying the severity of clinical acute pancreatitis. J Surg Res 1977; 22:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/29\">",
"      Ranson JH. Etiological and prognostic factors in human acute pancreatitis: a review. Am J Gastroenterol 1982; 77:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/30\">",
"      Shah AM, Eddi R, Kothari ST, et al. Acute pancreatitis with normal serum lipase: a case series. JOP 2010; 11:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/31\">",
"      Steinberg WM, Goldstein SS, Davis ND, et al. Diagnostic assays in acute pancreatitis. A study of sensitivity and specificity. Ann Intern Med 1985; 102:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/32\">",
"      Tietz NW, Huang WY, Rauh DF, Shuey DF. Laboratory tests in the differential diagnosis of hyperamylasemia. Clin Chem 1986; 32:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/33\">",
"      Werner M, Steinberg WM, Pauley C. Strategic use of individual and combined enzyme indicators for acute pancreatitis analyzed by receiver-operator characteristics. Clin Chem 1989; 35:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/34\">",
"      Levitt MD. Clinical use of amylase clearance and isoamylase measurements. Mayo Clin Proc 1979; 54:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/35\">",
"      Johnson SG, Ellis CJ, Levitt MD. Mechanism of increased renal clearnace of amylase/creatinine in acute pancreatitis. N Engl J Med 1976; 295:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/36\">",
"      Levine RI, Glauser FL, Berk JE. Enhancement of the amylase-creatinine clearance ratio in disorders other than acute pancreatitis. N Engl J Med 1975; 292:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/37\">",
"      Gumaste VV, Dave PB, Weissman D, Messer J. Lipase/amylase ratio. A new index that distinguishes acute episodes of alcoholic from nonalcoholic acute pancreatitis. Gastroenterology 1991; 101:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/38\">",
"      Tenner SM, Steinberg W. The admission serum lipase:amylase ratio differentiates alcoholic from nonalcoholic acute pancreatitis. Am J Gastroenterol 1992; 87:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/39\">",
"      King LG, Seelig CB, Ranney JE. The lipase to amylase ratio in acute pancreatitis. Am J Gastroenterol 1995; 90:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/40\">",
"      Sadowski DC, Sutherland LR. The lipase/amylase ratio: sensitive but not specific. Gastroenterology 1992; 103:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/41\">",
"      Balthazar EJ, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. Radiology 1990; 174:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/42\">",
"      Balthazar EJ. CT diagnosis and staging of acute pancreatitis. Radiol Clin North Am 1989; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/43\">",
"      McMenamin DA, Gates LK Jr. A retrospective analysis of the effect of contrast-enhanced CT on the outcome of acute pancreatitis. Am J Gastroenterol 1996; 91:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/44\">",
"      Lecesne R, Taourel P, Bret PM, et al. Acute pancreatitis: interobserver agreement and correlation of CT and MR cholangiopancreatography with outcome. Radiology 1999; 211:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/45\">",
"      Morgan DE, Baron TH, Smith JK, et al. Pancreatic fluid collections prior to intervention: evaluation with MR imaging compared with CT and US. Radiology 1997; 203:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/46\">",
"      Taylor AC, Little AF, Hennessy OF, et al. Prospective assessment of magnetic resonance cholangiopancreatography for noninvasive imaging of the biliary tree. Gastrointest Endosc 2002; 55:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10679/abstract/47\">",
"      Arvanitakis M, Delhaye M, De Maertelaere V, et al. Computed tomography and magnetic resonance imaging in the assessment of acute pancreatitis. Gastroenterology 2004; 126:715.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5643 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-33308A762F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10679=[""].join("\n");
var outline_f10_27_10679=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AMYLASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Macroamylase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Causes of elevated serum amylase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LIPASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1151735618\">",
"      Causes of elevated serum lipase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      APPROACH TO THE PATIENT WITH AN ELEVATED AMYLASE OR LIPASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Repeating the test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Amylase or lipase alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Amylase-to-creatinine clearance ratio (ACCR)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Lipase-to-amylase ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5643\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5643|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/48/21250\" title=\"algorithm 1\">",
"      Approach elevated amylase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5643|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/15/40188\" title=\"table 1\">",
"      Conditions assoc high amylase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/6/8301\" title=\"table 2\">",
"      Drugs affecting serum amylase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/19/13627\" title=\"table 3\">",
"      Conditions assoc high lipase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/6/103\" title=\"table 4\">",
"      Drugs affecting serum lipase",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/5/20569?source=related_link\">",
"      Clinical manifestations and diagnosis of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/50/41765?source=related_link\">",
"      Mechanisms of nutrient absorption and malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/38/33381?source=related_link\">",
"      Serum enzymes in patients with renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10680="Clinical features and etiology of colic";
var content_f10_27_10680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and etiology of colic",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Teri Lee Turner, MD, MPH, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Shea Palamountain, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Marilyn Augustyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10680/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/27/10680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent or excessive crying is one of the most distressing problems of infancy. It is distressing for the infant, the parents, and the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/1\">",
"     1",
"    </a>",
"    ]. The parents of the irritable infant may view the crying as an indictment of their caregiving ability or as evidence of illness in their child [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/2\">",
"     2",
"    </a>",
"    ]. Colic is a benign self-limited condition that resolves with time. However, the family's beliefs concerning the cause of crying and their interactions with the healthcare system related to the crying may affect the way in which they view the child and the healthcare system long after the crying has resolved.",
"   </p>",
"   <p>",
"    The clinical features and etiology of prolonged or excessive crying in young infants are reviewed here. The evaluation and management is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15177?source=see_link\">",
"     \"Evaluation and management of colic\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Normal patterns of crying",
"    </span>",
"    &nbsp;&mdash;&nbsp;All infants, whether or not they have colic, cry more during the first three months of life than at any other time. In a meta-analysis of 24 studies of parental crying diaries, mean duration of crying was 110 to 118 minutes per day during the first six weeks of life, and decreased to 72 minutes per day by 10 to 12 weeks, but varied widely from infant to infant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One hypothesis for increased crying among some infants is that the accumulated excitement caused by environmental stimuli during the day was discharged in the form of crying during late afternoon and evening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few people agree as to how much crying is considered excessive. The average duration of crying during the first three months of life varies from 42 minutes to 2 hours per day [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/2\">",
"     2",
"    </a>",
"    ]. One author argues that a cutoff point based upon duration is wrong in principle and not helpful clinically because \"normal\" and \"abnormal\" crying depend upon the context and quality of crying. In addition, adhering to a strict definition is not helpful to the families whose child does not meet the definition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the features of crying in infants with colic also occur in normal infants but with less frequency and shorter duration. The early peak and evening clustering, as an example, have been described in widely disparate societies and in normal preterm infants at two months corrected age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Colic",
"    </span>",
"    &nbsp;&mdash;&nbsp;No standard definition of the term \"colic\" exists. The word \"colic\" is used broadly by parents, clinicians, and researchers in Western cultures to refer to infants who cry for no apparent reason during the first three months of life and whose parents become concerned and seek help for this problem [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/7\">",
"     7",
"    </a>",
"    ]. Other terms that interchangeable with colic include &ldquo;cry-fuss behavior&rdquo;, &ldquo;excessive crying&rdquo;, &ldquo;unsettled infant behavior&rdquo;, and &ldquo;period of purple crying&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Niels Ros&eacute;n von Rosenstein described colic in detail in the first Swedish pediatric textbook in 1764 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/9\">",
"     9",
"    </a>",
"    ]. The word \"colic\" stems from the Greek \"kolikos\", the adjective of kolon; many people believe that colic is a gastrointestinal disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/7\">",
"     7",
"    </a>",
"    ]. Colic also can be viewed as a social phenomenon because it is the caretaker's perception of what is excessive and prolonged and the caretaker's ultimate response to these episodes that define whether the crying is seen as a problem.",
"   </p>",
"   <p>",
"    The most widely accepted definition for colic is the Wessel criteria or the \"rule of three\": crying that lasts for more than three hours per day, occurs on more than three days per week, and persists for more than three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/10\">",
"     10",
"    </a>",
"    ]. This definition also requires that the infant is \"otherwise healthy and well fed\". The criterion of persistence for three weeks has been dropped by most authors because few parents or clinicians are able to wait three weeks before evaluation or intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colic may encompass more than excessive crying, at least in some infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition to meeting the Wessel criteria, some authors suggest that the diagnosis of colic should require three of four additional criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal &ndash; The first criterion is that the episodes are paroxysmal. Each \"colicky\" episode has a clear beginning and end. The onset seems to be unrelated to what the infant was doing just before the \"attack\". The infant may have been happy, fussy, feeding, or even sleeping. These spells of crying occur suddenly, and often cluster during the evening hours. They are clearly delineated from other times when the infant is \"just crying\".",
"     </li>",
"     <li>",
"      Qualitatively different from normal crying &ndash; The second criterion is that episodes of crying are more intense and the acoustic characteristics of the crying are different from normal crying episodes. Colicky crying is louder, higher, and more variable in pitch and has more turbulence or disphonation than does noncolicky crying [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/12,14,15\">",
"       12,14,15",
"      </a>",
"      ]. Colicky crying may sound as if the infant is in pain or is screaming rather than crying [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/12\">",
"       12",
"      </a>",
"      ]. The mothers of colicky infants rate their infant's cries as more urgent, piercing, grating, arousing, aversive, distressing, discomforting, and irritating than do the mothers of noncolicky infants [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/2,15,16\">",
"       2,15,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associated with hypertonia &ndash; The third criterion is that the infants manifest physical characteristics that are associated with hypertonia (",
"      <a class=\"graphic graphic_table graphicRef78133 \" href=\"UTD.htm?4/13/4315\">",
"       table 1",
"      </a>",
"      ). These signs usually occur in clusters; it is the number of signs, rather than a specific sign, that is important [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inconsolability &ndash; The fourth criterion is that the infants are difficult or impossible to console no matter what the parents do. Periods when the crying stops somewhat may occur, but the infant remains fussy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/12\">",
"       12",
"      </a>",
"      ]. Relief may be noted after the passage of flatus or feces.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The phenomenon of colic remains an enigma. Some researchers feel that what is called \"colic\" is the upper end of the normal range of crying rather than a discrete categorical disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/17\">",
"     17",
"    </a>",
"    ]. Others have identified features unique to colic (eg, prolonged duration of crying bouts and inability to be soothed) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/18\">",
"     18",
"    </a>",
"    ]. Still others have proposed classification systems based upon phenomenology rather than etiology of crying [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal concern",
"     </li>",
"     <li>",
"      Non-Wessel's crying",
"     </li>",
"     <li>",
"      Wessel's crying",
"     </li>",
"     <li>",
"      Crying due to organic disease",
"     </li>",
"     <li>",
"      Wessel's plus crying (overlaps the last two categories and includes the additional characteristics outlined by Lester et al)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another framework delineates the patterns of colic and excessive crying (",
"    <a class=\"graphic graphic_table graphicRef77427 \" href=\"UTD.htm?6/2/6188\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/12\">",
"     12",
"    </a>",
"    ]. These distinctions may seem trivial or academic. However, they represent different experiences for parents, and treatment may vary according to category. As the patterns of crying are better delineated and understood, clinicians may be better prepared to help parents cope when an identifiable organic etiology is not found.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Estimates of the prevalence of colic in infants range from 8 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/10,19-24\">",
"     10,19-24",
"    </a>",
"    ]. The wide range is due to inconsistency in the criteria used for diagnosis and differences in study designs, populations, and family perceptions of \"excessive and prolonged\" crying [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/19,25\">",
"     19,25",
"    </a>",
"    ]. As an example, only 35 percent of infants considered to be \"colicky\" by their mothers met the \"rule of three\" criteria when parental diaries were used [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some investigators have noted an increased incidence of colic in first-born children and siblings of colicky children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/23\">",
"     23",
"    </a>",
"    ]; others have found no such relationship [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/27\">",
"     27",
"    </a>",
"    ]. No differences have been noted between genders, breast- versus bottle-fed, or full-term versus preterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Some researchers have suggested that colic occurs only in industrialized countries and is more frequent in Caucasian infants and in areas at greater distance from the equator [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/28,30\">",
"     28,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associations between colic and dissatisfaction in the marital relationship, parental perception of stress, lack of parental self-confidence during the pregnancy, dissatisfaction with the delivery, and levels of family stress have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/10,31\">",
"     10,31",
"    </a>",
"    ]. The causal relationship between colic and family stress is difficult to determine because both factors affect parental perception of, and response to, crying.",
"   </p>",
"   <p>",
"    A complex interaction exists between colic and family dynamics, which also are affected by pre- and postnatal factors. Families with colicky infants had more problems in family structure, functioning, and affective state both during the colicky period and one year later when compared with families without such an infant [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any etiology that is proposed for colic must account for the timing, the individual variability, the nonrandom distribution throughout the day, and the tendency to cluster during the evening hours [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/33\">",
"     33",
"    </a>",
"    ]. Theories of causation abound, but evidence for any one theory is scant. Colic probably represents a final common pathway for numerous etiologic factors [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/28\">",
"     28",
"    </a>",
"    ]. Gastrointestinal, biologic, and psychosocial etiologies have been proposed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Cow's milk protein",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for an association between cow's milk protein intolerance and colic is equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/28\">",
"     28",
"    </a>",
"    ]. However, a reasonable assumption is that a subgroup of infants with colic have symptoms that are caused at least in part by allergy to either casein or whey; these infants have a significant reduction in symptoms within a few days of initiating a hypoallergenic diet (eg, a protein hydrolysate formula) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]. Data regarding the efficacy of hypoallergenic diets by breastfeeding mothers are inconclusive but suggest that they may be of some benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=see_link\">",
"     \"Food protein-induced proctitis/colitis and enteropathy of infancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Lactose intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"     lactase",
"    </a>",
"    on infant colic were evaluated in two randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Neither study found a significant difference between treatment and placebo groups, indicating that lactose intolerance plays a minimal role, if any, in the development of colic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Fruit juice intolerance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of fruit juice-related carbohydrate malabsorption on infantile colic were evaluated in a study of 30 infants, 16 with and 14 without colic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/44\">",
"     44",
"    </a>",
"    ]. The infants within each group were randomly assigned to receive 120 mL of white grape juice (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"     sorbitol",
"    </a>",
"    free, fructose:glucose ratio of 1:1) or apple juice (0.5",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    sorbitol and fructose:glucose ratio of 2.6:1). Crying, sleeping, physical activity, and energy expenditure were measured 30 minutes before and three hours after the juice feedings. Breath hydrogen analysis was performed after the juice feeding. Mean breath hydrogen excretion increased significantly only in the group of infants with colic who were fed apple juice. This group also had increased crying, physical activity, and energy expenditure compared with the other groups. The findings of this study suggest that carbohydrate intolerance related to sorbitol-containing fruit juices with a high fructose:glucose ratio may play a role in infantile colic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Immaturity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another theory proposes that colic is related to the incomplete absorption of carbohydrates in the small intestine. Excessive gas is produced when the unabsorbed carbohydrate is fermented by colonic bacteria. Breath hydrogen excretion was measured in infants with and without colic in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The results were inconsistent: two of the studies found an association between elevated breath hydrogen and colic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]; the third found no such association [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/47\">",
"     47",
"    </a>",
"    ]. However, in each study, a greater proportion of colicky than noncolicky infants had positive breath tests (62 versus 32 percent in one study) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Intestinal motility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal hypermotility secondary to a presumed autonomic imbalance also has been proposed as an etiology for colic. The evidence for this hypothesis is contradictory [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. In one case-control study, vasoactive intestinal peptide and gastrin levels were not elevated in infants with colic compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/51\">",
"     51",
"    </a>",
"    ]. However, in this and another case-control study, motilin concentrations were raised in colicky infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Motilin stimulates gastric emptying and intestinal peristalsis, thereby reducing transit time in the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/48\">",
"     48",
"    </a>",
"    ]. Further support for the role of motilin in colic is provided by a prospective study of 78 term infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/53\">",
"     53",
"    </a>",
"    ]. On day one of life and at 6 and 12 weeks of age, motilin concentrations were higher in cord blood of infants with colic than controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Fecal microflora",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have demonstrated differences in intestinal microflora between infants with colic and control infants, particularly",
"    <em>",
"     Klebsiella",
"    </em>",
"    species, anaerobic gram-negative bacteria, coliform bacteria,",
"    <em>",
"     Escherichia coli",
"    </em>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/5/1108?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    <em>",
"    </em>",
"    species (",
"    <em>",
"     L. brevis",
"    </em>",
"    and",
"    <em>",
"     L. lactis",
"    </em>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. One study also found a twofold increase in fecal calprotectin, a marker of intestinal neutrophil infiltration, among colicky infants compared with controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of fecal microflora in colic is supported by a randomized trial comparing",
"    <em>",
"     L. reuteri",
"    </em>",
"    and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/58\">",
"     58",
"    </a>",
"    ]. Treatment with",
"    <em>",
"     L. reuteri",
"    </em>",
"    was associated with a greater reduction in",
"    <span class=\"nowrap\">",
"     crying/day,",
"    </span>",
"    increased fecal Lactobacilli, and decreased fecal",
"    <em>",
"     E. coli",
"    </em>",
"    , suggesting that",
"    <em>",
"     L. reuteri",
"    </em>",
"    may promote gut health by reducing",
"    <em>",
"     E. coli",
"    </em>",
"    colonization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15177?source=see_link&amp;anchor=H24#H24\">",
"     \"Evaluation and management of colic\", section on 'Probiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Biologic factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Feeding techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Underfeeding, overfeeding, infrequent burping, and swallowing air all have been described as possible etiologies of colic. One study found that infants fed with an antivacuum bottle spent more time awake and content than did those who were fed with a conventional bottle [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Motor regulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the mechanisms that regulate motor activity are immature in infants. The immaturity of these mechanisms may result in increased vulnerability to feeding intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Thus, colic may be a common clinical manifestation in the subpopulation of infants who have maturational dysfunction in one or more of the aspects of motility regulation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Increased serotonin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Random urinary concentrations of 5-hydroxy-3-indole",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/39/42610?source=see_link\">",
"     acetic acid",
"    </a>",
"    (5-OH IAA), a serotonin metabolite, were measured in infants with and without colic in a study designed to investigate the pathogenesis of colic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/62\">",
"     62",
"    </a>",
"    ]. Urinary 5-OH IAA concentrations were greater in infants with colic than in control infants, suggesting that elevated serotonin concentrations may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Tobacco smoke and nicotine exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal smoking during pregnancy or in the post-partum period has been associated with an increased risk of infantile colic in several cohort studies [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. In the largest study, the prevalence of colic (using Wessel criteria) was 9.4 among infants of smokers versus 7.3 percent among infants of nonsmokers (adjusted odds ratio [OR] 1.3, 95% CI 1.2-1.4) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/65\">",
"     65",
"    </a>",
"    ]. Prenatal exposure to nicotine replacement therapy also was associated with an increased risk of infantile colic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Psychosocial",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Temperament",
"    </span>",
"    &nbsp;&mdash;&nbsp;Healthy behavior and development are believed to be predicted on the \"goodness of fit\" between the child's environment and his or her innate characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/66-69\">",
"     66-69",
"    </a>",
"    ]. Supporting evidence for the individual elements of this interaction paradigm is limited. The most direct evidence of an interactional basis for colic is provided by therapeutic trials aimed at modifying parental behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. In one controlled clinical trial, when parents of colicky infants were counseled regarding effective responses to crying, the crying decreased from 2.6 to 0.8 hours per day [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/71\">",
"     71",
"    </a>",
"    ]. In another controlled trial, parental counseling was more effective than were dietary changes in reduction of crying (from 3.2 to 1.1 hours per day in the counseling group and from 3.2 to 2.0 hours per day in the dietary change group) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hypersensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another proposed hypothesis is that crying at the end of the day represents discharge after a long day of shutting out intrusive environmental stimuli and is a means of maintaining homeostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Parental variables",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various parental psychosocial factors, including family stress and transmission of tension from the mother to the infant, have been proposed to be associated with colic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/10,73\">",
"     10,73",
"    </a>",
"    ]. One prospective study reported that mothers of excessive criers had psychologic conflicts regarding the maternal role, hostility toward the infant, and an insensitive or inconsistent style in maternal-infant interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/49\">",
"     49",
"    </a>",
"    ]. In contrast, another prospective study found that maternal emotional factors did not play a role in excessive infant crying; however, an association was found between infantile colic and a history of emotional tension or depression early in the pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/74\">",
"     74",
"    </a>",
"    ]. A similar association between maternal distress during pregnancy and excessive infantile crying was reported in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/75\">",
"     75",
"    </a>",
"    ]. Paternal depressive symptoms during pregnancy have also been associated with excessive crying in infants [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10680/abstract/76\">",
"     76",
"    </a>",
"    ]. This finding was noted even after controlling for maternal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/53/38738?source=see_link\">",
"       \"Patient information: Colic (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/7/1140?source=see_link\">",
"       \"Patient information: Colic (excessive crying) in infants (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The average duration of crying during the first three months of life varies from 42 minutes to 2 hours per day. Normal crying peaks at approximately six weeks of age. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Normal patterns of crying'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no standard definition of the term \"colic\". It is used broadly by parents, clinicians, and researchers in Western cultures to refer to crying for no apparent reason that is of concern to the parents and for which they seek help. A framework for distinguishing colic from excessive crying is provided in the table (",
"      <a class=\"graphic graphic_table graphicRef77427 \" href=\"UTD.htm?6/2/6188\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Colic'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colic probably represents a final common pathway for numerous etiologic factors. Gastrointestinal, biologic, and psychosocial etiologies have been proposed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastrointestinal factors that may contribute to colic in some infants include cow's milk protein intolerance,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"       sorbitol",
"      </a>",
"      -containing fruit juice (eg, apple juice), incomplete absorption of carbohydrates in the small intestine, intestinal hypermobility, and alterations of fecal microflora. Lactose intolerance appears to play a minimal role. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Gastrointestinal'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biologic factors that may contribute to colic include feeding techniques (eg, overfeeding, infrequent burping), immature motor regulation, increased serotonin, and tobacco smoke exposure. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Biologic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychosocial factors that may contribute to colic include infant temperament, increased sensitivity to environmental stimuli, family stress, and emotional tension during pregnancy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Psychosocial'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/1\">",
"      Taubman B. A new answer to the old question of colic. Contemp Pediatr 1991; 8:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/2\">",
"      Lehtonen LA, Rautava PT. Infantile colic: natural history and treatment. Curr Probl Pediatr 1996; 26:79.",
"     </a>",
"    </li>",
"    <li>",
"     Wolke D, Samara M, Alvarez Wolke M. Meta&ndash;analysis of fuss/cry durations and colic prevalence across countries: Proceedings of the11th International Infant Cry Research Workshop, June, 2011, The Netherlands.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/4\">",
"      BRAZELTON TB. Crying in infancy. Pediatrics 1962; 29:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/5\">",
"      Fleisher DR. Coping with colic. Contemp Pediatr 1998; 15:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/6\">",
"      Barr RG. Normality: a clinically useless concept. The case of infant crying and colic. J Dev Behav Pediatr 1993; 14:264.",
"     </a>",
"    </li>",
"    <li>",
"     StJames-Roberts I. Distinguishing between infant fussing, crying, and colic: How many phenomenon?. In: Colic and Excessive Crying: Report of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus, OH 1997. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/8\">",
"      Douglas P, Hill P. Managing infants who cry excessively in the first few months of life. BMJ 2011; 343:d7772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/9\">",
"      Lindberg T. Infantile colic: aetiology and prognosis. Acta Paediatr 2000; 89:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/10\">",
"      WESSEL MA, COBB JC, JACKSON EB, et al. Paroxysmal fussing in infancy, sometimes called colic. Pediatrics 1954; 14:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/11\">",
"      Gormally S, Barr RG. Of clinical pies and clinical clues: Proposal for a clinical approach to complaints of early crying and colic. Ambulatory Child Health 1997; 3:137.",
"     </a>",
"    </li>",
"    <li>",
"     Lester BM. Definition and diagnosis of colic. In: Colic and Excessive Crying: Report of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Divisions, Columbus, OH 1997. p.8.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/13\">",
"      Lester BM, Boukydis CF, Garcia-Coll CT, Hole WT. Colic for developmentalists. Infant Ment Health J 1990; 11:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/14\">",
"      Fuller BF, Keefe MR, Curtin M. Acoustic analysis of cries from \"normal\" and \"irritable\" infants. West J Nurs Res 1994; 16:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/15\">",
"      Lester BM, Boukydis CF, Garcia-Coll CT, et al. Infantile colic: Acoustic cry characteristics, maternal perception of cry, and temperament. Infant Behav Dev 1992; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/16\">",
"      Pinyerd BJ. Infant colic and maternal mental health: nursing research and practice concerns. Issues Compr Pediatr Nurs 1992; 15:155.",
"     </a>",
"    </li>",
"    <li>",
"     Carey WB. Colic: Prolonged or excessive crying in young infants. In: Developmental-Behavioral Pediatrics, 4th ed, Carey WB, Crocker AC, Coleman WL, et al (Eds), Saunders Elsevier, Philadelphia 2009. p.557.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/18\">",
"      Barr RG, Paterson JA, MacMartin LM, et al. Prolonged and unsoothable crying bouts in infants with and without colic. J Dev Behav Pediatr 2005; 26:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/19\">",
"      Lehtonen L, Korvenranta H. Infantile colic. Seasonal incidence and crying profiles. Arch Pediatr Adolesc Med 1995; 149:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/20\">",
"      ILLINGWORTH RS. Three-months' colic. Arch Dis Child 1954; 29:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/21\">",
"      Hide DW, Guyer BM. Prevalence of infant colic. Arch Dis Child 1982; 57:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/22\">",
"      Rubin SP, Prendergast M. Infantile colic: incidence and treatment in a Norfolk community. Child Care Health Dev 1984; 10:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/23\">",
"      St&aring;hlberg MR. Infantile colic: occurrence and risk factors. Eur J Pediatr 1984; 143:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/24\">",
"      Wake M, Morton-Allen E, Poulakis Z, et al. Prevalence, stability, and outcomes of cry-fuss and sleep problems in the first 2 years of life: prospective community-based study. Pediatrics 2006; 117:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/25\">",
"      Reijneveld SA, Brugman E, Hirasing RA. Excessive infant crying: the impact of varying definitions. Pediatrics 2001; 108:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/26\">",
"      Barr RG, Rotman A, Yaremko J, et al. The crying of infants with colic: a controlled empirical description. Pediatrics 1992; 90:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/27\">",
"      St James-Roberts I, Halil T. Infant crying patterns in the first year: normal community and clinical findings. J Child Psychol Psychiatry 1991; 32:951.",
"     </a>",
"    </li>",
"    <li>",
"     Parker S, Magee T. Colic. In: The Zuckerman Parker Handbook of Developmental and Behavioral Pediatrics for Primary Care, 3rd ed, Augustyn M, Zuckerman B, Caronna EB (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. p.182.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/29\">",
"      Clifford TJ, Campbell MK, Speechley KN, Gorodzinsky F. Infant colic: empirical evidence of the absence of an association with source of early infant nutrition. Arch Pediatr Adolesc Med 2002; 156:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/30\">",
"      Brazelton TB, Robey JS, Collier GA. Infant development in the Zinacanteco Indians of southern Mexico. Pediatrics 1969; 44:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/31\">",
"      Rautava P, Helenius H, Lehtonen L. Psychosocial predisposing factors for infantile colic. BMJ 1993; 307:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/32\">",
"      R&auml;ih&auml; H, Lehtonen L, Korvenranta H. Family context in infantile colic. Infant Mental Health 1995; 16:206.",
"     </a>",
"    </li>",
"    <li>",
"     Lester BM. Introduction. In: Colic and Excessive Crying: of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus, OH 1997. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/34\">",
"      Garrison MM, Christakis DA. A systematic review of treatments for infant colic. Pediatrics 2000; 106:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/35\">",
"      Campbell JP. Dietary treatment of infant colic: a double-blind study. J R Coll Gen Pract 1989; 39:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/36\">",
"      Evans RW, Fergusson DM, Allardyce RA, Taylor B. Maternal diet and infantile colic in breast-fed infants. Lancet 1981; 1:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/37\">",
"      Hill DJ, Hudson IL, Sheffield LJ, et al. A low allergen diet is a significant intervention in infantile colic: results of a community-based study. J Allergy Clin Immunol 1995; 96:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/38\">",
"      Forsyth BW. Colic and the effect of changing formulas: a double-blind, multiple-crossover study. J Pediatr 1989; 115:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/39\">",
"      Lothe L, Lindberg T, Jakobsson I. Cow's milk formula as a cause of infantile colic: a double-blind study. Pediatrics 1982; 70:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/40\">",
"      Lothe L, Lindberg T. Cow's milk whey protein elicits symptoms of infantile colic in colicky formula-fed infants: a double-blind crossover study. Pediatrics 1989; 83:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/41\">",
"      Lucassen PL, Assendelft WJ, Gubbels JW, et al. Infantile colic: crying time reduction with a whey hydrolysate: A double-blind, randomized, placebo-controlled trial. Pediatrics 2000; 106:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/42\">",
"      Miller JJ, McVeagh P, Fleet GH, et al. Effect of yeast lactase enzyme on \"colic\" in infants fed human milk. J Pediatr 1990; 117:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/43\">",
"      St&aring;hlberg MR, Savilahti E. Infantile colic and feeding. Arch Dis Child 1986; 61:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/44\">",
"      Duro D, Rising R, Cedillo M, Lifshitz F. Association between infantile colic and carbohydrate malabsorption from fruit juices in infancy. Pediatrics 2002; 109:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/45\">",
"      Moore DJ, Robb TA, Davidson GP. Breath hydrogen response to milk containing lactose in colicky and noncolicky infants. J Pediatr 1988; 113:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/46\">",
"      Miller JJ, McVeagh P, Fleet GH, et al. Breath hydrogen excretion in infants with colic. Arch Dis Child 1989; 64:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/47\">",
"      Hyams JS, Geertsma MA, Etienne NL, Treem WR. Colonic hydrogen production in infants with colic. J Pediatr 1989; 115:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/48\">",
"      Miller AR, Barr RG. Infantile colic. Is it a gut issue? Pediatr Clin North Am 1991; 38:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/49\">",
"      STEWART AH, WEILAND IH, LEIDER AR, et al. Excessive infant crying (colic) in relation to parent behavior. Am J Psychiatry 1954; 110:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/50\">",
"      FORUP S. Colonic hyperperistalsis in neurolabile infants; studies in so-called dyspepsia in breast-fed infants. Acta Paediatr Suppl 1952; 41:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/51\">",
"      Lothe L, Ivarsson SA, Lindberg T. Motilin, vasoactive intestinal peptide and gastrin in infantile colic. Acta Paediatr Scand 1987; 76:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/52\">",
"      Savino F, Grassino EC, Guidi C, et al. Ghrelin and motilin concentration in colicky infants. Acta Paediatr 2006; 95:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/53\">",
"      Lothe L, Ivarsson SA, Ekman R, Lindberg T. Motilin and infantile colic. A prospective study. Acta Paediatr Scand 1990; 79:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/54\">",
"      Rhoads JM, Fatheree NY, Norori J, et al. Altered fecal microflora and increased fecal calprotectin in infants with colic. J Pediatr 2009; 155:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/55\">",
"      Savino F, Cresi F, Pautasso S, et al. Intestinal microflora in breastfed colicky and non-colicky infants. Acta Paediatr 2004; 93:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/56\">",
"      Savino F, Cordisco L, Tarasco V, et al. Molecular identification of coliform bacteria from colicky breastfed infants. Acta Paediatr 2009; 98:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/57\">",
"      Savino F, Bailo E, Oggero R, et al. Bacterial counts of intestinal Lactobacillus species in infants with colic. Pediatr Allergy Immunol 2005; 16:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/58\">",
"      Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010; 126:e526.",
"     </a>",
"    </li>",
"    <li>",
"     Lucas A, StJames-Roberts I. Colic, crying, fussing, and feeding. In: Colic and Excessive Crying: ort of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus, OH 1997. p.68.",
"    </li>",
"    <li>",
"     Berseth CL. Immaturity in neonatal regulation of motor activity: Setting the stage for colic. In: Colic and Excessive Crying: Report of the 105th Ross Conference on Pediatric Research, Lester BM, Barr RG (Eds), Ross Products Division, Columbus, OH 1997. p.77.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/61\">",
"      Baker J, Berseth CL. Postnatal change in inhibitory regulation of intestinal motor activity in human and canine neonates. Pediatr Res 1995; 38:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/62\">",
"      Kurtoglu S, Uz&uuml;m K, Hallac IK, Coskum A. 5-Hydroxy-3-indole acetic acid levels in infantile colic: is serotoninergic tonus responsible for this problem? Acta Paediatr 1997; 86:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/63\">",
"      S&oslash;ndergaard C, Henriksen TB, Obel C, Wisborg K. Smoking during pregnancy and infantile colic. Pediatrics 2001; 108:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/64\">",
"      Reijneveld SA, Brugman E, Hirasing RA. Infantile colic: maternal smoking as potential risk factor. Arch Dis Child 2000; 83:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/65\">",
"      Milidou I, Henriksen TB, Jensen MS, et al. Nicotine replacement therapy during pregnancy and infantile colic in the offspring. Pediatrics 2012; 129:e652.",
"     </a>",
"    </li>",
"    <li>",
"     Henderson LJ. The Fitness of the Environment: An Inquiry into the Biological Significance of the Properties of Matter, Macmillan Co, New York 1913.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/67\">",
"      Carey WB. Infantile colic: a pediatric practitioner-researcher's point of view. Infant Mental Health J 1990; 11:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/68\">",
"      Carey WB. \"Colic\"--primary excessive crying as an infant-environment interaction. Pediatr Clin North Am 1984; 31:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/69\">",
"      Carey WB. Clinical applications of infant temperament measurements. J Pediatr 1972; 81:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/70\">",
"      Carey WB. Maternal anxiety and infantile colic. Is there a relationship? Clin Pediatr (Phila) 1968; 7:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/71\">",
"      Taubman B. Clinical trial of the treatment of colic by modification of parent-infant interaction. Pediatrics 1984; 74:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/72\">",
"      Taubman B. Parental counseling compared with elimination of cow's milk or soy milk protein for the treatment of infant colic syndrome: a randomized trial. Pediatrics 1988; 81:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/73\">",
"      Spock B. Etiological factors in the hypertrophic stenosis and infantile colic. Psychosom Med 1944; 6:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/74\">",
"      Paradise JL. Maternal and other factors in the etiology of infantile colic. Report of a prospective study of 146 infants. JAMA 1966; 197:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/75\">",
"      S&oslash;ndergaard C, Olsen J, Friis-Hasch&egrave; E, et al. Psychosocial distress during pregnancy and the risk of infantile colic: a follow-up study. Acta Paediatr 2003; 92:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10680/abstract/76\">",
"      van den Berg MP, van der Ende J, Crijnen AA, et al. Paternal depressive symptoms during pregnancy are related to excessive infant crying. Pediatrics 2009; 124:e96.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 609 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10680=[""].join("\n");
var outline_f10_27_10680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Normal patterns of crying",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Cow's milk protein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Fruit juice intolerance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Immaturity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Intestinal motility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Fecal microflora",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Biologic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Feeding techniques",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Motor regulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Increased serotonin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Tobacco smoke and nicotine exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Psychosocial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Temperament",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hypersensitivity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Parental variables",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/609\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/609|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/13/4315\" title=\"table 1\">",
"      Hypertonia in infantile colic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/2/6188\" title=\"table 2\">",
"      Crying framework",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15177?source=related_link\">",
"      Evaluation and management of colic",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/52/34631?source=related_link\">",
"      Food protein-induced proctitis/colitis and enteropathy of infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/53/38738?source=related_link\">",
"      Patient information: Colic (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/7/1140?source=related_link\">",
"      Patient information: Colic (excessive crying) in infants (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10681="OnabotulinumtoxinA (botulinum toxin type A, Botox): Drug information";
var content_f10_27_10681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   OnabotulinumtoxinA (botulinum toxin type A, Botox): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?15/55/16245?source=see_link\">",
"    see \"OnabotulinumtoxinA (botulinum toxin type A, Botox): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/18/295?source=see_link\">",
"    see \"OnabotulinumtoxinA (botulinum toxin type A, Botox): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9605655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information. For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Botox&reg;;",
"     </li>",
"     <li>",
"      Botox&reg; Cosmetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F141937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Botox&reg;;",
"     </li>",
"     <li>",
"      Botox&reg; Cosmetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Neuromuscular Blocker Agent, Toxin;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Toxin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The lowest recommended dose should be used when initiating treatment (regardless of indication). In adults treated for more than one indication, the maximum cumulative dose should be &le;360 units/3 months. Canadian labeling recommends a maximum cumulative dose of 6 units/kg (up to 360 units) over 3 months in adult patients receiving additional treatment for noncosmetic indications.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Bladder dysfunction:",
"     </b>",
"     Intradetrusor:",
"     <b>",
"      Note:",
"     </b>",
"     Prophylactic antimicrobial therapy (excluding aminoglycosides) should be administered 1-3 days prior to, on the day of, and for 1-3 days following onabotulinumtoxinA administration to decrease risk of urinary tract infection (UTI).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Detrusor overactivity associated with neurologic condition:",
"     </i>",
"     30 injections of 1 mL (recommended concentration: ~6.7 units/mL) for a total dose of 200 units/30 mL (maximum: 200 units); for the final injection, ~1 mL of sterile NS should be injected to ensure that the remaining medication in the needle is delivered to the bladder; may consider retreatment with diminishing effect but no sooner than 12 weeks from previous administration (median time until second treatment in studies: 42-48 weeks).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Overactive bladder:",
"     </i>",
"     20 injections of 0.5 mL (recommended concentration: 10 units/mL) for a total dose of 100 units/10 mL (maximum: 100 units); for the final injection, ~1 mL of sterile NS should be injected to ensure that the remaining medication in the needle is delivered to the bladder; may consider retreatment with diminishing effect but no sooner than 12 weeks from the previous administration (median time until second treatment in studies: ~24 weeks)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Blepharospasm:",
"     </b>",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Botox&reg;: Initial dose: 1.25-2.5 units injected into the medial and lateral pretarsal orbicularis oculi of the upper lid and lateral pretarsal orbicularis oculi of lower lid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dose may be increased up to twice the previous dose if the response from the initial dose lasted &le;2 months; maximum dose per site: 5 units. Tolerance may occur if treatments are given more often than every 3 months, but the effect is not usually permanent. Cumulative dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"     &le;200 units in 30-day period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     Botox&reg;: &le;200 units in 2-month period",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical dystonia:",
"     </b>",
"     I.M.: For dosing guidance, the mean dose is 236 units (25th to 75th percentile range 198-300 units) divided among the affected muscles in patients previously treated with botulinum toxin (maximum: &le;50 units/site). Initial dose in previously untreated patients should be lower. Sequential dosing should be based on the patient's head and neck position, localization of pain, muscle hypertrophy, patient response, and previous adverse reactions. The total dose injected into the sternocleidomastoid muscles should be &le;100 units to decrease the occurrence of dysphagia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Canadian labeling (not in U.S. labeling):",
"     </i>",
"     I.M.: Botox&reg;: Effective range of 200-360 units has been used in clinical practice; administer no more frequently than every 2 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic migraine:",
"     </b>",
"     I.M.: Administer 5 units/0.1 mL per site. Recommended total dose is 155 units once every 12 weeks. Each 155 unit dose should be equally divided and administered bilaterally, into 31 total sites as described below (refer to prescribing information for specific diagrams of recommended injection sites):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corrugator: 5 units to each side (2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Procerus: 5 units (1 site only)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Frontalis: 10 units to each side (divided into 2 sites/side)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Temporalis: 20 units to each side (divided into 4 sites/side)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Occipitalis: 15 units to each side (divided into 3 sites/side)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervical paraspinal: 10 units to each side (divided into 2 sites/side)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Trapezius: 15 units to each side (divided into 3 sites/side)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity (focal):",
"     </b>",
"     I.M.: Individualize dose based on patient size, extent, and location of muscle involvement, degree of spasticity, local muscle weakness, and response to prior treatment. In clinical trials, total doses up to 360 units (Botox&reg;) were administered as separate injections typically divided among selected muscles; may repeat therapy at &ge;3 months with appropriate dosage based upon the clinical condition of patient at time of retreatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suggested guidelines for the treatment of upper limb spasticity. The lowest recommended starting dose should be used and &le;50 units/site should be administered.",
"     <b>",
"      Note:",
"     </b>",
"     Dose listed is total dose administered as individual or separate intramuscular injection(s):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Biceps brachii: 100-200 units (divided into 4 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor digitorum profundus: 30-50 units (1 site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor digitorum sublimes: 30-50 units (1 site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor carpi radialis: 12.5-50 units (1 site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor carpi ulnaris: 12.5-50 units (1 site)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Suggested guidelines for the treatment of stroke-related upper limb spasticity:",
"     <i>",
"      Canadian labeling:",
"     </i>",
"     <b>",
"      Note:",
"     </b>",
"     Dose listed is total dose administered as individual or separate intramuscular injection(s):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Biceps brachii: 100-200 units (up to 4 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor digitorum profundus: 15-50 units (1-2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor digitorum sublimes: 15-50 units (1-2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor carpi radialis: 15-60 units (1-2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor carpi ulnaris: 10-50 units (1-2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adductor pollicis: 20 units (1-2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Flexor pollicis longus: 20 units (1-2 sites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strabismus:",
"     </b>",
"     I.M.:",
"     <b>",
"      Note:",
"     </b>",
"     Several minutes prior to injection, administration of local anesthetic and ocular decongestant drops are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vertical muscles and for horizontal strabismus &lt;20 prism diopters: 1.25-2.5 units in any one muscle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Horizontal strabismus of 20-50 prism diopters: 2.5-5 units in any one muscle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Persistent VI nerve palsy &ge;1 month: 1.25-2.5 units in the medial rectus muscle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Re-examine patients 7-14 days after each injection to assess the effect of that dose. Subsequent doses for patients experiencing incomplete paralysis of the target may be increased up to twice the previous administered dose. The maximum recommended dose as a single injection for any one muscle is 25 units. Do not administer subsequent injections until the effects of the previous dose are gone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary axillary hyperhidrosis:",
"     </b>",
"     Intradermal: 50 units/axilla. Injection area should be defined by standard staining techniques. Injections should be evenly distributed into multiple sites (10-15), administered in 0.1-0.2 mL aliquots, ~1-2 cm apart. May repeat when clinical effect diminishes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Cosmetic uses:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Reduction of glabellar lines:",
"     </b>",
"     Adults &le;65 years: I.M.: An effective dose is determined by gross observation of the patient's ability to activate the superficial muscles injected. The location, size, and use of muscles may vary markedly among individuals. Inject 0.1 mL (4 units) dose into each of five sites, two in each corrugator muscle and one in the procerus muscle for a total dose 0.5 mL (20 units) administered no more frequently than every 3-4 months.",
"     <b>",
"      Note:",
"     </b>",
"     Treatment of adults &gt;65 years is approved in the Canadian labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reduction of forehead lines",
"     </b>",
"     <i>",
"      (Canadian labeling; not in U.S. labeling):",
"     </i>",
"     I.M.: Inject 2-6 units into each of four sites in the frontalis muscle every 1-2 cm along either side of forehead crease and 2-3 cm above eyebrows for total dose of 24 units.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Reduction of lateral canthus lines;",
"     </b>",
"     <i>",
"      (Canadian labeling; not in U.S. labeling):",
"     </i>",
"     I.M.: Inject 2-6 units into each of 1-3 injection sites, lateral to the lateral orbital rim.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F141957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/18/295?source=see_link\">",
"      see \"OnabotulinumtoxinA (botulinum toxin type A, Botox): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     The lowest recommended dose should be used when initiating treatment (regardless of indication). Canadian labeling (not in U.S. labeling) recommends a maximum cumulative dose of 6 units/kg (up to 200 units) over 3 months in pediatric patients receiving treatment for more than 1 indication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Blepharospasm/strabismus:",
"     </b>",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical dystonia:",
"     </b>",
"     Children &ge;16 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Spasticity (cerebral palsy related [dynamic equinus foot deformity]):",
"     </b>",
"     Botox&reg;:",
"     <i>",
"      Canadian labeling (not approved in U.S. labeling):",
"     </i>",
"     Children &ge;2 years: I.M.: 4 units/kg (total dose) divided into two injections into medial and lateral heads of the gastrocnemius of affected leg; if clinically indicated, may repeat every 2 months (maximum dose: 200 units); in diplegia, the recommended dose is 6 units/kg (total dose) divided between affected limbs",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Initiate therapy at lowest recommended dose. Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Botox&reg;:",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     type A neurotoxin complex 100 units,",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     type A neurotoxin complex 200 units [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Botox&reg; Cosmetic:",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     type A neurotoxin complex 100 units,",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     type A neurotoxin complex 50 units [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F10076323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Botox&reg;: Botulinum toxin A 50 units [contains albumin (human)], 100 units [contains albumin (human)], 200 units [contains albumin (human)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Botox Cosmetic&reg;: Botulinum toxin A 50 units [contains albumin (human)], 100 units [contains albumin (human)], 200 units [contains albumin (human)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F8104244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176360.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM176360.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bladder dysfunction (including overactive bladder and detrusor overactivity associated with neurologic condition): Intradetrusor:  Prophylactic antimicrobial therapy (excluding aminoglycosides) should be administered 1-3 days prior to, on the day of, and for 1-3 days following onabotulinumtoxinA administration. If a local anesthetic is instilled into the bladder prior to treatment, drain bladder and irrigate with normal saline prior to injection. Instill saline into bladder to optimize visualization but avoid overdistention. The injection needle should be primed with ~1 mL of reconstituted onabotulinumtoxinA prior to injection to remove any air. Administer onabotulinumtoxinA via flexible or rigid cystoscope by inserting needle with the recommended volume ~2 mm into the detrusor (avoid the trigone). Injections should be spaced ~1 cm apart. After completion of injections, drain saline from bladder and monitor patient for &ge;30 minutes. In overactive bladder patients, a spontaneous void should also occur prior to patient leaving the clinic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Blepharospasm: Use a 27- or 30-gauge needle without electromyography guidance. Avoid injecting near the levator palpebrae superioris (may decrease ptosis); avoid medial lower lid injections (may decrease diplopia). Apply pressure at the injection site to prevent ecchymosis in the soft eyelid tissues.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cervical dystonia: Use 25-, 27-, or 30-gauge needle for superficial muscles and a longer 22-gauge needle for deeper musculature; electromyography may help localize the involved muscles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic migraines: Use a 0.5 inch, 30 gauge needle to administer 5 units/0.1 mL to each of the 31 sites.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Detrusor overactivity associated with neurologic condition: Prophylactic antimicrobial therapy (excluding aminoglycosides) should be administered 1-3 days prior to, on the day of, and for 1-3 days following onabotulinumtoxinA administration. If a local anesthetic is instilled into the bladder prior to treatment, drain bladder and irrigate with normal saline prior to injection. Instill saline into bladder to optimize visualization but avoid overdistention. Administer onabotulinumtoxinA via flexible or rigid cystoscope by inserting needle ~2 mm into the detrusor. A total of 30 injections (1 mL per injection) should be administered ~1 cm apart. After completion of injections, drain saline from bladder and monitor patient for &ge;30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Spasticity (cerebral palsy related; Canadian labeling [not in U.S. labeling]): Use a 23- to 26-gauge needle for administration into the medial and lateral heads of the gastrocnemius muscle of the affected limb.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Spasticity (focal): Use a 25-, 27-, or 30-gauge needle for superficial muscles and a longer 22-gauge needle for deeper musculature; electromyography or nerve stimulation may help localize the involved muscles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strabismus injections: Must use surgical exposure or electromyographic guidance; use the electrical activity recorded from the tip of the injections needle as a guide to placement within the target muscle. Local anesthetic and ocular decongestant should be given before injection. The volume of injection should be 0.05-0.15 mL per muscle. Many patients will require additional doses because of inadequate response to initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Primary axillary hyperhidrosis: Inject each dose intradermally to a depth of ~2 mm and at a 45&deg; angle. Do not inject directly into areas marked in ink (to avoid permanent tattoo effect). Prior to administration, injection area should be defined by standard staining techniques such as Minor's Iodine-Starch Test.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Instructions for Minor's Iodine-Starch Test: Patient should shave underarms and refrain from using deodorants or antiperspirants for 24 hours prior to test. At 30 minutes prior to test, patient should be at rest, no exercise, and not consume hot beverages. Underarm area should be dried and immediately painted with iodine solution. After area dries, lightly sprinkle with starch powder. Gently blow off excess powder. A deep blue-black color will develop over the hyperhidrotic area in ~10 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reduction of glabellar lines (Botox&reg; Cosmetic): Use a 30- to 33-gauge needle. Inject into each of 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle). Ensure injected volume/dose is accurate and where feasible keep to a minimum. Avoid injection near the levator palpebrae superioris. Lateral corrugator injections should be at least 1 cm above the bony supraorbital ridge. Do not inject toxin closer than 1 cm above the central eyebrow.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of strabismus and blepharospasm associated with dystonia (including benign essential blepharospasm or VII nerve disorders) in patients &ge;12 years of age; treatment of cervical dystonia (spasmodic torticollis) in patients &ge;16 years of age; temporary improvement in the appearance of lines/wrinkles of the face (moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity) in adult patients &le;65 years of age; treatment of severe primary axillary hyperhidrosis in adults not adequately controlled with topical treatments; treatment of focal spasticity (specifically upper limb spasticity) in adults; prophylaxis of chronic migraine headache (&ge;15 days/month with &ge;4 hours/day headache duration) in adults; treatment of urinary incontinence due to detrusor overactivity associated with neurologic conditions in adults; treatment of overactive bladder (with symptoms of urge urinary incontinence, urgency, and frequency) in adults with an inadequate response or intolerance to anticholinergic medication.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Dynamic equinus foot deformity in pediatric cerebral palsy patients; treatment of forehead, lateral canthus, and glabellar lines in adults &gt;65 years of age",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F141969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of oromandibular dystonia, spasmodic dysphonia (laryngeal dystonia) and other dystonias (ie, writer's cramp, focal task-specific dystonias); treatment of dynamic muscle contracture in pediatric cerebral palsy patients",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7728706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Botulinum products are not interchangeable; potency differences may exist between the products.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6474807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects usually occur in 1 week and may last up to several months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      &gt;10%:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Bladder dysfunction:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (18% to 49%), urinary retention (17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Cervical dystonia:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (32%), headache (&le;11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dysphagia (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Focal weakness (17%), neck pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Other indications (blepharospasm, primary axillary hyperhidrosis, strabismus):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Ptosis (blepharospasm 21%; strabismus 1% to 38%), vertical deviation (strabismus 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      1% to 10%:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Bladder dysfunction:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Dysuria (4% to 9%), urinary retention (6%), bacteriuria (4%), hematuria (4%), residual urine volume increased (not requiring catheterization: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscular weakness (4%), gait disturbance (3%), muscle spasm (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cervical dystonia:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, fever, malaise, speech disorder",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction: Soreness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, hypertonia, numbness, stiffness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia, ptosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Cerebral palsy spasticity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (1% to 2%), fever (1%), lethargy (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Falling, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Chronic migraines:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), worsening migraine (4%), facial paresis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neck pain (9%), stiffness(4%), weakness (4%), myalgia (3%), musculoskeletal pain (3%), muscle spasm (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Eyelid ptosis (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Injection site pain (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Focal spasticity:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Pain in extremity, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Bronchitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Other indications (blepharospasm, primary axillary hyperhidrosis, reduction of glabellar lines, strabismus):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, headache, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, skin tightness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction: Hemorrhage, pain, soreness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, facial pain, neck pain, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Diplopia, irritation/tearing (includes dry eye, lagophthalmos, photophobia); keratitis, ptosis, superficial punctate keratitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pharyngitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome, infection, nonaxillary sweating",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      &lt;1% (Limited to important or life-threatening):",
"     </b>",
"     <i>",
"      Any indication:",
"     </i>",
"     Abdominal distension, abdominal pain, abnormal dreams, acute angle closure glaucoma, allergic reactions, alopecia, anaphylaxis, ankle pain, anorexia, anterior segment eye ischemia, appetite decreased, arrhythmia, arthralgia, aspiration pneumonia, asthma, autonomic dysreflexia, blurred vision, brachial plexopathy, cardiovascular insufficiency, ciliary ganglion damage, circulatory collapse, colitis, conjunctivitis, corneal perforation, denervation, dermatitis, dermatitis psoriasiform, diaphoresis, diarrhea, dysarthria, dysphonia, ectropion, entropion, erythema, erythema multiforme, eye edema, eye pain, eyelid edema, facial palsy, facial weakness, fatigue, focal facial paralysis, glaucoma, hearing loss, herpes zoster, hypoacusis, hypoesthesia, injection site inflammation, knee pain, leg cramps, lethargy, lymphadenopathy, madarosis, MI, muscle atrophy, myalgia, myasthenia gravis exacerbation, neutralizing antibody formation, numbness (local), paresthesia, peripheral edema, peripheral neuropathy, pneumonia, psoriasiform eruption, radiculopathy, reduced blinking leading to corneal ulceration, respiratory depression, respiratory failure, retinal vein occlusion, retrobulbar hemorrhage, seizure, somnolence, syncope, tinnitus, tremor, trismus, urticaria, vertigo with nystagmus, visual disturbances, vitreous hemorrhage, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to botulinum toxin, or any component of the formulation; infection at the proposed injection site(s); intradetrusor injection in patients with a urinary tract infection; intradetrusor injection in patients with urinary retention  and in patients with post-void residual (PVR) urine volume &gt;200 mL who are not routinely performing clean intermittent self-catheterization",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur rarely; immediate treatment (including epinephrine 1:1000) should be available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antibody formation: Higher doses or more frequent administration may result in neutralizing antibody formation and loss of efficacy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autonomic dysreflexia: Has been observed with therapy in patients with detrusor overactivity associated with a neurologic condition; acts as stimuli to trigger an exaggerated sympathetic and parasympathetic response. Clinical presentation often includes headache, a marked increase in blood pressure, and diaphoresis; prompt treatment may be required in patients presenting with severe symptoms (eg, hypertensive crisis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular events: Rarely, arrhythmia and myocardial infarction have been reported, sometimes in patients with preexisting cardiovascular disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dysphagia: Common when used for cervical dystonia and may persist anywhere from 2 weeks up to 5 months after administration. In severe cases, patients may require alternative feeding methods. Risk factors include smaller neck muscle mass, bilateral injections into the sternocleidomastoid muscle, or injections into the levator scapulae.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: Use with caution in patients with bleeding disorders and/or receiving anticoagulation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic toxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence which may develop within hours or weeks following injection. The risk is likely greatest in children treated for the unapproved use of spasticity. Systemic effects have occurred following use in approved and unapproved uses, including low doses.",
"     </b>",
"     Immediate medical attention required if respiratory, speech, or swallowing difficulties appear.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary retention: An increased incidence of urinary retention and need for catheterization has been observed in patients receiving therapy for bladder dysfunction (overactive bladder or detrusor overactivity associated with a neurologic condition); due to the risk of urinary retention, treatment should only be used in patients able and willing to initiate post-treatment catheterization, if required. Patients with diabetes had an increased incidence of urinary retention. Patients experiencing difficulty in voiding should be instructed to consult their healthcare provider.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Urinary tract infection (UTI): Therapy in patients with overactive bladder increases the incidence of urinary tract infections (UTIs); clinical trials for overactive bladder excluded patients with &gt;2 UTIs in the previous 6 months and those taking chronic antibiotics for prophylaxis of recurrent UTIs. Consider risks vs benefits when contemplating use in these patients or patients experiencing recurrent UTIs during treatment.  Patients with diabetes had an increased incidence of UTI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Episodic migraines: Safety and efficacy have not been established in patients with 14 or fewer headaches per month.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular disease: Use with caution in patients with neuromuscular diseases such as myasthenia gravis or Lambert- Eaton syndrome and neuropathic disorders (such as amyotrophic lateral sclerosis). Risk of adverse events including severe dysphagia and respiratory compromise may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Retrobulbar hemorrhages may occur from needle penetration into orbit when treating strabismus; spatial disorientation, double vision, or past-pointing may occur if one or more extraocular muscles are paralyzed. Covering the affected eye may help. Careful testing of corneal sensation, avoidance of lower lid injections, and treatment of epithelial defects are necessary. Use caution in patients with angle closure glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use extreme caution in patients with pre-existing respiratory disease; treatment with botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular transmission: Use with extreme caution in patients receiving other agents that may interfere with neuromuscular transmission (eg, aminoglycosides, neuromuscular-blocking agents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Albumin: Product contains albumin and may carry a remote risk of virus transmission.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Product interchangeability: Botulinum products (abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bladder dysfunction: Appropriate use: Rule out acute urinary tract infection (UTI) prior to treatment; appropriate prophylactic antimicrobial therapy is required prior to, during, and following treatment. Discontinue antiplatelet therapy at least 3 days prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic therapy: Long-term effects of chronic therapy unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous tasks: May impair ability to drive and/or operate machinery due to the intended effects of treatment; if loss of strength, muscle weakness, or impaired vision occur, patients should avoid driving or engaging in other hazardous activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection site: Use with caution if there is excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present. Serious events (including fatalities) have been observed with direct injection into the esophagus, stomach, salivary glands and oro-lingual-pharyngeal region. Use caution when administering in close proximity to the lungs; pneumothorax has been reported following administration near the thorax.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Primary axillary hyperhidrosis: Appropriate use: Evaluate for secondary causes prior to treatment (eg, hyperthyroidism). Safety and efficacy for treatment of hyperhidrosis in other areas of the body have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Temporary reduction in glabellar lines: Appropriate use: Do not use more frequently than every 3 months (Canadian labeling states not to use more frequently than every 2 months). Patients with marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart were excluded from clinical trials. Use with caution in patients with surgical alterations to the facial anatomy. Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration. Spatial disorientation, double vision, or past pointing may occur if one or more extraocular muscles are paralyzed.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141912\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: OnabotulinumtoxinA may enhance the adverse neuromuscular effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: May enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: OnabotulinumtoxinA may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F141914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F141926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreased fetal body weight, delayed ossification, maternal toxicity, abortions, and fetal malformations were observed in animal studies. Human reproduction studies have not been conducted. Avoid use in pregnancy. Based on limited case reports, adverse fetal effects have not been observed with inadvertent administration during pregnancy. It is currently recommended to ensure adequate contraception in women of childbearing potential.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F141943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F141925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Botox Cosmetic Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 unit (1): $346.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 unit (1): $630.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Botox Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 unit (1): $630.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 unit (1): $1260.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13836598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Detrusor overactivity associated with neurologic condition: Evaluate postvoid residual (PVR) urine volume within 2 weeks post-treatment and periodically thereafter up to 12 weeks in patients not catheterizing. Initiate catheterization with PVR urine volume &gt;200 mL and continue until PVR &lt;200 mL.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Botox (AR, AU, BE, CH, CZ, DE, DK, ES, FI, FR, GB, HR, IE, IT, LU, NL, NO, PL, SE);",
"     </li>",
"     <li>",
"      Dysport (BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, PL, SE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     OnabotulinumtoxinA (previously known as botulinum toxin type A) is a neurotoxin produced by",
"     <i>",
"      Clostridium botulinum",
"     </i>",
"     , spore-forming anaerobic bacillus, which appears to affect only the presynaptic membrane of the neuromuscular junction in humans, where it prevents calcium-dependent release of acetylcholine and produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls. Intradetrusor injection affects efferent pathways of detrusor activity by inhibiting release of acetylcholine. Intradermal injection results in temporary sweat gland denervation, reducing local sweating.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action (improvement):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Blepharospasm: ~3-4 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervical dystonia: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detrusor overactivity associated with neurologic condition: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reduction of glabellar lines (Botox&reg; Cosmetic): 1-2 days, increasing in intensity during first week",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spasticity: Focal and cerebral palsy related: &lt;2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Strabismus: ~1-2 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Blepharospasm: ~3-4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervical dystonia: &le;3-4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Detrusor overactivity associated with neurologic condition: ~42-48 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Primary axillary hyperhidrosis: 201 days (mean)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reduction of glabellar lines (Botox&reg; Cosmetic): ~3-4 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spasticity: ~3-3.5 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Strabismus: ~2-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Not expected to be present in peripheral blood at recommended doses following intramuscular (I.M.) injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Blepharospasm: 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervical dystonia: ~6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spasticity (focal): 4-6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Strabismus: Within first week",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Batra RS, Dover JS, and Arndt KA, \"Adverse Event Reporting for Botulinum Toxin Type A,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2005, 53(6):1080-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/16310074/pubmed\" id=\"16310074\" target=\"_blank\">",
"        16310074",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Borodic GE and Pearce LB, &ldquo;New Concepts in Botulinum Toxin Therapy,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1994, 11(3):145-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/7811397/pubmed\" id=\"7811397\" target=\"_blank\">",
"        7811397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Brisinda G, Maria G, Bentivoglio AR, et al, &ldquo;A Comparison of Injections of Botulinum Toxin and Topical Nitroglycerin Ointment for the Treatment of Chronic Anal Fistula,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1999, 341:65-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/10395629/pubmed\" id=\"10395629\" target=\"_blank\">",
"        10395629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bushara KO, Jones JW, and Park DM, &ldquo;Localized Graying of Eyebrow Hair, A Side Effect of Botulinum Toxin Injections,&rdquo;",
"      <i>",
"       Mov Disord",
"      </i>",
"      , 1995, 10:382.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Childers MK, Brashear A, Jozefczyk P, et al, &ldquo;Dose-Dependent Response to Intramuscular Botulinum Toxin Type A for Upper-Limb Spasticity in Patients After a Stroke,&rdquo;",
"      <i>",
"       Arch Phys Med Rehab",
"      </i>",
"      , 2004, 85(7):1063-69.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/15241751/pubmed\" id=\"15241751\" target=\"_blank\">",
"        15241751",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clinical Use of Botulinum Toxin,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1991, 48(12):1294-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/1845036/pubmed\" id=\"1845036\" target=\"_blank\">",
"        1845036",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen S and Parkman HP, &ldquo;Treatment of Achalasia - Whalebone to Botulinum Toxin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(12):815-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/7862188/pubmed\" id=\"7862188\" target=\"_blank\">",
"        7862188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Cosmetic Use of Botulinum Toxin,&rdquo;",
"      <i>",
"       Medical Letter",
"      </i>",
"      , 1999, 41:63-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/10436771/pubmed\" id=\"10436771\" target=\"_blank\">",
"        10436771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cot&eacute; TR, Mohan AK, Polder JA, et al, \"Botulinum Toxin Type A Injections: Adverse Events Reported to the U.S. Food and Drug Administration in Therapeutic and Cosmetic Cases,\"",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2005, 53(3):407-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/16112345/pubmed\" id=\"16112345\" target=\"_blank\">",
"        16112345",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cruz F, Herschorn S, Aliotta P, et al, &ldquo;Efficacy and Safety of OnabotulinumtoxinA in Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity: A Randomised, Double-Blind, Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Eur Urol",
"      </i>",
"      , 2011, 60(4):742-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/21798658/pubmed\" id=\"21798658\" target=\"_blank\">",
"        21798658",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ferrari AP Jr, Siqueira ES, and Brant CQ, &ldquo;Treatment of Achalasia in Chagas' Disease With Botulinum Toxin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 332(12):824-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jankovic J and Brin MF, &ldquo;Therapeutic Uses of Botulinum Toxin,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1991, 324(17):1186-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/2011163/pubmed\" id=\"2011163\" target=\"_blank\">",
"        2011163",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Naumann M and Jankovic J, \"Safety of Botulinum Toxin Type A: A Systematic Review and Meta-Analysis,\"",
"      <i>",
"       Curr Med Res Opin",
"      </i>",
"      , 2004, 20(7):981-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/15265242/pubmed\" id=\"15265242\" target=\"_blank\">",
"        15265242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasricha PJ, Ravich WJ, Hendrix TR, et al, &ldquo;Intrasphincteric Botulinum Toxin for the Treatment of Achalasia,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1995, 322(12):774-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/2308606/pubmed\" id=\"2308606\" target=\"_blank\">",
"        2308606",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasricha PJ, Ravich WJ, Hendrix TR, et al, &ldquo;Treatment of Achalasia With Intrasphincteric Injection of Botulinum Toxin,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1994, 121(8):590-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/8085691/pubmed\" id=\"8085691\" target=\"_blank\">",
"        8085691",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Repka MX, Savino PJ, and Reinecke RD, &ldquo;Treatment of Acquired Nystagmus With Botulinum Neurotoxin A,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 1994, 112(10):1320-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/7945034/pubmed\" id=\"7945034\" target=\"_blank\">",
"        7945034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sheean GL, Murray NM, and Marsden CD, &ldquo;Pain and Remote Weakness in Limbs Injected With Botulinum Toxin A for Writer's Cramp,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1995, 346(8968):154-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/27/10681/abstract-text/7603232/pubmed\" id=\"7603232\" target=\"_blank\">",
"        7603232",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9161 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10681=[""].join("\n");
var outline_f10_27_10681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9605655\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141936\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141937\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141973\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141939\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141957\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141940\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141917\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10076323\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141903\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8104244\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141919\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141918\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141969\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7728706\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6474807\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141922\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141907\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299790\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141912\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141914\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141926\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141943\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141925\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13836598\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038541\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141906\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141921\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9161\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9161|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/55/16245?source=related_link\">",
"      OnabotulinumtoxinA (botulinum toxin type A, Botox): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?0/18/295?source=related_link\">",
"      OnabotulinumtoxinA (botulinum toxin type A, Botox): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10682="Transplantation immunobiology";
var content_f10_27_10682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transplantation immunobiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10682/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10682/contributors\">",
"     John Vella, MD, FACP, FRCP, FASN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10682/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10682/contributors\">",
"     Daniel C Brennan, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10682/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/27/10682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/27/10682/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/27/10682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mammalian immune system is an extraordinarily complex system that has developed in response to evolutionary stressors provided by co-existence with micro-organisms over millions of years. The system can be divided into two components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Natural immunity, which refers to the nonspecific immune response",
"     </li>",
"     <li>",
"      Adaptive immunity, which refers to the response to a specific antigen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In organ transplantation, the principal target of the immune response to the graft are the Major Histocompatibility Complex (MHC) molecules expressed on the surface of donor cells (allo-MHC); this feature is a form of adaptive immunity.",
"   </p>",
"   <p>",
"    The immunobiology of solid transplantation will be reviewed here. The immunobiology of bone marrow or stem transplantation, which primarily involves graft-versus-host and graft-versus-tumor effects, is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=see_link\">",
"     \"Biology of the graft-versus-tumor effect following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To adequately understand the immune response to transplanted tissue, it is helpful to also review the general immune response; there will be an emphasis upon those elements involved in the response to donor antigens. More detailed discussions concerning various aspects of the immune system are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"     \"The humoral immune response\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NATURAL AND ADAPTIVE IMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural or innate immunity refers to the older, nonspecific immune system that involves the recruitment and involvement of macrophages, neutrophils, natural killer cells, cytokines, certain cellular receptors, and complement components [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/1\">",
"     1",
"    </a>",
"    ]. Physical damage and infective agents recruit a variety of inflammatory processes that do not involve recognition of specific antigens. However, they induce a robust inflammatory response due to the induction, presence,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    absence of specific features, such as the absence of complement inhibitory receptors on most foreign organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/2\">",
"     2",
"    </a>",
"    ]. A detailed review of the innate immune system is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, adaptive immunity involves recognition of specific antigen and confers both",
"    <strong>",
"     specificity",
"    </strong>",
"    and a",
"    <strong>",
"     memory",
"    </strong>",
"    effect by T and B lymphocytes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-cells recognize antigen in the form of peptide bound to MHC proteins [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"       \"The adaptive cellular immune response\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      B cells have immunoglobulin receptors that can recognize the antigenic portions of intact molecules. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=see_link\">",
"       \"The humoral immune response\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"       \"Function and clinical applications of immunoglobulins\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The natural and adaptive immune systems are closely interrelated. Antigen-specific T-cell activation leads to the production and secretion of cytokines and chemokines which recruit components of the \"natural immune\" system as well as the specific mechanisms of alloantibody production and CD8 positive cell-mediated cytotoxicity. In addition, local tissue production of complement components appears essential for full T-cell activation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An example of adaptive immunity involving B cells and its manipulation to permit transplantation involves ABO antigens. Previously, a classic contraindication to transplantation is the presence of ABO-incompatibility between donor and possible recipient, a setting in which the presence of preformed donor-specific antibodies rapidly destroy an allograft. The current principal method of circumventing this difficulty involves desensitization protocols, in which plasmapheresis, (possibly) splenectomy, and aggressive immunosuppressive regimens result in the removal of these antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, transplantation of such incompatible organs to infants, in whom humoral immunity has not yet developed, may also result in tolerance. This was reported in infants who have received and accepted ABO-incompatible hearts for several years, with evidence suggesting tolerance due to the deletion of donor-specific B cell clones [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of antibodies that target non-HLA endothelial cell antigens has long been suspected in solid organ transplantation. One study explored the relationship between anti-endothelial cell antibodies and rejection in 226 kidney allograft recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/6\">",
"     6",
"    </a>",
"    ]. Although pre-existing antibodies were not associated with increased rejection or decreased",
"    <span class=\"nowrap\">",
"     recipient/graft",
"    </span>",
"    survival, de novo antibodies were associated with an increased risk of early acute rejection. Acute rejections were generally more severe and associated with glomerulitis and peritubular capillary inflammation. More patients with de novo anti-endothelial antibodies developed graft dysfunction. A test to evaluate the presence of these antibodies is being developed (XM-ONE, Absorber, Stockhold, Sweden) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     T-cell activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-cell recognition of antigen is the primary event that initiates the effector mechanisms of the immune response. This key step requires the following two discrete signals (",
"    <a class=\"graphic graphic_figure graphicRef72231 \" href=\"UTD.htm?16/15/16625\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signal 1 is provided by the interaction of the T-cell receptor (TCR) with antigen presented as a peptide by the antigen-presenting cell (APC).",
"     </li>",
"     <li>",
"      Signal 2 is provided by a costimulatory",
"      <span class=\"nowrap\">",
"       receptor/ligand",
"      </span>",
"      interaction on the",
"      <span class=\"nowrap\">",
"       T-cell/APC",
"      </span>",
"      cell surface [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once activated, T-cells undergo clonal expansion under the influence of mitogenic growth and differentiation factors, such as interleukin-2. These activated T-cells then perform the following functions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Induce CD8 positive T-cell mediated cytotoxicity",
"     </li>",
"     <li>",
"      Provide help for B cell antibody production",
"     </li>",
"     <li>",
"      Provide help for macrophages to induce delayed type hypersensitivity responses (",
"      <a class=\"graphic graphic_algorithm graphicRef54098 \" href=\"UTD.htm?22/61/23518\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The individual components that contribute to the immune response are outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MHC STRUCTURE AND FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major histocompatibility complex is a region of highly polymorphic genes located on the short arm of human chromosome 6 in humans (",
"    <a class=\"graphic graphic_figure graphicRef51352 \" href=\"UTD.htm?0/15/255\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .) The protein products of the MHC are expressed on the surfaces of a variety of cells. The human system is called HLA and is analogous to the H-2 and RT1 systems in mice and rats, respectively.",
"   </p>",
"   <p>",
"    These cell surface proteins are the principal antigenic determinants of graft rejection. Thus, organs transplanted between MHC identical individuals are readily accepted, whereas organs transplanted between MHC antigen mismatched individuals are inevitably rejected in the absence of immunosuppressive agents.",
"   </p>",
"   <p>",
"    The normal biological role of these proteins was elucidated during the 1970s. It was discovered that antigen specific T-cells do not recognize antigen in free or soluble form or as intact protein. Instead, T-cells recognize portions of protein antigens that have been fragmented into peptides bound to MHC molecules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, MHC molecules are a major component of the immune system, as they provide the means for displaying antigenic peptides to T-cells. T-cells are exquisitely selected during development in the thymus to have moderate affinity with self-MHC molecules, so that they may bind to antigenic peptides in the context of MHC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link\">",
"     \"Normal B and T lymphocyte development\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The protein products of the MHC have been classified into two major groups (class I and II). The structures of antigen-presenting MHC class I and II molecules are similar. They each contain a &szlig;-pleated sheet that provides a platform supporting two alpha-helical regions, thus forming a groove in which rests a peptide antigen (",
"    <a class=\"graphic graphic_figure graphicRef56966 \" href=\"UTD.htm?33/61/34774\">",
"     figure 3",
"    </a>",
"    ). The &szlig;-pleated regions are relatively conserved, as there is a great deal of sequence homology between individuals with different MHC genes. By comparison, the alpha-helical regions are more variable or polymorphic. All the polymorphisms contribute to the variable shapes of the peptide binding groove and determine the motifs for peptide selection.",
"   </p>",
"   <p>",
"    Immunogens are defined as foreign proteins that induce an immune response, with antigens being the targets of that response. In general, immunogens are also antigens. Such proteins tend to have defined regions of immunogenic amino acid sequences, termed epitopes, that may incite an immune response, as well as sequences that do not incite an immune response. The ability of an MHC molecule to bind antigen is determined by the amino-acid side chain structure of both the MHC molecule and the peptide which bind to it. The physiochemical structure of the peptide binding groove determines the type of peptides that may be bound.",
"   </p>",
"   <p>",
"    MHC polymorphism exists as a consequence of the vertebrate evolutionary response to microbial invasion and ensures the continuity of species in the presence of pandemic infection. Thus, a few individuals within a species will survive a pandemic (such as plague) because of the protective effect of MHC gene polymorphisms, thereby ensuring the survival of the species even if the majority of individuals succumb to the illness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     MHC class I and II",
"    </span>",
"    &nbsp;&mdash;&nbsp;MHC class I and II molecules differ in structure, expression, and the cellular compartment from which they obtain antigenic peptides to present to T-cells (",
"    <a class=\"graphic graphic_table graphicRef70970 \" href=\"UTD.htm?42/62/44011\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Class I",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class I MHC molecules contain two separate polypeptide chains:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MHC encoded alpha-chain which is divided into three domains (a1, a2 and a3)",
"     </li>",
"     <li>",
"      Non-MHC encoded &szlig; chain, &szlig;2 microglobulin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The portion of the MHC class I molecule that interacts with peptide antigen consists of the a1 and a2 domains which comprise approximately 180 amino acids starting at the amino terminus. Structurally, this region is comprised of a platform of &szlig;-pleated sheet that supports two parallel strands of alpha-helix which together form the peptide binding groove.",
"   </p>",
"   <p>",
"    Class I MHC molecules present cytoplasm-derived peptides that are representative of the normal components of the same cell or of intracellular parasites, principally viruses. Such proteins are degraded in the proteosome within the cytoplasm; the resultant peptide residues are transferred to the endoplasmic reticulum by",
"    <strong>",
"     T",
"    </strong>",
"    ransporters associated with",
"    <strong>",
"     A",
"    </strong>",
"    ntigen",
"    <strong>",
"     P",
"    </strong>",
"    resentation (TAP transporters). The final",
"    <span class=\"nowrap\">",
"     MHC/antigen",
"    </span>",
"    complex assembly then occurs within the endoplasmic reticulum before transportation to the cell surface.",
"   </p>",
"   <p>",
"    Once on the cell surface, class I MHC molecules present peptide antigens to",
"    <strong>",
"     CD8 positive T-cells",
"    </strong>",
"    . The CD8 positive T-cells subsequently induce cell lysis by either activating the cell's self destruct cycle (inducing apoptosis) or actively killing the infected cell via the release of a number of cytotoxic proteins. As viral infection can occur in most nucleated mammalian cells, MHC class I molecules are found on almost all cell types (except red blood cells), although the level of expression varies. Particularly high levels of class I MHC expression are expressed on antigen-presenting cells (APC), including dendritic cells, macrophages, B lymphocytes, and vascular endothelial cells.",
"   </p>",
"   <p>",
"    The nomenclature of MHC class I proteins in different species is the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Humans &mdash; HLA-A, HLA-B, and HLA-C",
"     </li>",
"     <li>",
"      Mouse &mdash; H-2 K, H-2 D, and H-2 L",
"     </li>",
"     <li>",
"      Rat &mdash; RT1.A and RT1.E.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Class II",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class II MHC molecules are alpha-beta heterodimers composed of noncovalently associated polypeptide chains. The two chains are similar in overall structure. Each chain contains a relatively conserved &szlig;-pleated sheet region as well as a more polymorphic alpha-helical region.",
"   </p>",
"   <p>",
"    The antigen binding region of the class II molecule is formed by an eight-stranded, pleated sheet platform supporting two alpha-helices that make up the walls of the antigen binding cleft, thereby resulting in an overall structure which is similar to that of class I MHC. As with class I molecules, genetic polymorphisms of class II MHC molecules determine the chemical surface of the cleft and are the principal determinants of the specificity and affinity of peptide binding and T-cell recognition.",
"   </p>",
"   <p>",
"    MHC class II molecules bind peptides derived from",
"    <strong>",
"     extracellular",
"    </strong>",
"    (exogenous) proteins. Within the endocytoplasmic reticulum, the alpha and &szlig; chains are associated, although the antigen binding groove is initially filled and protected by an invariant chain. The invariant chain is degraded once proper folding has occurred, resulting in the release of a class II associated invariant chain peptide (CLIP). Meanwhile, exogenous proteins that have been endocytosed and fragmented are transferred to the \"",
"    <strong>",
"     c",
"    </strong>",
"    ompartment for",
"    <strong>",
"     p",
"    </strong>",
"    eptide",
"    <strong>",
"     l",
"    </strong>",
"    oading\" (CPL) where they displace the CLIP from the MHC antigen binding groove. The tripartite structure (MHC alpha and &szlig; chain with peptide) is then brought to the cell surface where it is presented to",
"    <strong>",
"     CD4 positive T-cells",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    Class II MHC molecules are expressed constitutively only on the surface of interstitial dendritic cells, macrophages, and B cells. Epithelial cell and vascular endothelial cell MHC class II expression is strongly upregulated after exposure to a variety of pro-inflammatory cytokines which include IL-2 and IFN-gamma.",
"   </p>",
"   <p>",
"    The nomenclature used to describe MHC class II proteins in different species is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Humans &mdash; HLA-DP, HLA-DQ, and HLA-DR",
"     </li>",
"     <li>",
"      Rat &mdash; RT1.H, RT1.B, and RT1.D",
"     </li>",
"     <li>",
"      Mouse &mdash; I-A and I-E.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MINOR TRANSPLANTATION ANTIGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune response that develops in response to donor tissue is primarily directed against the MHC proteins. In contrast,",
"    <strong>",
"     minor",
"    </strong>",
"    histocompatibility antigens were initially described in the mouse as non MHC-encoded histocompatibility differences that led to allograft rejection. The tempo of rejection in mice that are mismatched for minor, but not major, antigens is slower compared with that observed with MHC incompatibility.",
"   </p>",
"   <p>",
"    Minor antigens are derived from polymorphic cellular proteins bound to MHC class I of the recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/9\">",
"     9",
"    </a>",
"    ]. Such antigens, for example, may be encoded by the Y chromosome in males (H-Y) and may thus induce an alloimmune response if male tissue is transplanted into a female recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/10\">",
"     10",
"    </a>",
"    ]. Another possibility is that the peptide antigen may be autosomally derived and represent polymorphisms among autosomal proteins or enzymes [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These minor antigens are generally peptides recognized by T-cells in the context of self-MHC and are most often recognized by CD8 positive T-cells that are cytotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/9\">",
"     9",
"    </a>",
"    ]. In a mouse model, slight modification of such a minor antigen resulted in the manufacture of regulatory T-cells that aided tolerance induction, suggesting that chronic low level stimulation of the T-cell receptor may promote tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/12\">",
"     12",
"    </a>",
"    ]. Minor antigens do not induce alloantibody responses.",
"   </p>",
"   <p>",
"    In bone marrow transplantation, minor antigens play an important role in graft-versus-host (GVH) disease in six HLA antigen matched individuals. In this setting, donor MHC that is identical to that of the recipient presents minor antigen in the context of \"self MHC\", thereby enhancing the GVH response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=see_link\">",
"     \"Pathogenesis of graft-versus-host disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MECHANISMS OF ALLORECOGNITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;T-cell recognition of alloantigen is the primary and central event that leads to the cascade of events that result in rejection of a transplanted organ. Individual T-cells (or colonies of identical T-cell clones) are monospecific as they recognize only a single peptide antigen presented in the context of MHC. Such clones are further defined on the basis of the identity of their T-cell receptor, their phenotype (CD4 or CD8 positive), and the pattern of cytokines produced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are at least two distinct, but not necessarily mutually exclusive, pathways of allorecognition, the direct and indirect pathways (",
"    <a class=\"graphic graphic_figure graphicRef64598 \" href=\"UTD.htm?18/61/19409\">",
"     figure 4",
"    </a>",
"    ). Each leads to the generation of different sets of allospecific T-cell clones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Direct pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the direct pathway, host T-cells recognize intact allo-MHC molecules on the surface of the",
"    <strong>",
"     donor",
"    </strong>",
"    or stimulator cell. Since MHC molecules that lack bound peptide are unstable and are therefore unrecognizable by T-cells, peptides derived from endogenous proteins that are bound into the groove of the donor MHC play a role in this mode of allorecognition [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct allorecognition by T-cells of intact surface MHC molecules has",
"    <strong>",
"     not",
"    </strong>",
"    been demonstrated outside of alloimmunity, so it is this phenomenon that uniquely distinguishes alloimmunity from ordinary immunity to microorganisms. This pathway is thought to be the",
"    <strong>",
"     dominant",
"    </strong>",
"    pathway involved in the early alloimmune response as the relative number of T-cells that proliferate on contact with allogeneic or donor cells is extraordinarily high compared with the number of clones that target antigen presented by self-APC [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, direct allorecognition is of major importance in acute allorejection. The transplanted organ carries a variable number of passenger APCs in the form of interstitial dendritic cells. Such APCs have a high density of allo-MHC molecules, and are capable of directly stimulating the recipient's T-cells.",
"   </p>",
"   <p>",
"    \"Professional APCs\" also provide the necessary costimulatory signals for full T-cell activation. Parenchymal cells, which may express donor MHC antigens, are frequently deficient in costimulatory molecules, and are less able to fully activate T-cells (\"non-professional APCs\"). However, evidence in transgenic animals suggests that some non-professional APCs, particularly vascular endothelial cells, may be sufficient to activate T-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, the corollary of this hypothesis is that as donor origin APCs are depleted over time after engraftment, the relative contribution provided by the direct pathway to the alloimmune response may dwindle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Indirect pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the indirect pathway, T-cells recognize processed alloantigen presented as peptides by",
"    <strong>",
"     self",
"    </strong>",
"    -APCs (host-APCs) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/16\">",
"     16",
"    </a>",
"    ]. The basic premise for indirect allorecognition as a mechanism involved in allograft rejection is that donor MHC molecules are shed from the graft, taken up by recipient APCs, and then presented to T-cells.",
"   </p>",
"   <p>",
"    Despite the misleading name, this pathway corresponds to the normal system of antigen recognition whereby the host's immune system recognizes foreign or exogenously derived peptide as presented by self-MHC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .) Numerous experimental studies have indicated that, in general, the dominant epitopes are mostly confined to the hypervariable regions that encode the peptide binding regions of the MHC molecule (see above). By comparison, the nonpolymorphic regions (structural regions) are relatively silent immunologically.",
"   </p>",
"   <p>",
"    In the setting of organ transplantation, peptides corresponding to polymorphic regions of the MHC induce a strong alloimmune response, whereas nonpolymorphic peptides fail to induce such a response. Whether a given section of MHC is immunogenic depends upon its amino acid sequence and on the structure of the MHC molecules in which it is itself presented. There is increasing interest in this \"indirect\" pathway as peptide antigens are relatively simple structures that can be readily synthesized [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This novel experimental approach permits the investigation of the molecular mechanisms of allograft rejection, which has led to several important findings. Allopeptide-reactive T-cells are present during both acute and chronic rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Although primary immune responses are characterized by T-cell proliferative responses to a limited number of immunogenic MHC allopeptides, secondary responses such as those that occur in",
"    <strong>",
"     chronic or late acute rejection",
"    </strong>",
"    are associated with T-cell proliferative responses to a more variable repertoire [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/16\">",
"     16",
"    </a>",
"    ]. This repertoire includes responses to peptides that were previously immunologically silent.",
"   </p>",
"   <p>",
"    Such a change in the pattern of T-cell responses has been termed epitope switching or spreading and can occur to peptides representing alternative regions within a given MHC hypervariable region (intramolecular spreading) or to peptides representing different MHC chains (intermolecular spreading) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/20\">",
"     20",
"    </a>",
"    ]. The precursor frequency of such MHC allopeptide reactive T-cells is typically low, as evidenced by studies in humans with chronic renal allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/18\">",
"     18",
"    </a>",
"    ]. However, such a finding is not unexpected given the indolent nature of chronic rejection. Since it is currently possible to assay donor specific MHC allopeptide specific T-cell activity, it may be possible to translate such information to clinical usefulness to predict rejection.",
"   </p>",
"   <p>",
"    Studies have also provided a link between MHC allopeptide-primed T-cells and the development of acute vascular type rejection mediated in part by accelerated alloantibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/21\">",
"     21",
"    </a>",
"    ]. Such studies also suggest that chronic allograft vasculopathy, the sine qua non of experimental chronic rejection, may be mediated by T-cells primed by the indirect pathway.",
"   </p>",
"   <p>",
"    In addition to the data that cast light on the molecular mechanisms underlying T-cell activation, MHC peptides may also be used therapeutically. Under some circumstances, animal studies reveal that administering donor specific class II MHC peptides to allograft recipients in the peritransplant period either orally or intrathymically can lead to transplantation tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     T-CELL COSTIMULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two signal model of T-cell activation implies that T-cells require two separate signals to enter the cell cycle (",
"    <a class=\"graphic graphic_figure graphicRef72231 \" href=\"UTD.htm?16/15/16625\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signal 1 is antigen-specific and is provided by the engagement of the T-cell receptor with peptide complexed with MHC on the antigen presenting cell (as above). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"       \"The adaptive cellular immune response\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Signal 2 is provided by the interaction of one or more T-cell surface receptors with their specific ligands on the APC cell surface (",
"      <strong>",
"       costimulatory pathways",
"      </strong>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     CD28, B7, and CTLA4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the numerous costimulatory pathways identified thus far, that provided by the interaction of",
"    <strong>",
"     CD28",
"    </strong>",
"    on the T-cell surface with its APC cell surface ligands,",
"    <strong>",
"     B7-1 or B7-2",
"    </strong>",
"    , has been most studied (",
"    <a class=\"graphic graphic_figure graphicRef60611 \" href=\"UTD.htm?17/21/17746\">",
"     figure 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/8,26-31\">",
"     8,26-31",
"    </a>",
"    ]. T-cell anergy and apoptosis induced by TCR signaling alone is prevented by signaling through CD28 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to these ligands that transduce a costimulatory or activating signal, cytotoxic T lymphocyte-associated antigen 4, or",
"    <strong>",
"     CTLA4",
"    </strong>",
"    , which also binds B7-1 and B7-2, provides an inhibitory signal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Although CD28 is expressed on resting T-cells, CTLA4 is expressed on the cell surface only after initial T-cell activation.",
"   </p>",
"   <p>",
"    Engagement of CTLA4 by binding with high affinity to its B7 counter-receptors appears to downregulate immune responses, suggesting that CTLA4 plays a critical feedback role in terminating T-cell responses. The importance of CTLA4 can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetically engineered mice in which the genes for CTLA4 have been deleted develop massive lymphoproliferative disease, culminating in early death [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The administration of blocking anti-CTLA4 monoclonal antibodies exacerbates autoimmune disease and prevents induction of T-cell anergy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Abatacept (CTLA4-Ig)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interest in the manipulation of the CD28:B7 pathway in transplantation has focused on the administration of CTLA4-Ig (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ), which is a recombinant fusion protein that contains the extracellular domain of soluble CTLA4 combined with an IgG1 heavy chain. CTLA4Ig is a competitive inhibitor of CD28 binding, resulting in T-cell anergy in vitro.",
"   </p>",
"   <p>",
"    In some transplantation models, the systemic administration of CTLA4Ig effectively dampened the immune response and prevented experimental acute and chronic rejection, resulting in prolonged graft survival and tolerance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a rat acute renal allograft rejection model, systemic tolerance induced by the administration of CTLA4Ig was associated with selective inhibition of Th1 (IL-2, IFN-g) and sparing of Th2 (IL-4, IL-10) cytokines in the target organ (",
"      <a class=\"graphic graphic_figure graphicRef77465 \" href=\"UTD.htm?10/47/10993\">",
"       figure 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CTLA4Ig can prevent or interrupt the development of chronic rejection in rat models of cardiac and renal transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/38\">",
"       38",
"      </a>",
"      ]. These data indicate that T-cell activation is a proximal event in the cascade that culminates in the arteriosclerosis of chronic rejection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the beneficial effect of CTLA4Ig is abrogated when coadministered with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/39\">",
"     39",
"    </a>",
"    ]. Although acute rejection was prevented, chronic rejection still occurred with combination therapy.",
"   </p>",
"   <p>",
"    This finding is of major potential importance with regard to human clinical transplantation since CTLA4Ig and other agents active in blocking T-cell costimulation (eg, CD40L antibody, see below) are soon to undergo clinical trials.",
"   </p>",
"   <p>",
"    To this end, a high affinity variant of CTLA4-Ig, named LEA29Y (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/41/43669?source=see_link\">",
"     belatacept",
"    </a>",
"    ), with significant immunosuppressive characteristics has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44135?source=see_link\">",
"     \"Investigational immunosuppressive drugs and approaches in clinical kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     CD40 and CD40L",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been great deal of interest in the role played by another costimulatory molecule, CD40, and its ligand, CD40L (CD154) in the alloimmune response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/29,42\">",
"     29,42",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on B cells and other APCs, including dendritic cells.",
"     </li>",
"     <li>",
"      CD40 ligand, CD40L (CD154), is expressed early on activated T-cells.",
"     </li>",
"     <li>",
"      CD40L is responsible for the main form of X-linked hyper IgM syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Binding of CD40L to CD40 is critical in providing cognate T-cell help for B cell Ig production and class switching; a defect in CD40L is responsible for the hyper IgM syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=see_link\">",
"     \"Primary humoral immune deficiencies: An overview\"",
"    </a>",
"    .) In addition, CD40L deficient T-cells fail to undergo effective clonal expansion. CD40 ligand is expressed by human vascular endothelial cells, smooth muscle cells, and human macrophages in vitro, and is coexpressed with its receptor CD40 in human atherosclerotic lesions in situ [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CD40 and CD40L are coexpressed in acutely rejecting murine cardiac allografts, although not in normal hearts or syngeneic grafts. In addition, CD40 and CD40L have been demonstrated in human cardiac allograft vessels during rejection. Such data provide the rationale for targeting this pathway to prevent rejection.",
"   </p>",
"   <p>",
"    The majority of studies reveal some prolongation of allograft survival by the administration of monoclonal antibodies directed against CD40L [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/42\">",
"     42",
"    </a>",
"    ]. Interestingly, costimulatory blockade (using the combination of CD28 and CD40L blockade) synergistically enhances allogeneic murine skin and cardiac allograft survival, and prevents the development of allograft vasculopathy in a murine aortic transplantation model [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Novel costimulatory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of additional T-cell costimulatory pathways have also been discovered. These include molecules related to the CD28-B7 family, namely ICOS-B7RP-1 and PD-1-PD-L, and newer members of the tumor necrosis factor (TNF)-TNF-receptor superfamily [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/46\">",
"     46",
"    </a>",
"    ]. The exact role of these pathways in the transplant setting is unclear. Emerging evidence suggests that some of these pathways, particularly ICOS-B7RP-1, are important in activating effector T-cells in transplant models [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     T-CELL HOMING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Naive T-cells are generated and mature in the thymus. Such T-cells wander within the blood and lymphocyte circulation; they preferentially leave via lymph nodes when they encounter antigen. Subsequently, T-cell activation ensues, leading to a cascade of events orchestrated by both cell surface and soluble proteins that target and amplify the alloimmune response. Once activated, the T-cells enter the cell cycle and express a variety of cell surface proteins that mediate adhesion to other cells and matrix proteins.",
"   </p>",
"   <p>",
"    These changes result in an increase in the number of activated, antigen-specific T-cells that are more adherent to accessory cells, particularly endothelial cells. In addition, antigen non-specific T-cells may also be activated and recruited into a rejection lesion when the level of inflammation is intense.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Leukocyte migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte migration from the circulation to a site of inflammation involves four discrete, coordinated steps [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/48\">",
"     48",
"    </a>",
"    ]. These steps include (",
"    <a class=\"graphic graphic_figure graphicRef60528 \" href=\"UTD.htm?42/23/43376\">",
"     figure 7",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rolling, which is selectin mediated",
"     </li>",
"     <li>",
"      Triggering, which is chemokine mediated",
"     </li>",
"     <li>",
"      Firm adhesion, which is integrin mediated",
"     </li>",
"     <li>",
"      Transmigration, which is PECAM and chemokine mediated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Rolling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step of rolling is mediated by the selectins, a family of three closely related proteins found on leukocytes, endothelial cells, and platelets (L, E and P Selectins, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/49\">",
"     49",
"    </a>",
"    ]. L-selectin is expressed constitutively on leukocytes. One of its ligands, GlyCAM, is expressed on high endothelial venules of lymph nodes.",
"   </p>",
"   <p>",
"    L-selectin binding of its ligand occurs rapidly, is of low affinity, and permits leukocyte rolling. This process slows leukocyte movement through the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukocyte activation or triggering is then required before the cascade of events can proceed further. Such an activating signal is provided by chemokines (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Chemokines and chemokine receptors'",
"    </a>",
"    below), which are produced by both leukocytes and endothelial cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Firm adhesion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Firm adhesion of leukocytes to the endothelium is mediated by cell surface integrins. VLA-4 ligation of endothelial VCAM-1 provides the principal interaction leading to adhesion, although several other integrins play important roles [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Transmigration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmigration, the process whereby leukocytes traverse the endothelial barrier and extracellular matrix, then occurs. This process is mediated predominantly by the PECAM-1:PECAM-1 homotypic interaction, usually in the direction of an increasing concentration gradient of chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Chemokines and chemokine receptors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Attraction of leukocytes to sites of tissue injury, infection, or allotransplantation is essential for the induction of the acute inflammatory response. This process is controlled by a group of low molecular weight (8 to 10 kd) \"chemoattractant cytokines\" or chemokines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/51\">",
"     51",
"    </a>",
"    ]. More than 40 chemokines have been identified and have been divided into families on the basis of the structural location of cysteine residues within the protein.",
"   </p>",
"   <p>",
"    The majority of chemokine proteins are composed of a single amino acid chain which contains four cysteine residues that link to form two intra-chain disulphide bonds. The largest families are the alpha- and &szlig;-chemokines. The alpha-chemokine family is characterized by cysteine residues that are separated by a single amino acid (CXC), while the cysteine residues in &szlig;-chemokines are adjacent (CC). By comparison, lymphotoxin, a member of a third group, has only a single pair of cysteines. Chemokines are tethered to the cell membrane by highly sulphated anionic structures on glycosaminoglycans, particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and chondroitin-sulfates [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemokines provide the signals that convert the low affinity selectin-mediated leukocyte rolling into the integrin-mediated leukocyte-endothelial adhesion that presages transmigration. The local production of chemokines also results in a chemoattractant gradient, thereby directing leukocyte trafficking through the tissues, blood, and lymph nodes. This process brings naive lymphocytes into contact with antigen and so enhances the effecter and memory functions of the immune response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The leukocyte response to chemokines requires cell surface expression of the appropriate chemokine receptor(s). Among the large number of known receptors, certain members of the CC family of chemokine receptors are predominantly expressed during an allograft rejection. These include chemokine receptor 1 (CCR1), CCR2, CXCR3, and CCR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Data from animal models and clinical observations suggest that CCR5, a high affinity receptor for the CC chemokines, MIP-1alpha, MIP-1beta, and RANTES, has a significant role in leukocyte trafficking in transplanted allografts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/55-58\">",
"     55-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CYTOKINES AND T HELPER CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;T helper cells have classically been divided into two distinct populations, type 1 and type 2 cells; they each produce their own repertoire of cytokines that mediate separate effector functions (",
"    <a class=\"graphic graphic_figure graphicRef77465 \" href=\"UTD.htm?10/47/10993\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/59-61\">",
"     59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A third T-cell subset (TH17) that secretes IL-17 has also been defined (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=see_link\">",
"     \"T helper subsets: Differentiation and role in disease\"",
"    </a>",
"    ).",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    IL-17 induces cytokines and chemokines and recruits neutrophils. Th17 cells appear to be involved in the early response to pathogens, such as bacteria and fungi, and function in autoimmunity and tissue inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Type 1 helper T-cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 helper T-cells (Th1 cells) produce IL-2 and interferon (IFN)-gamma and induce macrophage activation, leading to delayed type hypersensitivity (DTH) responses. Acute allograft rejection is predominantly mediated by a Th1 immune response. Acutely rejecting allografts clearly express both mRNA transcripts as well as protein levels of IL-2 and IFN-gamma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Type 2 helper T-cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 helper T-cells (Th2 cells) produce IL-4, IL-5, IL-10, and IL-13, and provide help for B cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/65\">",
"     65",
"    </a>",
"    ]. IL-4 is a growth factor for B cells and antibody production, and also can directly inhibit T-cell maturation into the Th1 pathway. Such responses have been implicated in clearing parasitic (predominantly helminthic) infections in mammals.",
"   </p>",
"   <p>",
"    A switch from a Th1 to a Th2 cytokine expression is associated with allograft tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/66\">",
"     66",
"    </a>",
"    ]; however, a causal relationship between a deviation in the alloimmune response towards Th2 cell function and tolerance induction has not been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9959729\">",
"    <span class=\"h2\">",
"     Type 17 helper T-cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;T helper (Th) type 17 cells are a T-cell subset that may contribute to allograft rejection and act as a barrier to the induction of transplant tolerance. Despite accumulating evidence, the precise impact of Th17 cells on transplant rejection and the induction of tolerance require further clarification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chronic rejection, both clinically and experimentally, has been associated with a number of fibrogenic cytokines, which include tissue growth factor (TGF)-&szlig; and fibroblast growth factor (FGF)-1. In addition, such cytokines may be up-regulated by the concomitant use of calcineurin inhibitors such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , thus exacerbating graft fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9959713\">",
"    <span class=\"h2\">",
"     Regulatory T-cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regulatory T-cells suppress the immune response and maintain tolerance. There are multiple types of regulatory T-cells with variable expression of CD4, CD25 and Foxp3 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MOLECULAR MECHANISMS OF T-CELL ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following T-cell activation, four major biochemical events occur within the cytoplasm. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hydrolysis of membrane bound inositol phospholipid",
"     </li>",
"     <li>",
"      Increases in cytoplasmic calcium",
"     </li>",
"     <li>",
"      Tyrosine phosphorylation of a variety of proteins",
"     </li>",
"     <li>",
"      Increases in protein kinase C activity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These pathways ultimately lead to activation of cytokine DNA promoter regions within the nucleus, permitting transcription of mRNA (",
"    <a class=\"graphic graphic_figure graphicRef60611 \" href=\"UTD.htm?17/21/17746\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Within minutes of TCR engagement, membrane bound phosphatidylinositol 4,5-bisphosphate (PIP) is hydrolyzed to inositol triphosphate (IP3) and diacylglycerol (DAG). The increase in IP3 causes the endoplasmic reticulum to release stored calcium leading to a marked and sustained elevation in intracellular calcium. This elevation in calcium promotes the formation of calcium:calmodulin complexes that activate a number of kinases including the phosphatase calcineurin.",
"   </p>",
"   <p>",
"    Calcineurin dephosphorylates cytoplasmic NFAT (nuclear factor of activated T-cells), permitting its translocation to the nucleus where it binds to the IL-2 promoter sequence and then stimulates transcription of IL-2 mRNA [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/70\">",
"     70",
"    </a>",
"    ]. Calcineurin is the ultimate target of both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    binds to an intracellular protein, cyclophilin, a member of the immunophilin family (",
"    <a class=\"graphic graphic_figure graphicRef60611 \" href=\"UTD.htm?17/21/17746\">",
"     figure 5",
"    </a>",
"    ). It is this complex that binds to and inhibits the phosphatase activity of calcineurin.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    binds to the FKBP (FK506 Binding Protein), another immunophilin, which inhibits calcineurin in a similar manner. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, rapamycin has a different mode of action. Although this compound binds to FKBP, it works by blocking a",
"    <span class=\"nowrap\">",
"     p70/S6",
"    </span>",
"    kinase that is involved in transducing the IL-2 receptor signal [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/72\">",
"     72",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef60611 \" href=\"UTD.htm?17/21/17746\">",
"     figure 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in renal transplantation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In parallel with the events described above, a number of other intracellular events also occur, including protein kinase C (PKC) activation by DAG and activation of Nuclear Factor kB (NFkB).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DAG induces protein phosphorylation which leads to activation of immediate genes in the nucleus.",
"     </li>",
"     <li>",
"      NFkB is another important nuclear transcription factor that is activated by several different signals that include TNF, IL-1, and LPS [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/73\">",
"       73",
"      </a>",
"      ]. In the resting cell, this molecule is found in a heterodimeric form in the cytoplasm bound to inhibitors of kB (IkBs). Signal induced degradation of the IkBs frees the NFkB, permitting it to enter the nucleus where it binds to its specific binding site. Transcription of a number of different genes including MHC class I, Ig and IL-2 then ensues. This pathway is disrupted by the administration of corticosteroid therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The JAK-STAT (Janus kinase-signal transducer and activator of transcription) pathway, which is involved in transducing signals provided by interferons and many other cytokines, also appears to be highly important [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/75\">",
"     75",
"    </a>",
"    ]. Initial experiments demonstrated that interferon-activated transcription factors undergo tyrosine phosphorylation, with tyrosine kinase being essential for interferon responses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Subsequently, four Janus kinases were identified that play central roles in cytokine-signaling pathways. More than 30 cytokines use the JAK-STAT pathway, making it an attractive target for therapeutic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     EFFECTOR MECHANISMS ASSOCIATED WITH ALLOGRAFT REJECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alloantigen-dependent and alloantigen-independent factors contribute to the effecter mechanisms underlying allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/78-81\">",
"     78-81",
"    </a>",
"    ]. A unifying hypothesis linking these apparently divergent mechanisms has been proposed (",
"    <a class=\"graphic graphic_algorithm graphicRef54098 \" href=\"UTD.htm?22/61/23518\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-immunologic \"injury responses\" (such as the response to ischemic damage) first induces a non-specific inflammatory response; this leads to increased antigen presentation to T-cells by up-regulating the expression of adhesion molecules, class II MHC, chemokines, and cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/82\">",
"     82",
"    </a>",
"    ]. Non-specific inflammation also promotes the shedding of intact, soluble HLA which may prime the indirect allorecognition pathway. Once activated, CD4 positive T-cells initiate macrophage mediated delayed type hypersensitivity (DTH) responses and provide help to B cells for alloantibody production.",
"   </p>",
"   <p>",
"    CD8 positive T-cells that mediate cell mediated cytotoxicity reactions kill either by delivering a \"lethal hit\" or alternatively by inducing apoptosis. After encountering a class I MHC molecule that is presenting antigen, the T-cell secretes perforin, an inducer of pore formation, and granzyme B, a serine protease that activates the ICE protease pathway that together induce cell death. This pathway is probably dominant during microbial infections. Alternatively, the T-cell may utilize the FAS pathway which induces \"activation-induced cell death.\" The FAS pathway is of importance in limiting T-cell proliferation in response to antigenic stimulation. Cell mediated cytotoxicity has been shown to play an important role in acute, although not chronic, allograft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detailed sequential immunohistologic as well as reverse transcriptase-polymerase chain reaction (RT-PCR) studies of chronically rejected allografts reveal gene upregulation of T-cells and T-cell derived cytokines (including IL-2 and IFN-gamma) early after transplantation. Other somewhat later events include expression of the &szlig;-chemokines RANTES, IP-10, and MCP-1, which precedes and promotes intense macrophage infiltration of the allograft [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/84,85\">",
"     84,85",
"    </a>",
"    ]. The potent smooth muscle and mesangial cell mitogen IL-6, the inflammatory cytokine TNF-alpha, inducible nitric oxide synthase and growth factors, such as transforming growth factor (TGF)-&szlig;, platelet-derived growth factor, and endothelin, are also expressed at approximately the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?10/27/10682/abstract/86,87\">",
"     86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial cells that are activated by T-cell derived cytokines and macrophages express class II MHC, adhesion molecules and costimulatory molecules and they can present antigen and activate more T-cells. Growth factors, including TGF-&szlig; and endothelin, lead to smooth muscle cell proliferation, neointimal thickening, interstitial fibrosis, and in the case of the kidney, glomerulosclerosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24500229\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The immune response involved in organ transplantation is a form of adaptive immunity, or one in which the response is to a specific antigen. The principal targets of the immune are the major histocompatibility complex (MHC) molecules expressed on the surface of donor cells (allo-MHC). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T-cell recognition of antigen is the primary event that initiates the immune response. This key step requires the interaction of the T-cell receptor with antigen presented as a peptide by the antigen-presenting cell (APC) and a costimulatory",
"      <span class=\"nowrap\">",
"       receptor/ligand",
"      </span>",
"      interaction on the",
"      <span class=\"nowrap\">",
"       T-cell/APC",
"      </span>",
"      cell surface. Activated T-cells are directly cytotoxic and provide help for B cell antibody production and macrophage-induced delayed type hypersensitivity responses. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'T-cell activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proteins encoded by the MHC are the principal antigenic determinants of graft rejection. Organs transplanted between MHC identical individuals are readily accepted, whereas organs transplanted between MHC antigen mismatched individuals are inevitably rejected in the absence of immunosuppressive agents. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'MHC structure and function'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antigen presenting protein products of the MHC have been classified into class I and II groups that are characterized by structure, expression, and the cellular compartment from which they obtain antigenic peptides to present to T-cells. Class I MHC molecules include HLA-A, HLA-B and HLA-C molecules and are found on all cell types except red blood cells. Class I molecules present cytoplasm-derived peptide antigens to CD8 positive T-cells which induce cell lysis.",
"      <br/>",
"      <br/>",
"      Class II MHC molecules include HLA-DP, HLA-DQ, and HLA-DR molecules. Class II MHC molecules are constitutively expressed on interstitial dendritic cells, macrophages, and B cells but expression may be upregulated on epithelial cell and vascular endothelial cell after exposure to pro-inflammatory cytokines. Class II molecules present peptides derived from extracellular proteins to CD4 positive T-cells. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'MHC class I and II'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The activation of costimulatory pathways are required for T-cell entry into the cell cycle. Multiple costimulatory molecules have been identified including CD28 and CD40. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mechanisms of allorecognition'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'T-cell costimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukocyte migration from the circulation to a site of inflammation involves four steps including selectin-mediated rolling, chemokine-mediated triggering, integrin-mediated firm adhesion and PECAM- and chemokine-mediated transmigration. Chemokine-regulated attraction of leukocytes to sites of tissue injury, infection, or allotransplantation is essential for the induction of the acute inflammatory response. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Leukocyte migration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T helper cells are divided into two distinct populations, type 1 (Th1) and type 2 (Th2) cells. Type 1 helper T-cells (Th1 cells) produce IL-2 and interferon (IFN)-gamma and induce macrophage activation leading to delayed type hypersensitivity (DTH) responses. Acute allograft rejection is predominantly mediated by a Th1 immune response. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Cytokines and T helper cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      T-cell activation results in intracellular signalling that activates cytokine DNA promoter regions permitting transcription of mRNA. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Molecular mechanisms of T-cell activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alloantigen-dependent and alloantigen-independent factors contribute to the effecter mechanisms underlying allograft rejection. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Effector mechanisms associated with allograft rejection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/1\">",
"      Wyburn KR, Jose MD, Wu H, et al. The role of macrophages in allograft rejection. Transplantation 2005; 80:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/2\">",
"      Andrade CF, Waddell TK, Keshavjee S, Liu M. Innate immunity and organ transplantation: the potential role of toll-like receptors. Am J Transplant 2005; 5:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/3\">",
"      Lakkis FG, Sayegh MH. Memory T cells: a hurdle to immunologic tolerance. J Am Soc Nephrol 2003; 14:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/4\">",
"      Pratt JR, Basheer SA, Sacks SH. Local synthesis of complement component C3 regulates acute renal transplant rejection. Nat Med 2002; 8:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/5\">",
"      Fan X, Ang A, Pollock-Barziv SM, et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004; 10:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/6\">",
"      Sun Q, Cheng Z, Cheng D, et al. De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int 2011; 79:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/7\">",
"      Breimer ME, Rydberg L, Jackson AM, et al. Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009; 87:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/8\">",
"      Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/9\">",
"      Warren EH, Greenberg PD, Riddell SR. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution. Blood 1998; 91:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/10\">",
"      Scott DM, Ehrmann IE, Ellis PS, et al. Why do some females reject males? The molecular basis for male-specific graft rejection. J Mol Med (Berl) 1997; 75:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/11\">",
"      Simpson E, Roopenian D. Minor histocompatibility antigens. Curr Opin Immunol 1997; 9:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/12\">",
"      Chen TC, Waldmann H, Fairchild PJ. Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. J Clin Invest 2004; 113:1754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/13\">",
"      Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu Rev Immunol 1993; 11:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/14\">",
"      Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/15\">",
"      Kreisel D, Krupnick AS, Gelman AE, et al. Non-hematopoietic allograft cells directly activate CD8+ T cells and trigger acute rejection: an alternative mechanism of allorecognition. Nat Med 2002; 8:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/16\">",
"      Vella, J, Knoflach, A, Waaga, A, Sayegh, M. T cell mediated immune responses in chronic allograft rejection: Role of indirect allorecognition and costimulatory pathways. Graft 1998; 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/17\">",
"      Azzi J, Sayegh MH. Clinical transplantation tolerance: a myth no more, but... Am J Kidney Dis 2009; 54:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/18\">",
"      Vella JP, Spadafora-Ferreira M, Murphy B, et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997; 64:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/19\">",
"      Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/20\">",
"      Vella JP, Vos L, Carpenter CB, Sayegh MH. Role of indirect allorecognition in experimental late acute rejection. Transplantation 1997; 64:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/21\">",
"      Vella JP, Magee C, Vos L, et al. Cellular and humoral mechanisms of vascularized allograft rejection induced by indirect recognition of donor MHC allopeptides. Transplantation 1999; 67:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/22\">",
"      Sayegh MH, Perico N, Imberti O, et al. Thymic recognition of class II major histocompatibility complex allopeptides induces donor-specific unresponsiveness to renal allografts. Transplantation 1993; 56:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/23\">",
"      Sayegh MH, Perico N, Gallon L, et al. Mechanisms of acquired thymic unresponsiveness to renal allografts. Thymic recognition of immunodominant allo-MHC peptides induces peripheral T cell anergy. Transplantation 1994; 58:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/24\">",
"      Habicht, A, Sayegh, MH. T cell costimulatory pathways in allograft rejection and tolerance: What's new? Curr Opin Org Transpl 2007; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/25\">",
"      Durrbach A, Francois H, Jacquet A, et al. Co-signals in organ transplantation. Curr Opin Organ Transplant 2010; 15:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/26\">",
"      Stamper CC, Zhang Y, Tobin JF, et al. Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses. Nature 2001; 410:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/27\">",
"      Schwartz JC, Zhang X, Fedorov AA, et al. Structural basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature 2001; 410:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/28\">",
"      Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/29\">",
"      Clarkson MR, Sayegh MH. T-cell costimulatory pathways in allograft rejection and tolerance. Transplantation 2005; 80:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/30\">",
"      Larsen CP, Knechtle SJ, Adams A, et al. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am J Transplant 2006; 6:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/31\">",
"      Zang X, Allison JP. To be or not to be B7. J Clin Invest 2006; 116:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/32\">",
"      Radvanyi LG, Shi Y, Vaziri H, et al. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol 1996; 156:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/33\">",
"      Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994; 1:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/34\">",
"      Hodi FS. Cytotoxic T-lymphocyte-associated antigen-4. Clin Cancer Res 2007; 13:5238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/35\">",
"      Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995; 3:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/36\">",
"      Perez VL, Van Parijs L, Biuckians A, et al. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997; 6:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/37\">",
"      Schaub M, Stadlbauer TH, Chandraker A, et al. Comparative strategies to induce long-term graft acceptance in fully allogeneic renal versus cardiac allograft models by CD28-B7 T cell costimulatory blockade: role of thymus and spleen. J Am Soc Nephrol 1998; 9:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/38\">",
"      Azuma H, Chandraker A, Nadeau K, et al. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A 1996; 93:12439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/39\">",
"      Chandraker A, Russell ME, Glysing-Jensen T, et al. T-cell costimulatory blockade in experimental chronic cardiac allograft rejection: effects of cyclosporine and donor antigen. Transplantation 1997; 63:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/40\">",
"      Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/41\">",
"      Vincenti F. Costimulation blockade--what will the future bring? Nephrol Dial Transplant 2007; 22:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/42\">",
"      Denton MD, Reul RM, Dharnidharka VR, et al. Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection. Pediatr Transplant 1998; 2:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/43\">",
"      DiSanto JP, Bonnefoy JY, Gauchat JF, et al. CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM. Nature 1993; 361:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/44\">",
"      Reul RM, Fang JC, Denton MD, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation 1997; 64:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/45\">",
"      Sun H, Subbotin V, Chen C, et al. Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation 1997; 64:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/46\">",
"      Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/47\">",
"      Sandner SE, Clarkson MR, Salama AD, et al. Mechanisms of tolerance induced by donor-specific transfusion and ICOS-B7h blockade in a model of CD4+ T-cell-mediated allograft rejection. Am J Transplant 2005; 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/48\">",
"      Fuggle SV, Koo DD. Cell adhesion molecules in clinical renal transplantation. Transplantation 1998; 65:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/49\">",
"      Brady HR. Leukocyte adhesion molecules: potential targets for therapeutic intervention in kidney diseases. Curr Opin Nephrol Hypertens 1993; 2:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/50\">",
"      Walcheck B, Moore KL, McEver RP, Kishimoto TK. Neutrophil-neutrophil interactions under hydrodynamic shear stress involve L-selectin and PSGL-1. A mechanism that amplifies initial leukocyte accumulation of P-selectin in vitro. J Clin Invest 1996; 98:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/51\">",
"      Luster AD. Chemokines--chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/52\">",
"      Ali S, Malik G, Burns A, et al. Renal transplantation: examination of the regulation of chemokine binding during acute rejection. Transplantation 2005; 79:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/53\">",
"      Hancock WW, Gao W, Faia KL, Csizmadia V. Chemokines and their receptors in allograft rejection. Curr Opin Immunol 2000; 12:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/54\">",
"      Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation 2002; 74:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/55\">",
"      Fairchild RL. Raising the direction signposts that guide T cell trafficking into allografts. Transplantation 2005; 79:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/56\">",
"      Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001; 72:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/57\">",
"      Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal-transplant survival. Lancet 2001; 357:1758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/58\">",
"      Abdi R, Tran TB, Sahagun-Ruiz A, et al. Chemokine receptor polymorphism and risk of acute rejection in human renal transplantation. J Am Soc Nephrol 2002; 13:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/59\">",
"      Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/60\">",
"      Goriely S, Goldman M. The interleukin-12 family: new players in transplantation immunity? Am J Transplant 2007; 7:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/61\">",
"      Joffre O, Santolaria T, Calise D, et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008; 14:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/62\">",
"      Bettelli E, Korn T, Oukka M, Kuchroo VK. Induction and effector functions of T(H)17 cells. Nature 2008; 453:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/63\">",
"      Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/64\">",
"      Crome SQ, Wang AY, Levings MK. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010; 159:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/65\">",
"      Hancock WW, Sayegh MH, Kwok CA, et al. Oral, but not intravenous, alloantigen prevents accelerated allograft rejection by selective intragraft Th2 cell activation. Transplantation 1993; 55:1112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/66\">",
"      Sayegh MH, Akalin E, Hancock WW, et al. CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J Exp Med 1995; 181:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/67\">",
"      Chadha R, Heidt S, Jones ND, Wood KJ. Th17: contributors to allograft rejection and a barrier to the induction of transplantation tolerance? Transplantation 2011; 91:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/68\">",
"      Shihab FS, Andoh TF, Tanner AM, et al. Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. Kidney Int 1996; 49:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/69\">",
"      Tsaur I, Gasser M, Aviles B, et al. Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney Int 2011; 79:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/70\">",
"      Wesselborg S, Fruman DA, Sagoo JK, et al. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). J Biol Chem 1996; 271:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/71\">",
"      Bierer BE, Holl&auml;nder G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/72\">",
"      Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/73\">",
"      Zuckerman SH, Evans GF, Guthrie L. Transcriptional and post-transcriptional mechanisms involved in the differential expression of LPS-induced IL-1 and TNF mRNA. Immunology 1991; 73:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/74\">",
"      Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/75\">",
"      Ransohoff RM. Cellular responses to interferons and other cytokines: the JAK-STAT paradigm. N Engl J Med 1998; 338:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/76\">",
"      Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994; 264:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/77\">",
"      Velazquez L, Fellous M, Stark GR, Pellegrini S. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 1992; 70:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/78\">",
"      Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation 1995; 59:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/79\">",
"      Le Moine A, Goldman M, Abramowicz D. Multiple pathways to allograft rejection. Transplantation 2002; 73:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/80\">",
"      Adams AB, Williams MA, Jones TR, et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003; 111:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/81\">",
"      Jabs WJ, Maurmann S, Wagner HJ, et al. Time course and frequency of Epstein-Barr virus reactivation after kidney transplantation: linkage to renal allograft rejection. J Infect Dis 2004; 190:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/82\">",
"      Halloran PF, Homik J, Goes N, et al. The \"injury response\": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc 1997; 29:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/83\">",
"      Forbes RD, Zheng SX, Gomersall M, et al. Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rat heart allograft model. Transplantation 1994; 57:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/84\">",
"      Nadeau KC, Azuma H, Tilney NL. Sequential cytokine dynamics in chronic rejection of rat renal allografts: roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci U S A 1995; 92:8729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/85\">",
"      Segerer S, Cui Y, Eitner F, et al. Expression of chemokines and chemokine receptors during human renal transplant rejection. Am J Kidney Dis 2001; 37:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/86\">",
"      Watschinger B, Sayegh MH. Endothelin in organ transplantation. Am J Kidney Dis 1996; 27:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/27/10682/abstract/87\">",
"      Suthanthiran M. Molecular analyses of human renal allografts: differential intragraft gene expression during rejection. Kidney Int Suppl 1997; 58:S15.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7346 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-4FB60DB4AC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10682=[""].join("\n");
var outline_f10_27_10682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24500229\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NATURAL AND ADAPTIVE IMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      T-cell activation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MHC STRUCTURE AND FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MHC class I and II",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Class I",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Class II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MINOR TRANSPLANTATION ANTIGENS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MECHANISMS OF ALLORECOGNITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Direct pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Indirect pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      T-CELL COSTIMULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CD28, B7, and CTLA4",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Abatacept (CTLA4-Ig)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CD40 and CD40L",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Novel costimulatory pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      T-CELL HOMING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Leukocyte migration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Rolling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Firm adhesion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Transmigration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Chemokines and chemokine receptors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CYTOKINES AND T HELPER CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Type 1 helper T-cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Type 2 helper T-cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9959729\">",
"      Type 17 helper T-cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9959713\">",
"      Regulatory T-cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MOLECULAR MECHANISMS OF T-CELL ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      EFFECTOR MECHANISMS ASSOCIATED WITH ALLOGRAFT REJECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24500229\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7346|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?22/61/23518\" title=\"algorithm 1\">",
"      Intracellular signaling in graft rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7346|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/15/16625\" title=\"figure 1\">",
"      Two signal model for T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/15/255\" title=\"figure 2\">",
"      Map of the MHC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/61/34774\" title=\"figure 3\">",
"      MHC class I and II structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/61/19409\" title=\"figure 4\">",
"      Direct indirect allorecognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/21/17746\" title=\"figure 5\">",
"      Signal transduction in T cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/47/10993\" title=\"figure 6\">",
"      Th1 and Th2 cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/23/43376\" title=\"figure 7\">",
"      Extravasation of circulating leukocytes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/62/44011\" title=\"table 1\">",
"      Comparison MHC class I and II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/43/44729?source=related_link\">",
"      Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/6/44135?source=related_link\">",
"      Investigational immunosuppressive drugs and approaches in clinical kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43706?source=related_link\">",
"      Maintenance immunosuppressive therapy in renal transplantation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/24/18826?source=related_link\">",
"      Pathogenesis of graft-versus-host disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24326?source=related_link\">",
"      Primary humoral immune deficiencies: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41897?source=related_link\">",
"      T helper subsets: Differentiation and role in disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27624?source=related_link\">",
"      The humoral immune response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_27_10683="Degree blood loss and symptoms";
var content_f10_27_10683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Symptoms related to blood loss with postpartum hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Blood loss, percent (mL)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Blood pressure, mm Hg",
"      </td>",
"      <td class=\"subtitle1\">",
"       Signs and symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 to 15 (500 to 1000)",
"      </td>",
"      <td>",
"       Normal",
"      </td>",
"      <td>",
"       Palpitations, lightheadedness, tachycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15 to 25 (1000 to 1500)",
"      </td>",
"      <td>",
"       Slightly low",
"      </td>",
"      <td>",
"       Weakness, sweating, tachycardia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25 to 35 (1500 to 2000)",
"      </td>",
"      <td>",
"       70 to 80",
"      </td>",
"      <td>",
"       Restlessness, confusion, pallor, oliguria",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       35 to 45 (2000 to 3000)",
"      </td>",
"      <td>",
"       50 to 70",
"      </td>",
"      <td>",
"       Lethargy, air hunger, anuria, collapse",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bonnar, J. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10683=[""].join("\n");
var outline_f10_27_10683=null;
var title_f10_27_10684="Dining out allergy tips PI";
var content_f10_27_10684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Avoiding food allergens when dining out",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Tips:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       1. Consumers should clearly state that they have a food allergy (not just a distaste for the food) to the person who is directly responsible for preparing the meal (ie, the cook or manager, rather than the waitstaff).",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       2. Carry a supply of pre-printed cards with clear information about which foods cannot be eaten (see below). Remind the cook or manager that cooking containers and serving utensils cannot be contaminated with the allergenic food. As an example, it may be necessary to use a clean pan or glassware rather than a shared grill or blender.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       3. Food that is fried in oil may be reused for frying allergenic foods and should be avoided. The oil becomes contaminated easily with protein from previously cooked foods.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       4. Ingredient lists on menus should not be trusted at face value. If a food allergen is not listed, the person should verify that it is not used to prepare or garnish the dish. This also applies to \"secret\" ingredients. Avoid the food if the server/cook is not sure about the ingredients.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       5. People with peanut or tree nut allergies should be especially careful of ice cream parlors, bakeries, and Asian restaurants. These types of restaurants frequently use peanut/tree nut ingredients and are prone to cross-contact.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       6. Buffets and salad bars should probably be avoided because of the high risk of cross-contact.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       7. Report allergic reactions to restaurant staff immediately. Do not wait to see if the reaction will get better on its own. Staff should call 911 immediately.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Example of pre-printed food allergy card",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       I am allergic to peanuts and tree nuts. This includes peanut butter, peanut oil, peanuts, walnuts, almonds, pine nuts, and cashews. If I eat even a tiny amount of one of these foods, I may have a sudden, severe allergic reaction, stop breathing, or even die. I cannot eat foods prepared in oil used to fry any of the foods listed above (even if it was days ago). If a dish contains nuts, it is not enough to pick out the nuts. The person preparing my food needs to wash their hands and put on clean gloves before preparing my food. The food prep surface needs to be cleaned with a cleaning solution to eliminate any peanut or tree nut residue.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10684=[""].join("\n");
var outline_f10_27_10684=null;
var title_f10_27_10685="No interaction theophylline";
var content_f10_27_10685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66236&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs that have been documented NOT to interact with theophylline or NOT to have clinically important interactions with theophylline",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Albuterol, systemic and inhaled",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoxicillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ampicillin,",
"with or without sulbactam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atenolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Azithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Caffeine, dietary",
"ingestion",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cefaclor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Co-trimoxazole (trimethoprim and sulfamethoxazole)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diltiazem",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dirithromycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Enflurane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Famotidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Felodipine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Finasteride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydrocortisone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoflurane",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isoniazid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Isradipine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Influenza vaccine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ketoconazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"1\">",
"            Lomefloxacin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td>",
"            Mebendazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Medroxyprogesterone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Methylprednisolone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metronidazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Metoprolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nadolol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nifedipine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nizatidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Norfloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ofloxacin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Omeprazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paroxetine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Prednisone, prednisolone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ranitidine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifabutin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Roxithryomycin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sertraline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sorbitol (purgative doses do not",
"inhibit theophylline absorption)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sucralfate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Terbutaline, systemic",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Terfenadine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tetracycline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tocainide",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Hendeles, L, Jenkins, J, Temple, R, Pharmacotherapy 1995; 15:409.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10685=[""].join("\n");
var outline_f10_27_10685=null;
var title_f10_27_10686="Mediterranean diet and CAD";
var content_f10_27_10686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Coronary benefits of a Mediterranean diet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 255px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Evaluation of the importance of diet in the Lyon Diet Heart Study which evaluated patients after a first myocardial infarction. Left panel: Patients who ate a Mediterranean diet had a lower incidence of major endpoints (cardiac death, nonfatal MI, unstable angina, HF, stoke, and thromboembolism) after one year than those who ate a \"prudent\" diet (p&lt;0.0001). Right panel: Benefits from the Mediterranean diet were also observed when major and minor endpoints (hospitalization for angina, need for elective revascularization, and restenosis after PTCA) were combined (p&lt;0.002).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: deLongeril, M, Salen, P, Martin, JL, et al. J Am Coll Cardiol 1996; 28:1103.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10686=[""].join("\n");
var outline_f10_27_10686=null;
var title_f10_27_10687="Doxorubicin monitoring children";
var content_f10_27_10687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Guidelines for monitoring anthracycline cardiotoxicity in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 339px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ECG = electrocardiogram; Echo = echocardiogram; RNA = radionuclide angiocardiogram; RT = radiation therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Steinherz, LJ, Graham, T, Hurwitz, R, et al, Pediatrics 1992; 89:942.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_27_10687=[""].join("\n");
var outline_f10_27_10687=null;
